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PREFACE
“I don’t have a choice as to my “new” normal, so I do what I can to continue to find
enjoyment and fulfillment in life.” –Ed Steger, head and neck cancer survivor
My dad, late Dr Vijay Prakash (Professor, Internal Medicine & Cardiology) and my mother
Dr. Aruna Prakash (Gynecology & Obstetrics) devoted their entire life to the service of their
patients and their immense dedication has inspired me the most in my journey as an
epidemiologist with training in dentistry to pursue head and neck cancer research. Working
as a dentist in India with oral cancer patients, losing beloved family members and friends to
cancer and having witnessed the immense suffering that cancer brings to the patient and their
families has further fueled my passion to pursue to pursue head and neck cancer research.
Lower cranial neuropathy (LCNP) is a clinical condition of great concern, often accompanied
with late radiation-associated dysphagia, which may enhance risk of aspiration pneumonia
and contribute to debilitating functional morbidity with increased feeding tube dependence,
hospitalization, weight loss, and life-threatening complications. During data abstraction, I
have often observed LCNP patients describe their anguish with problems eating, swallowing,
and embarrassment in eating in social settings contributing to feelings of social isolation
which can be exacerbated sometimes by speech and hearing problems. It is my hope that this
dissertation research will improve our understanding of late LCNP, to inform ongoing
surveillance recommendations, targeted prevention, supportive care, and treatment
interventions for patients with late LCNP to prevent functional decline and improve quality
of life in these patients.
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ABSTRACT

Background: Lower cranial neuropathy (LCNP) is a rare but potentially disabling late effect
of radiotherapy (RT) and other head and neck cancer therapies. Survivors who develop late
LCNP may experience profound functional impairment with deficits in swallowing, speech,
and voice. The aims of this research were: 1) to quantify the cumulative incidence of late
LCNP and identify clinical predictors of late LCNP; 2) to investigate the impact of late
LCNP on severity of cancer treatment-related symptoms, general functional impairment
(GFI), and single item scores of the most severe symptoms; and 3) to quantify the association
of late LCNP with swallowing-related quality of life (QoL) and functional status among
long-term oropharyngeal cancer (OPC) survivors.
Methods: For the first aim of this dissertation the study population included 2,021 OPC
survivors (median survival: 6.8 years) who received primary treatment at MD Anderson
Cancer Center from 2000 to 2013. A retrospective cohort study was conducted and late
LCNP events for all three studies were defined by neuropathy of the glossopharyngeal (IX),

vagus (X), and/or hypoglossal (XII) nerves ≥3-months after cancer therapy and abstracted
from medical records along with other study variables. For the second and third study, a
cross-sectional survey analysis among 889 OPC survivors nested within a retrospective
cohort of OPC survivors treated during January 2000 -December 2013 at MD Anderson
Cancer Center was conducted (56% response rate). The survey included MD Anderson
Symptom Inventory Head and Neck Cancer Module (MDASI-HN) and MD Anderson
Dysphagia Inventory (MDADI) among other items. For the first study, cumulative incidence
of LCNP was estimated using the Kaplan Meir method with adjustment for competing risks
using time to event as the underlying metric. Log-rank test was used to assess differences
between groups by LCNP status, and multivariable Cox proportional hazard models were fit.
For the second study, the primary outcome variable was the mean of the top 5 most severely
scored symptoms from MD Anderson Symptom Inventory Head and Neck Cancer Module
(MDASI-HN) out of all 22 core and HNC-specific symptoms. Secondary outcomes included
mean MDASI-HN interference scores and single item scores of the most severe symptoms.
Multivariate models regressed MDASI-HN scores on late LCNP status adjusting for clinical
covariates. Finally, for the third study, multivariate models regressed MDADI scores on late
LCNP status adjusting for clinical covariates.
Results: For the first study; 4.4% (n=88) OPC survivors were diagnosed with late LCNP
with median time to LCNP onset after treatment of 5.4 (range, 0.3-14.1; IQR: 1.6-8.5) years
post-treatment. Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI:
0.02-0.03), 0.06 (95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and
18 years of follow-up, respectively. Multivariable Cox regression identified T4 stage vs T1

stage (HR: 3.82; 95%CI: 1.85-7.86, p=0.000) and accelerated RT fractionation vs standard
RT fractionation (HR 2.15, 95%CI 1.34-3.45, p=0.002) independently associated with late
LCNP status, adjusting for age, subsite, T-stage, smoking and therapeutic modality.
In the second and third, cross-sectional survey analysis study overall, 4% (n=36) of 889 OPC
survivors (median survival time: 7 years) developed late LCNP with median time to onset of
5.25 years post-treatment. Late LCNP was significantly associated with worse mean top 5
MDASI-HN symptom scores (coefficient, 1.54; 95%CI, 0.8, 2.2) adjusting for age, survival
time, sex, therapeutic modality, T-stage, subsite, type of radiotherapy, smoking, and normal
diet prior to treatment. Late LCNP was also associated with single item scores for difficulty
swallowing/chewing (coefficient, 2.25; 95%CI, 1.3, 3.1), mucus (coefficient, 1.97; 95%CI,
1.0, 2.9), fatigue (coefficient, 1.35; 95%CI, 0.4, 2.2), choking (coefficient, 1.53; 95%CI, 0.6,
2.4), and voice/ speech symptoms (coefficient, 2.3; 95%CI, 1.6, 3.0) in multivariable models.
However late LCNP was not significantly associated with mean interference scores after
correction for multiple comparisons. LCNP cases reported significantly worse mean
composite MDADI (LCNP: 68.0 vs. no LCNP: 80.2, p<0.001). Late LCNP independently
associated with worse mean composite MDADI (β= -6.7, p=0.015, 95%CI: -12.0, -1.3) as
well as all MDADI domains after multivariate adjustment. Finally, LCNP cases were more
likely to have a feeding tube at time of survey (OR= 20.5; 95%CI, 8.6 to 48.9), history of
aspiration pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), and tracheostomy (OR= 26.9; 95%CI,
6.0 to 121.7).

Conclusion: Risk of late LCNP progressed over time to exceed 10% cumulative risk over
survivors’ lifetime even though it is considered a rare late effect. Our prediction model
enabled identification of OPC survivors who had T4 tumors and those who received
accelerated fractionation RT treatment as having higher risk of late LCNP. In the large
survey study, OPC survivors with late LCNP reported significantly worse cancer treatmentrelated symptoms, significantly poorer swallowing-related QOL and had significantly higher
likelihood of poor functional status demonstrating the impact of late LCNP on both symptom
severity and functional burden. Further, efforts are necessary to investigate the risk and
predictors for this disabling late effect of cancer treatment, address severity of treatmentrelated symptoms and optimize swallowing outcomes to improve QoL among growing
numbers of relatively younger OPC survivors, who are expected to survive decades after
treatment.
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BACKGROUND
Oropharyngeal Cancer (OPC)
The incidence of OPC is increasing by 5% each year and it is projected that by
2030 about half of head and neck cancers (HNC) will be OPC.1 This phenomenon is
attributable to the epidemic of HPV-associated OPC which is usually diagnosed in patients,
who are middle aged, male, white, non-smokers and non-drinkers and have a higher
socioeconomic status relative to individuals diagnosed with tobacco-related head and neck
cancers.1-4 They also tend to have a history of higher number of sexual partners and are often
diagnosed at a more advanced stage.1-4 As a consequence of modern regimens of organ
preserving radiotherapy, favorable biology, and improved prognosis due to better response to
treatment among HPV associated OPC patients, these patients have good survival rates and
are often expected to live for decades despite advanced stage disease. 2-4 HPV associated
HNC patients have a 3-year overall survival rates of 82%, in comparison to 57% among HPV
negative HNC patients (with tobacco related cancer). 2 HPV positive HNC also have better 5year overall survival (RR=0.4; 95%CI 0.2-1.08) than non-HPV related tumors.3 Further HPV
associated HNC are more likely to occur in the oropharynx, especially base of tongue or
tonsil and HPV positive tonsillar tumors at time of diagnosis. Primary tumors are more likely
to be smaller with regional lymph node metastasis making most stage IV at presentation. 4
As the lifespan of OPC survivors increase, they are more likely to experience severe
side-effects over time due to delayed or late adverse effects of tumor and cancer treatment.
OPC survivors experience excess morbidity and disability compared to other cancer
survivors, as these side-effects lead to problems in swallowing, eating, breathing, and
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speaking. According to a survey study in 2004, 52% of HNC patients of mixed sites
experience disability due to cancer treatment and are unable to work due to these problems. 5

Cranial Nerves
Cranial Nerves (CN) comprise of 12 pairs of nerves that emerge from the brainstem.
They regulate smell, sight, speech taste, movement of eyes, eye muscles, facial muscles,
shoulder and neck muscles, and many other physiologic processes in the body.6-8These
nerves are numbered using roman numerals, in the order they emerge from the brainstem and
their names convey their function.6-8
CN carry sensory or afferent fibers that conduct neural information from sensory
receptors in the head and neck region to the brain and terminate in sensory cranial nerve
nuclei. These nuclei are generally located laterally in the brainstem.8, 9The sensory
component of CN includes general sensory, visceral sensory, and special sensory fibers
which conduct smell, sight, taste, balance, and hearing signals to the brain.8, 9CN also carry
motor or efferent fibers, which conduct regulatory neural input back from brain to target
receptors (muscles) and other parts of the body. The neuronal cell bodies of these fibers are
present in the motor cranial nerve nuclei, located more medially in the brainstem. 8, 9 Further
CN also transmit somatic motor, branchial motor, and parasympathetic motor fibers which
supply voluntary muscles (skeletal muscles), involuntary muscles, and provide
parasympathetic innervation to the viscera respectively. 8,9 Most cranial CN are mixed,
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carrying both sensory and motor nerve fibers but some only carry sensory or only motor
fibers.8,9

Lower cranial nerves (LCN)
Lower cranial nerves (LCN) include glossopharyngeal (IX), vagus (X), accessory (XI) and
hypoglossal (XII) nerves which provide innervation to the pharynx, larynx, and shoulder,
neck and tongue muscles respectively.10

Glossopharyngeal Nerve (IX)
Glossopharyngeal Nerve (IX) is a mixed sensory and motor nerve, which innervates
the tongue and the pharynx.8, 9 General sensory fibers of CN IX provide general sensory
input from the soft palate, pharynx, oropharynx, tympanic membrane, Eustachian tube, and
the posterior third of the tongue (also supplied by special sensory fibers of CN IX which
provide taste sensation).8,9These fibers descend in the spinal trigeminal tract and the sensory
fibers from tongue, tonsils, soft palate, and pharynx terminate in the spinal trigeminal
nucleus.8,9 The sensory fibers from the tympanic nerve carry pain signals and also terminate
in the spinal trigeminal nucleus.8,9 Visceral sensory fibers from CN IX conduct neural
information from carotid body and sinus, to monitor blood pressure and arterial oxygen in the
internal carotid artery.8,9 They pass through the jugular foramen, enter the medulla, descend
in the tractus solitarius and terminate in the nucleus solitarius.8,9 Special sensory fibers from
CN IX carry taste signals from the taste buds in posterior one-third of the tongue, pass
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through the jugular foramen, enter the medulla, ascend in the tractus solitarius and terminate
in the rostral gustatory part of nucleus solitarius.8,9
Parasympathetic preganglionic motor CN IX fibers are located in the inferior
salivatory nucleus and the nucleus ambiguus in the medulla. 8, 9 Nerve axons from inferior
salivatory nucleus exit the cranial cavity via foramen ovale, synapse on the otic ganglion to
supply the parotid gland and regulate its secretory function. 8Axons from the nucleus
ambiguus innervate the carotid body and sinus and regulate the vasodilation of blood
vessels.8
Branchial motor fibers of CN IX emerge from the nucleus ambiguus, where the
synapse between upper motor neurons passing through the corticobulbular tract and lower
motor neurons occurs.8 These lower motor neuron axons exit the cranial cavity through the
jugular foramen.8 They innervate the stylopharyngeus muscle, which plays a role in
pharyngeal elevation to mediate swallowing and speech.8 This muscle facilitates swallowing,
by elevating pharynx and larynx, to allow bolus of food to pass. 6, 7

CN IX Injury: CN IX exits the medulla of the brain stem along with CN X and XI, via the
jugular foramen. Thereby tumor-related and treatment-related toxicity can affect all three
nerves together and lead to nerve impairment.8, 9 CN IX injury can lead to swallowing
impairment, from the loss of function of the stylopharyngeus and also contribute to ipsilateral
loss of taste sensation over the posterior third of tongue.8, 9
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Vagus Nerve (X)
Vagus Nerve is a mixed sensory and motor nerve. It innervates major areas of the
body from the brainstem to the splenic flexure in the transverse colon.8, 9 General sensory
fibers of CN X conduct somatosensory information including touch, temperature, and pain
from the larynx, laryngopharynx, concha, external auditory canal, tympanic membrane, and
the posterior meninges.8, 9 These fibers pass through the jugular foramen, enter the medulla,
ascend in the spinal trigeminal tract and synapse in the spinal trigeminal nucleus.8, 9 From
this nucleus, second-order axons carry neural information to the thalamus and the sensory
cortex.8 Visceral sensory fibers of CN X, conduct visceral neural input from the aortic arch
baroreceptors, aortic body chemoreceptors, the larynx above the vocal cords (via internal
laryngeal nerve),the larynx below the vocal cords (via recurrent laryngeal nerve), epiglottis,
and base of tongue.8 These afferent fibers pass through the jugular foramen, enter the
medulla, descend in tractus solitarius and synapse in the nucleus solitarius.8 Neural signals
from the nucleus are relayed to the reticular formation and the hypothalamus, and help to
regulate numerous cardiac, respiratory and gastrointestinal functions. 8 Branchial motor fibers
of CN X emerge from nucleus ambiguus, where the bilateral corticobulbular fibers carrying
upper motor neuron axons synapse.8These fibers exit the cranial cavity through the jugular
foramen and branch out into the pharyngeal, superior laryngeal, and recurrent laryngeal
nerves.8

Pharyngeal Branch of CN X: The pharyngeal branch via the pharyngeal plexus, provides
innervation to all the muscles of pharynx, soft palate (excluding stylopharyngeus, supplied by
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CN IX and tensor veli palitini by CN V), and the palatoglossus muscle in the base of tongue.8
The Palatoglossus; contracts to either lower the soft palate or raise the posterior part of the
tongue.11,12 The levator veli palatine; elevates and retracts the soft palate, the
palatopharyngeus; narrows the oropharynx, elevates the pharynx and guides the food bolus
down to lower pharynx and also produces some laryngeal elevation.11,12 The muscularis
uvulae; shortens and elevates the uvula.11,12

Superior laryngeal Nerve (Branch of CN X): This nerve supplies the cricothyroid muscles
and inferior pharyngeal constrictor.8, 9The cricothyroid muscles help to elongate and tighten
the vocal cords and thereby contribute to phonation.13The inferior pharyngeal constrictor
comprises of thryopharyngeus and cricopharyngeus, and the latter relaxes during swallowing
to enable food bolus to pass downwards towards the esophagus.6, 7

Recurrent laryngeal nerve (Branch of CN X): This nerve supplies the other intrinsic
muscles of the larynx, which contribute to phonation by altering the shape of the glottis and
altering the length and tension of the vocal cords.8, 9, 11-13
The parasympathetic motor fibers of CN X, emerge from the cell bodies in the dorsal
motor nucleus of CN X and medial part of nucleus ambiguus.8 These efferent fibers exit the
cranial cavity through the jugular foramen and innervate the pharynx, larynx, viscera of the
thorax and abdomen, cardiac muscle and the aortic bodies.8 They help to regulate numerous
cardiac, respiratory and gastrointestinal physiological functions. 8, 9 Overall CN X plays a
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critical role in swallowing, as it regulates the posterior elevation of tongue, soft palate
movement, velar elevation, closure of glottis and pharyngeal constriction allowing bolus
transport into the esophagus. It contributes to phonation by regulating intrinsic movements of
larynx.11, 12

CN X Injury: CN X is very similar to CN IX in structure, function and they arise from the
same cranial nerve nuclei in the brain stem and exit the skull base together through the
jugular foramen accompanied by CN XI.8, 9 Therefore, these nerves are likely to be injured
concurrently.8, 9
Damage to CN X, can lead to paralysis of the pharyngeal muscles, larynx and vocal
cords, and thereby contribute to dysphagia and speech impairment. 8-10 Unilateral vagal injury
can lead to reduced pharyngeal muscle movement, which can cause loss of adequate soft
palate elevation, dysphagia, palatal droop on the affected side. Palatal drooping can result in
passage of food into the nasal cavity during swallowing and thereby cause aspiration8, 9It can
also cause reduced vocal cord vibration, leading to hoarseness and reduced pitch of voice.8, 9
Thereby bilateral CN X injury, can cause bilateral pharyngeal paresis, severe dysphagia,
bilateral paralysis of vocal cords and severe speech impairment. 8, 9

Hypoglossal (XII) nerve
Hypoglossal (XII) nerve is a motor nerve and only carries somatic efferent
fibers.13These fibers emerge from the hypoglossal nucleus in the tegmentum of the medulla,
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from which neural information is relayed by the corticobulbular tract to the cortex. 8 Efferent
fibers of CN XII exit the cranial cavity, through the hypoglossal foramen and pass medially
to CN IX, X and XI.8 They innervate the extrinsic tongue muscles (except palatoglossus)
which regulate tongue movement.8,11,12 The genioglossus mediates tongue protrusion, tongue
retraction, and draws the tongue downward, thereby helping in food bolus transport.11,12 The
hyoglossus retracts and depresses the tongue and elevates the hyoid bone, whereas
styloglossus is responsible for upward and backward movement of the tongue. 11,12 These
efferent fibers also provide nerve supply to all the intrinsic tongue muscles which alter the
shape of the tongue.8,11,12 These muscles include the superior longitudinal; which shortens the
tongue and turns its tip upward, the inferior longitudinal; which shortens the tongue and
turns its tip downward, the transverse; which narrows and elongates tongue, and the vertical;
which flattens tongue.11,12

CN XII Injury: The hypoglossal nuclei are in close proximity to each other, therefore
tumor-related and treatment-related toxicity contributing to nuclear injury, is likely to affect
both nuclei leading bilateral nerve impairment of the tongue. 8, 9
Lesions of hypoglossal nuclei in the brainstem and unilateral lesions of CN XII can
cause ipsilateral tongue paralysis, atrophy of tongue muscles, wrinkled tongue appearance,
tongue fasciculations, and mild speech impairment.8,9 In cases with ipsilateral paralysis of
CN XII, when the tongue is protruded it deviates towards the affected side, due to the
genioglossus action on the unaffected side, which can over time lead to tongue fasciculations
and atrophy.8,9 Bilateral CN XII injury leads to bilateral tongue paresis, inability in tongue
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protrusion, atrophy, fibrillations, severe dysphagia, and speech impairment. Reduced lingual
motion may contribute to swallowing apraxia, oral residue, bolus formation problems, and
reduced bolus movement, thereby leading to extensive swallowing toxicity. 8-13
In summary injury to lower cranial nerves can lead to profound functional impairment
in terms of dysphagia, vocal cord paresis with or without accompanying lingual weakness
14,15

often with co-existing problems in speech and voice and shoulder impairment . 10,14,16,17

Therefore lower cranial nerve injury can have an adverse impact on swallowing-related QoL
among OPC patients.16,18

Lower Cranial Neuropathy (LCNP)
Lower cranial neuropathies (LCNP) are a rare, but severe late effect induced by
damage due to radiotherapy or surgery.14,15,19 LCNP can occur both unilaterally and
bilaterally and can affect glossopharyngeal (IX), vagus (X), accessory (XI), and hypoglossal
(XII) nerves.14,15,18,19These nerves are critical to the oropharyngeal phase of swallowing
mechanism and speech production and shoulder movement. 14-16, 18, 19
According to a recent report, the incidence of late LCNP among 59 OPC survivors
was 5% at 5.7years (Hutcheson, et al).15 Nerve palsies have delayed occurrence.14,
15,19

According to a previous study among NPC patients, late LCNP was reported 12 months

to 240 months after radiation treatment.19 Therefore, there is need for long-term surveillance
of late LCNP among HNC and OPC patients.14, 15, 19
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Previous studies have suggested that, malignant tumor invasion may cause upper
cranial nerve neuropathy, whereas radiation associated injury is more likely to cause lower
cranial nerves neuropathy (LCNP).20 Therefore, competing causes of nerve palsy, like second
primary, recurrent, and metastatic tumors need to be assessed, and such patients need to be
excluded, in order to identify patients with treatment-associated late LCNP.

Mechanism of Nerve Injury
Radiation injury to cranial nerves can be acute; days after exposure to radiation or
late; which occurs months and years after exposure to radiation. 21 Acute radiation injury is
rare with standard fractionation RT treatment among HNC patients, and late radiation
toxicity is more commonly reported. According to previous literature, different theories
postulate that, late LCNP can be caused by peripheral nerve and brainstem injury. 15, 21-23

Peripheral Nerve Injury Theory
Peripheral nerves including cranial nerves and spinal nerves are considered to be
relatively resistant to radiation injury.15, 21-23 Literature suggests however, that radiotherapy
may contribute to peripheral nerve injury by axonal degeneration, suppression of Schwann
cell proliferation, and fibrosis of connective tissues. 15, 21-24
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Axonal Degeneration
Radiotherapy (RT) can cause cranial nerve injury directly by axonal
degeneration.24This axonal injury may contribute to local demyelination, membrane
instability or vascular endothelial injury which may lead to ischemia, fibrosis, secondary
neural injury, and eventually myokymia.21, 25
Myokymia is clinically observable continuous rippling or undulating involuntary
muscular movement, which can be mistaken for fasciculations and has been documented
among neuropathies with nerve compression or entrapment. 25, 26 Myokymia can occur in
some muscles innervated by cranial nerves and is often a clinical symptom of radiation
associated LCNP.15

Vascular Injury
Radiotherapy(RT) may contribute to cranial nerve injury indirectly by causing
vascular endothelial injury.21 Endothelial cells in capillaries are extremely radiation sensitive
and RT injury can cause thrombosis, obstruction, and capillary destruction.21 It has been
suggested that at standard fractionation schedule, RT dose of 50-60 Gy can cause arterial
damage.27 However capillary injury can occur at RT doses > 40 Gy.27 This vascular injury
can lead to ischemia and fibrosis of surrounding connective and soft tissues adjacent to
nerves.21,27 Thereby damage to blood vessels can contribute to axonal degeneration and
cranial nerve injury.15,21
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Fibrosis
It is postulated that connective tissue and soft tissue fibrosis may lead to nerve
compression injury or loss of vascular supply to the nerve sheath. 21,26,28 Tissue pressure due
to fibrosis, can cause blood supply interference or direct neural vascular damage, extensive
vascular sclerosis, and microvascular damage contributing to axonal degeneration leading to
fibrosis induced nerve infiltration, compression, and thereby nerve injury.15,17,24,27-29
According to a previous study among NPC patients, 12/19 (63%) patients with radiationrelated cranial nerve palsy reported fibrosis of neck muscles and other studies have supported
this association.17 The authors postulated, neck fibrosis may cause compression of cranial
nerves passing through the neck, leading to cranial nerve palsy. 17 This idea was supported by
the fact, that CN XII, CN X, and recurrent laryngeal nerve (branch of CN X) were most
frequently damaged in this study and these nerves pass through the anterior portion of the
neck, which receives substantial amounts of RT.17 Other studies have shown similar
results.30-32 Another study reported 6/7 NPC patients, treated with parapharyngeal radiation
boost developed CN XII palsy on the boosted side.33 Other studies have speculated that
neurovascular fibrosis in the parapharyngeal region and fibrosis of the retroparotid space may
contribute to neuropathy of CN IX, X, XI, XII though exact mechanism was not described.
15,16,32
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Schwann cell Depletion
Schwann cells play a prominent role in the peripheral nervous system. They provide
support to neurons, produce the myelin sheath around axons, and help in axon regeneration
and neuronal survival.34 RT toxicity of cells, can cause increased expression of vascular
endothelial growth factor (VEGF), which can contribute to enhanced permeability of blood
vessels.34 Consequently interstitial edema may occur, leading to fibroblast cell growth
causing axonal compression, which in combination with hypoxia may contribute to axonal
degeneration and subsequent Schwann cell proliferation. 34 This Schwann cell accumulation,
may lead to increased cellular expression of RT injury and contribute to their cell death
(leading to depletion of Schwann cell), which in turn may trigger myelin loss and additional
axonal degeneration.34 Thereby Schwann cell depletion, may contribute to loss of nerve
fibers, nerve cell injury and eventually impairment of peripheral nerves.34

Wallerian Degeneration
RT-induced peripheral nerve injury can also lead to Wallerian Degeneration, which
involves axonal skeleton breakdown distal to injury site. 21,34,35 Schwann cells reject the
myelin component of their plasma membrane leading to disintegration of the myelin sheath.35
This degenerated myelin contains myelin-associated glycoprotein, which further suppresses
regeneration of damaged axons.35 Wallerian Degeneration may also lead to initiation of
inflammatory mechanisms and it has been suggested that the release of pro-inflammatory
cytokines and growth factors, may mediate biological processes including inflammation and
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fibrosis, which can cause late radiation nerve damage.21,34,35Thereby this degenerative
process, has been reported after RT in some studies and may contribute to nerve impairment
in both the peripheral and the central nervous system. 11
It has also been suggested that if surgery or tumor invasion damages the vascular
supply of cranial nerves, they may become more susceptible to radiation injury. 21
In summary, RT may contribute to extensive injury and ischemia of nerves, causing
functional nerve impairment, and late LCNP.15, 17

Brainstem Injury Theory
A complementary theory suggests, that high RT dose to malignant lesions or RT
targets near the base of the skull or the bulbar region can lead to brain stem injury, which in
turn can cause lower cranial nerve dysfunction.21, 36 This theory is supported by
documentation of LCNP among NPC, which is close to the skull base and brain stem.23 It is
postulated that base of skull irradiation, can lead to a different combination of CN X, XI, and
XII palsies.23 This is especially relevant with IMRT, which may lead to unintended higher
RT dose to non-target regions, like the brainstem relative to older RT planning methods.
Radiation field overlap may contribute to formation of “hot-spots” and could cause
development of radiation associated late LCNP.23, 37
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Brainstem
The brainstem is located in the posterior cranial fossa and is an extremely important
sensitive region of the brain containing sensory and motor neural pathways, that connect the
brain with rest of the body.9, 21 It comprises of the midbrain, the pons, and the medulla
oblongata.21 It also contains the corticospinal tract, posterior column medial lemniscus
pathway, and the spinothalamic tract and numerous cranial nerve nuclei. 21
All the cranial nerves except CN III (oculomotor) and CN IV (trochlear), emerge
from their nuclei located within the tegmentum of the brainstem.9, 21The nuclei of CN IX, X,
XI, and XII are located in close proximity to each other in the medulla, whereas the nuclei of
CN V, VI, VII, and VIII are located in the pons.21 Thereby, it is postulated that high radiation
dose to brainstem, may cause injury to the cranial nerve roots and the nuclei. 21 This theory
may be supported by Bulbar palsy, which includes CN IX, X, XI, and XII dysfunction which
is suggested to be caused by brainstem lesions in cranial nerve nuclei or lower cranial nerve
injury outside of brainstem.38
It has also been suggested that, brainstem damage may depend on volume of
brainstem tissue being irradiated, during fractionated radiation treatment rather than
maximum radiation dose received.21 A previous study reported that, RT dose of 60, 53 and
50 Gy when 1/3, 2/3 and 3/3 of the brainstem is irradiated at a fractionation of 2Gy/fraction
had a 5% brainstem injury risk after 5 years of RT exposure.39 Another study reported that,
total volume brainstem irradiation with a RT dose ≥ 65 Gy resulted in a 50% increased risk
of treatment related toxicity after 5 years post-RT.21 A multivariate analysis also revealed that
brainstem volume irradiated with > 60 Cobalt-Grey equivalent (CGE), was significantly
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associated with brainstem damage. In fact, if greater than 0.9cc of the brainstem was
irradiated with > 60 CGE, there was a significant increase in risk of brainstem injury. 21
It has also been suggested that, radiation associated risk of brainstem toxicity may
increase if targeted tumor is large, is in close proximity to the brainstem and radiation dose is
high.21 Further as cranial nerves are considered to be radiation resistant, it has been suggested
that RT dose of radiation to the brainstem may be a more influential factor leading to cranial
nerve injury.21Therefore, brainstem injury due to cancer treatment, may be a potential risk
factor for late LCNP and needs to be investigated in future prospective studies. 15, 21

Neuromuscular Junction and Muscle Contraction
Neural transmission of signals from the nerve to the muscle occurs at the
neuromuscular junction, which is initiated by the conduction of action potential to the axon
terminal.21, 40This leads to its depolarization, which enables the opening of voltage-dependent
calcium channels, to allow influx of Calcium ions into the axon terminal. These ions trigger
the release of neurotransmitter Acetylcholine (ACh) into the synaptic cleft. ACh in turn binds
to Nicotinic Acetycholine receptors located in post-synaptic membrane, leading to opening of
ion channels to enable sodium ion influx into muscle cell. This produces a muscle action
potential, which is transmitted by a chain of processes including, depolarization of
sarcolemma, excitation-contraction coupling and leads to myofibril contraction and
eventually target muscle contraction.21, 40 Muscle contraction and relaxation, is thereby
regulated by neural input from the cranial nerves.21,40 Therefore, RT can also potentially
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cause damage to the neuromuscular junction and lead to treatment related toxicities like late
LCNP.

Potential Risk Factors of LCNP
According to previous literature, potential factors which may predispose patients to
treatment associated late LCNP include radiation dose, radiation field, radiation
fractionation, surgery, systemic therapy, and individual sensitivity to treatment. 15, 18

Radiation Dose
Radiation dose is most commonly suggested in literature as the chief predisposing
factor for late LCNP, but the contributing threshold dose is not known.15 According to a
study among NPC patients cranial neuropathy is rare, but has, typically been reported among
patients treated with daily RT dose of 180-200 centigrays per day, which is the current
standard fractionated dose for OPC.17 Cumulative radiation dose to nasopharynx >70Gy was
identified as a significant predictor for cranial neuropathy (RR = 1.961, p =0.009) and lower
cranial neuropathy (RR= 3.088, p < 0.001), as it could potentially lead to muscle fibrosis and
subsequent nerve toxicity.20 Similarly, a previous study of late LCNP reported a total
radiation dose of about 70 Gy and higher among 3 among OPC survivors with LCNP.15,14
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Regional Dose along Nerve Tracts: It has been suggested that the dose to regions-of interest
(ROI) in the RT field, containing nerve tracts may play a more pivotal role in late treatmentrelated toxicity than total RT dose.41 The superior pharyngeal constrictor (SPC) region,
comprises of minor nerve tracts and the constrictor and longitudinal pharyngeal muscles,
which are important for pharyngeal shortening during swallowing for bolus propulsion into
the esophagus.41 A small retrospective case-control study of 38 OPC patients, reported that
mean SPC dose was significantly associated with cranial neuropathy and late radiation
associated dysphagia, controlling for T-stage and total RT dose.41 Majority (8/10) of LCNP
cases in the study, received a mean SPC dose of ≥ 70 Gy.41 The authors reported that a mean
threshold dose of 62 Gy to the SPC region can differentiate between OPC survivors with
LCNP versus those without LCNP. 41Mean SPC dose was also associated in numerous other
small clinical studies, with radiation associated dysphagia, use of feeding tubes during RT,
and oropharyngeal swallowing efficiency after chemoradiation.42-44 Thereby it has been
suggested that high mean SPC dose may have a detrimental impact on swallowing and
functional outcomes years after treatment, and can contribute to late toxic effects including
late LCNP among OPC survivors.41

Radiation Fields
HNC and OPC patients, may include irradiation fields comprised of healthy tissues,
lower cranial nerves, and pharyngeal mucosa, and ionizing RT treatment can cause nerve
injury, swallowing toxicity and speech impairment.39,45 Thereby RT field may be a
predisposing factor for late LCNP.15,39,45 Among NPC patients, incorporation of facial-
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cervical RT fields was suggested to be associated with lower radiation associated cranial
neuropathy incidence and longer latency in comparison to use of facial-cervical split
fields.16,46 Further overlap of radiation fields during IMRT treatment may lead to
development of “hot spots” as described earlier, and may contribute to late LCNP. 15, 23 Some
studies have documented a higher risk of LCNP among patients, who receive irradiation
involving the carotid sheath, the parapharyngeal space and large subdigastric and
retropharyngeal lymph nodes.15 It has also been suggested that CN XII injury only and CN X
injury only, may be due to RT toxicity to submandibular space and carotid sheath
respectively. 23

Path of Lower Cranial Nerves and Nerve Injury: Path of lower cranial nerves in the head
and neck region, may make them more susceptible to injury. NPC and OPC tumors may
cause compression of lower cranial nerves in the suprahyoid neck.42 NPC tumors can also
affect the carotid space and compress CN XII as it exits the Hypoglossal canal, and thereby
affect CN IX to CN XI as they pass through the jugular foramen.42 RT dose of ≥ 70Gy to the
carotid sheath, may result in lower cranial nerve injury, as CN XII passes through this region
to innervate the hyoglossus muscle and the tongue.18, 28 It is postulated that, proximity of CN
XII to the base of the tongue, which receives high RT dose, as well pressure from laryngeal
airway masks can lead to fibrosis, loss of vascularity, nerve entrapment, and damage.16, 43
Therefore LCNP among NPC patients can occur due to malignant tumor invasion, and at
lower doses of radiation treatment to the brain stem and oral cavity.28
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Chemotherapy
Chemotherapy drugs are cytotoxic as they can destroy cancer cells, and modify radio
sensitivity of cells either by, altering their cell-cycle phase or by interfering with repair of
radiation initiated double-strand DNA breaks.21 An earlier study among NPC patients,
reported that chemotherapy was significantly associated with development of cranial
neuropathy (RR=1.42, p=0.021).20 A clinical trial among stage III and stage IVB NPC
patients, revealed that late cranial neuropathy was significantly increased among patients
treated with RT and concurrent adjuvant chemotherapy (p=0.042) than those treated with RT
only.44 Similarly, in another study 6.3% of HNC patients, who received intra-arterial
Cisplatin therapy developed cranial neuropathy shortly after treatment.42 This is not a
standard procedure for cisplatin administration, and other studies have not reported similar
associations.42 Chemoradiotherapy, is standard multi-modality treatment for stage III-IV
HNC and OPC, but combined effects of RT and chemotherapy may contribute to increased
treatment-related toxicity. Therefor future studies need to assess chemotherapy, as a predictor
of late LCNP among HNC and OPC survivors.

Fractionation Schedule
Radiation dose fraction may also influence late LCNP. It has been suggested that
among NPC patients, if fractionation dose is increased from 180cGy to 420 cGy there may be
an increased risk of cranial nerve toxicity.17 A previous study among NPC patients, reported
that RT fractionation schedule was a significant predictor of upper cranial nerve neuropathy
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and not significantly associated lower cranial nerve neuropathy. 20 The authors suggested that
the lack of significant association between lower cranial nerve neuropathy and RT
fractionation schedule, maybe due to lower cranial nerves being more affected by fibrosis. 20
An earlier randomized trial among NPC patients, reported that accelerated hyperfractionation radiation treatment, was associated with higher late LCNP incidence than
conventional fractionation (13.0% vs 8.7%) over a median follow-up of 59.2
months.33,47Therefore, fractionation schedule of RT needs to be assessed in future studies, as
a predisposing factor for LCNP among OPC survivors.

Surgical Treatment
Surgical treatment along the course of cranial nerves may cause nerve damage and
contribute to late LCNP. It has been suggested that, if surgery causes damage to vascular
supply of cranial nerves, they may become more susceptible to radiation injury.21 Also
depending on the operating field, isolated cranial nerve palsy or multiple cranial nerve injury
may occur.42 Further, if surgery involves the sublingual region, hypoglossal nerve injury may
occur.35 Neck Dissection has also been documented to lead to paralysis of CN VII, CN X,
CN XI, and CN XII.33 Reports suggest CN XI paralysis is most common treatment related
toxicity related to radical neck dissection with an incidence of about 62%. 34, 35
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Genetic Susceptibility
A previous study postulated that individual sensitivity possibly due to genetic
susceptibility, may contribute to CN XII palsy among NPC patients treated with standard RT
dose of 66 Gy.28The authors supported their idea by reporting that 4/14 patients in the study,
with radiation-related neuropathy did not receive high dose of radiation. 28 In another
retrospective study among 130 OPC patients, ERCC4 T2505C polymorphism was suggested
to be associated with enhanced recovery from toxicity due to radiation treatment.49 ERCC4 is
a gene which plays a role in repairing cell damage, due to ionizing effects of radiation. 48 This
gene, is involved in recognition of site of injury, recombination repair, and mismatch
repair.48 ERCC4 T2505C polymorphism is reported with a allele frequency of about 36% and
was associated with lower risk of long term feeding tube placement (OR=0.2; 95%
confidence interval, 0.06-0.67) controlling for age, chemotherapy, T and N stage.48 Other
reports have suggested a positive association between genetic markers and risk of radiation
related tissue toxicity, and future genetic studies are needed to explore this association.
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In summary, earlier studies have suggested that radiation dose, radiation field,
radiation fractionation, surgery, systemic therapy, and individual sensitivity to treatment may
influence risk of late LCNP among NPC patients.7 Thereby these variables were assessed in
our study and investigated as potential predictors of late LCNP among OPC survivors.
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Latency Period for Cranial Neuropathy
A previous study among 59 OPC survivors by Hutcheson et al., reported a latency
period from time of RT treatment to presentation of late LCNP with a median of 5.7 years
and range of 4.6-7.6 years.15 An inverse relationship between the length of latency period
between radiation treatment and presentation of late LCNP symptoms and dose of treatment
has been suggested.16,20 This association has also been reported in clinical studies of injury of
brachial plexus and experimental animal studies. 23 It has been suggested that more precise
information about nerve palsy onset, may lead to a stronger association between latency
period and dose.23 Case reports have also suggested that, though there may be a substantial
delay in appearance late LCNP symptoms, but once nerve palsy occurs consequential decline
in functional status is progressive and rapid over subsequent months.15,25

Progression of late LCNP
Late LCNP is a progressive disease. An earlier prospective study among 3 OPC
survivors with LCNP, suggested that these patients could experience severe decline in
function overtime, as per patient reported MDADI scores.15 Long-term deterioration of
swallowing function was also noted using clinician rated modified barium swallow (MBS)
scores as per validated Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria,
as well as diet score rated on the Performance Status Scale of Head and Neck Cancer (PSSHN).15 An earlier study among NPC patients had reported a late LCNP cumulative incidence
of 5.7%, 17.4%, 27.1%, and 37.3% over a 5, 10, 15, and 20-year follow up respectively.20
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Therefore, the risk of cranial nerve damage increases overtime and as a late treatmentassociated toxicity, LCNP has long term implications on the functional status of survivors.
Further, as survival probabilities improve for OPC late-effects like neuropathy are more
likely to occur, and patients should be followed for extended periods of time to assess and
treat these late complications.

Late LCNP and Late Radiation-Associated Dysphagia (late RAD)
Late Radiation Associated Dysphagia (late RAD) is a severe form of dysphagia,
which occurs among HNC patients many years after RT. It may contribute to severe
problems in swallowing, eating, and extreme functional impairment in pharyngeal phase of
swallowing, which may cause swallowing inefficiency, pharyngeal residue, and silent
aspiration.19 Overtime about 85% of OPC survivors with late-RAD, develop pneumonia and
more than 60% of them required long-term gastronomy tube placement.19, 41
OPC patients in recent times tend to be middle-aged and are expected to survive
decades after treatment, thereby it is more likely that these patients may develop late
toxicities like late RAD.1, 19This idea is supported by findings from a recent study, which
reported that that 86% patients with late-RAD were OPC survivors.19
The prevalence of Late RAD is low with an estimated rate of 12%.19, 22 However as
majority of OPC patients survive and eventually transition from oncologic management to
care of primary care physicians, they may be lost to follow-up. Therefore, lack of adequate
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surveillance may contribute to lower prevalence estimates of late toxicities like late RAD and
even late LCNP.
Patients with late RAD also often present with lower cranial neuropathies. 19 It is
postulated that LCNP potentially leads to the accelerated functional decline among patients
with late RAD.19 Late RAD patients often have unilateral paralysis, muscle wasting leading
up to atrophy of lingual and pharyngeal musculature implicating a prominent role of nerve
injury in the functional decline experienced by these patients.47 In an earlier case series 48%
of patients with late RAD had clinically-detectable cranial neuropathies, and cranial nerve
XII and X palsies were most commonly reported.48 Further, another study reported that 90%
of patients with late RAD displayed evidence of some evidence of loss of innervation to
suprahyoid muscles in the pharynx when tested by EMG.50
Bulbar Palsy along with neuromuscular fibrosis, is suggested to contribute to
functional impairment among late RAD patients. 19 A recent case report indicated that
treatment-related LCNP may play a major role in late RAD, and precipitate delayed but
extreme chronic oropharyngeal impairment and increased pharyngeal impairment, as
recorded by modified barium swallow (MBS) studies.14 It was reported that Late LCNP
patients with late-RAD, experienced deterioration of diet and speech scores, as reflected by
Performance Status Scale for Head and Neck cancer (PSS-HN) scores.14 They reported low
scores with MD Anderson Dysphagia Inventory (MDADI), which reflected overall
impairment of swallowing related quality of life.14 Further, the functional status of cases
emulated the trajectory of neuropathy experienced by patient i.e. if the late LCNP remained
stable, physiologic impairment experienced by patient remained steady and if the late LCNP
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was progressive then patient experienced severe decline in function, and decline in body
weight.14 Most importantly late-RAD patients including those with late LCNP, do not
typically respond well to treatment and experience excess disease morbidity and functional
impairment overtime.14, 41
Late LCNP may have a significant impact on dysphagia experienced by OPC
survivors, many years after treatment and cause extensive functional impairment and result in
poor swallowing related QOL. The functional impact of late LCNP has not been studied in a
study with substantial numbers of OPC survivors and given that it is an area of concern
among late LCNP patients, we investigated the impact of late LCNP on dysphagia and
swallowing related QOL among OPC survivors.
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Gap in Knowledge/Unmet Need: Previous studies examining late radiation-associated
LCNP have mostly been case reports of nasopharyngeal cancer survivors. Few studies have
addressed late LCNP among OPC survivors, the largest to date comprising only 3 late LCNP
cases in a cohort of 59 OPC survivors.15With a rapidly growing pool of OPC survivors who
have received curative doses of radiotherapy, there is urgent need to investigate this disabling
late effect of therapy. Late LCNP is a debilitating, permanent condition, and can have a
profound impact on QOL of OPC survivors yet we know little to predict or understand the
continuum of associated toxicities.14 For the growing numbers of OPC survivors at risk for
and experiencing late LCNP, needed to identify risk profiles of those most vulnerable to late
LCNP and subsequent late effects to help in the development of more targeted preventive
strategies and interventions.
The overall objective of this research plan was to characterize risk and burden of late
LCNP among OPC survivors.
This research is expected to contribute to a comprehensive understanding about late LCNP in
terms of incidence, predictors of risk, and impact on functional outcomes including
swallowing-related QOL, symptom burden, and functional impairment and among OPC
survivors.
The contribution of the proposed research will be significant because once we identify
predictors of late LCNP and associated late toxicities; we can identify high-risk populations
who are most vulnerable for future implementation of targeted preventive interventions to
alleviate late effects of cancer treatment among OPC survivors. Also, our study may provide
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support for recommendations for ongoing surveillance of late-toxicities experienced by OPC
survivors to promote timely treatment of side-effects.
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Public Health Significance
This research will support future research of late effects experienced by OPC
survivors by providing information about late LCNP which has not been previously studied
among a large cohort of more than 2,000 OPC survivors and its impact on morbidity and
decline in function among these patients. Late LCNP experienced by OPC survivors may
lead to placement of feeding tubes, tracheostomy tubes, and aspiration which can lead to
pneumonia. Therefore, patients may be hospitalized and such adverse consequences lead to
increase in medical costs.
The results from this study have the potential to inform the development and
implementation of ongoing surveillance, risk-reduction, and preventive interventions which
could be implemented early and be personalized to meet individual needs to allow for more
strategic allocation of resources and lower health care cost.
OPC patients have excellent prognosis in terms of survival therefore de-escalation of
treatment may be a viable option to reduce treatment-associated late toxicities like LCNP.
Risk-based OPC treatment planning, use of targeted therapies, nerve-sparing RT planning to
decrease irradiation of vital structures which play an important role in swallowing, or
sequential chemoradiotherapy may help to alleviate late effects like LCNP and improve
function among survivors. Knowledge about predictors of late LCNP and its consequent
impact on swallowing function and overall symptom severity will allow more effective
delineation of de-escalation targets.
Among NPC patients, neuro-nutritional agents, glucocorticoids, and hyperbaric
oxygen can be administered early to alleviate functional symptoms and prevent progression
of nerve damage and such treatment, if viable, might be suggested to OPC patients with late
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LCNP.44 Further, as among NPC patients, laryngoplasty, tracheostomy, and gastrostomy tube
placement may help manage voice hoarseness, respiratory function, and maintain adequate
nutritional intake and thereby have the potential to improve QOL in such patients. 19 Similar
options can be explored for OPC patients and more informed treatment decisions can be
made with better understanding of the continuum of late LCNP and its associated functional
implications.
The study identified predictors of LCNP, which can inform future research in terms
of reducing treatment exposure. Currently, treatment of OPC does not vary by HPV status
and this study has the potential to inform future clinical trials investigating de-escalation of
OPC treatment based on HPV status. Further, this study has the potential to inform future
screening and surveillance recommendations among OPC survivors, given the delayed
progression of late LCNP. As neuropathies may be experienced among patients with other
head and neck cancers, findings from this study may be extrapolated to inform survivorship
research for such patients. The study will thereby address tertiary cancer prevention among
OPC patients and help alleviate disease morbidity experienced by OPC patients over time.
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SPECIFIC AIMS
The incidence of oropharygeal cancer (OPC) is increasing by 5% each year and it is
projected that by 2030 about half of head and neck cancers (HNC) will be OPC.1This
phenomenon is attributable to the to the epidemic of HPV-associated OPC which is usually
diagnosed in patients who are middle aged, and despite advanced-stage have biologically
favorable disease with excellent prognosis for long-term survival. Survivors may experience
severe side-effects over-time due to cancer treatment and thereby experience excess
morbidity and disability compared to other cancer survivors. It has been estimated that 20%50% HNC survivors experience disability from treatment toxicities and are unable to work. 2-5
Late lower cranial neuropathies (LCNP) are a rare, but potentially severe late effect induced
by damage due to radiotherapy (RT). Fibrosis of nerve tracts or adjacent soft tissues may lead
to delayed but progressive neuro-vascular damage and eventually neuropathy which over
time causes profound functional impairments.16 According to a recent report, the incidence of
delayed LCNP among 59 OPC survivors was 5% at 5.7years (Hutcheson, et al).15 While a
rare late effect, case reports suggest substantial functional burden including profound
impairment in swallowing, speech, voice and shoulder function and overall low quality of
life in survivors who develop LCNP.14-16,19

Gap in Knowledge/Unmet Need: Previous studies examining late radiation-associated
LCNP have been case reports or small cohorts of predominantly nasopharyngeal cancer
(NPC) survivors. Few studies have addressed late LCNP among OPC survivors. With an
ever-growing pool of OPC survivors who have received curative doses of radiotherapy likely
sufficient to induce LCNP, there is urgent need to investigate this disabling late effect of
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therapy. Late LCNP is a permanent condition and may have a profound impact on quality of
life (QoL) of OPC survivors yet we know little to predict or understand the continuum of
associated toxicities.14-16 For the growing numbers of OPC survivors at risk for and
experiencing LCNP, we must identify risk profiles of those most vulnerable to LCNP and
subsequent late effects to help in the development of more targeted preventive strategies and
interventions.

Objective: The overall objective of this application was to characterize risk and burden of
late LCNP among OPC survivors.

Central Hypothesis: Our central hypothesis was that OPC survivors with late LCNP will
experience higher levels of functional burden and symptom burden that impact their quality
of life (QoL) relative to survivors without LCNP, and that significant predictors of late
LCNP can be identified in this study to help target the high-risk populations for risk
reduction strategies.

Rationale: The rationale for this research was that once we identify predictors of late LCNP
and associated burden, we can identify high-risk populations who are most vulnerable for
future implementation of targeted risk reduction strategies to alleviate late effects of cancer
treatment and improve QoL among OPC survivors.
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Our study population comprised a cohort of disease-free OPC survivors diagnosed and
treated at MD Anderson Cancer Center, January 2000 -December 2013 with a nested crosssectional survivorship survey.

Specific aims:
Aim1: To estimate the risk of late lower cranial neuropathies (LCNP) in patients with
oropharyngeal cancer (OPC) and identify clinical predictors for late LCNP.
Aim 1(a): To estimate the cumulative incidence of late LCNP among OPC survivors.
Hypothesis: Based on preliminary data, we expected the 5-year incidence rate of late LCNP
will be estimated at 5%.
Aim 1(b): To identify clinical predictors for late LCNP among OPC survivors.
Hypothesis for Aim 1(b): We hypothesized that risk of LCNP, will be correlated with
tumor subsite and stage, radiation dose, fractionation schedule, smoking status, and systemic
therapy.

AIM 2: To compare severity of treatment related symptoms and swallowing-related
QoL by LCNP status among oropharyngeal cancer (OPC) survivors.
AIM 2(a): To compare the severity of treatment-related symptoms and subsequent
impact on General Functional Impairment (GFI), by LCNP status among
oropharyngeal cancer (OPC) survivors.
We assessed the impact of late LCNP on severity of treatment-related symptoms and general
functional impairment using the MD Anderson Symptom Inventory Head and Neck Cancer
Module (MDASI-HN) survey after end of cancer treatment.
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Hypothesis: We hypothesized that LCNP status among OPC survivors, will be associated
with higher symptom scores (per mean of top 5 most severe core and head and neck specific
scores on MDASI-HN survey) and significantly higher levels of GFI (per mean interference
scores on MDASI-HN survey) than those without LCNP.
AIM 2(b): To compare swallowing-related QoL by LCNP status among oropharyngeal
cancer (OPC) survivors.
Impact of late LCNP on swallowing-related QOL was assessed using the MD Anderson
Dysphagia Inventory (MDADI) survey after end of cancer treatment.
Hypothesis for Aim 2(a): We hypothesized that LCNP status among OPC survivors will be
associated with significantly worse swallowing-related QOL (per MDADI survey) than those
without LCNP.

Expected Outcomes:
It was anticipated that the aims will yield a comprehensive understanding about late LCNP in
terms of incidence, predictors of risk and impact on functional outcomes, symptom burden,
functional impairment and QOL among OPC survivors. We hope to inform the development
of effective risk reduction and management strategies for this rare but devastating late effect
of therapy.
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Figure 1: Overall Late LCNP Risk & Burden Study Aims

Figure 1: Overall Late LCNP Risk & Burden Study Aims.
OPC – Oropharyngeal Cancer, LCNP – Lower Cranial Neuropathy, MDADI – MD Anderson
Dysphagia Inventory, MDASI-HN - MD Anderson Symptom Inventory for Head and Neck Cancers
(MDASI-HN)
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GENERAL STUDY METHODOLOGY FOR SPECIFIC AIM 1 AND 2
Definition of Late LCNP
Late LCNP was defined as swallowing-associated neuropathy of glossopharyngeal
(IX), vagus (X) and hypoglossal (XII) nerves, which are critical to the oropharyngeal phase
of swallowing mechanism and speech production. The degeneration of these nerves
potentially results in substantial amounts of dysphagia and functional impairment, based on
case report evidence (Hutcheson, et al).14-16,18,19 CN XI or Accessory Nerve palsy was rare
and reports suggested that it occurs less frequently than CN X and CN XII palsy. It has been
suggested that this may be due to the course of CN XI, in the posterior part of the neck,
which may not receive as much radiation as the anterior part. Further, this nerve may also be
protected from radiation damage by the cervical nerve. 28 CN XI palsy was also
inconsistently recorded in medical charts. Thereby, CN XI was omitted from LNCP analysis
in this research, with the intent to focus on swallowing-associated LCNP.

Late effects of cancer treatment are often defined as severe treatment associated toxicities
which occur 3 months or more after end of cancer treatment. 51
Therefore, late LCNP due to treatment in our study was assessed 3 months or more after
the end of cancer treatment to focus on late effects of therapy as opposed to neuropathy
which may be tumor associated or an acute effect of treatment.
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Descriptive Analysis Methodology: Descriptive statistics (e.g., means, ranges, standard
deviations) and graphical methods (box-plots, histograms and scatter plots) were computed to
explore relationship between variables of interest. Normality of continuous variables was
tested, when normality assumption was met independent T-tests otherwise, Wilcoxon rank‐
sum test or Kruskal Wallis test was used to test for differences between groups. For
categorical variables, contingency tables, chi-square (X2) test and Fisher’s exact test were
used.

Clinically important covariates: included age, t-stage, subsite, treatment modality and
smoking.

HPV Status: HPV status was not available in about half of the cohort, as HPV testing was
not conducted consistently till 2007. But we classified patients as HPV – and HPV + based
on test results. Only exploratory analysis of HPV status was conducted; therefore, HPV
status information was not taken into consideration for our power analysis estimates.
Analysis Software: Data was be analyzed using the statistical software package Stata and
SAS.
Hypothesis Testing: All reported p-values were two-sided and were considered to be
statistically significant at p value of < 0.05.
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Human Subjects
This dissertation research was a secondary analysis of existing oropharyngeal cancer
data. Informed consents were signed by participants prior to participating in the crosssectional patient reported outcome survey and in the tumor registry data. There were no
benefits or risks for study participants in the conduct of the study. Only adults at least 18
years of age were recruited for this study and children were excluded.

Personal identifiers were used by selected study personnel for data abstraction and all
study personnel participated in institution approved human subjects training course.
Abstracted data was stored on a study database and access to database was protected by
passwords. Survey forms were stored in locked cabinets and on a password protected
database. Only de-identified data was used for analysis and was stored on encrypted
institution approved computers and devices.
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METHODS
Research and Methods for Specific Aim 1(a) & 1(b): Cumulative Incidence & Risk
Prediction

Study Design
This study was a retrospective cohort study.

Study population
This study included oropharyngeal cancer (OPC) patients diagnosed and treated at MD
Anderson Cancer Center, January 2000 - December 2013.

Exclusion criteria
1. Patients who were deceased, had a secondary primary malignancy (SPM) or recurrent
malignancy of the head and neck before 3 months of follow-up after end of cancer
treatment.
2. Patients diagnosed with LCNP before starting cancer treatment i.e. LCNP at baseline
or before treatment.
3. Patients who received cancer treatment with palliative intent.
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Research and Methods for Specific Aim 1(a) Cumulative Incidence
Data Collection
Primary Outcome Variable: The primary outcome variable for this aim is late LCNP
among all eligible OPC survivors in our study population.

Diagnosis of Lower Cranial Neuropathy (LCNP): LCNP status among patients was
assessed by clinical examination of cranial nerves by head and neck surgeon, radiation
oncologist and speech pathologist and is recorded in the charts of patients.

Data Abstraction from Medical Records: Medical records were reviewed to identify cases
of LCNP. Case status was verified by head and neck specialized physician review. Time to
event of LCNP diagnosis was also be collected.
.
Variables: Demographic, clinical information, treatment related factors, health behaviors
and HPV status were abstracted from medical charts using a structured study forms.
Demographic Variables: included age, sex, race and education.
Clinical Variables: included T and N staging, sub-site, OPC treatment modality, RT dose,
mode of RT, RT fractionation schedule, chemotherapy, surgery, lack of solid food diet at
baseline (as a surrogate of baseline dysphagia), and smoking status.
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Power Analysis
The power analysis of this aim addressed the precision of our cumulative incidence
estimate, by calculating 95% confidence intervals using late LCNP event rates between a
range of 0.02 – 0.10. An earlier study among 59 OPC survivors, treated on clinical trials at
MDACC by Hutcheson et al has suggested a LCNP cumulative incidence of 2.1% at 6-year
follow-up of (95% CI: 0.2%,10%) which suggests our assumption to detect a 5- year
incidence of LCNP of 5% is reasonable.7
On the basis of tumor registry estimates, assuming that 95% OPC patients are alive at
3 months such that late LCNP outcome can be assessed among these patients, as well as loss
to follow-up and missing data rate of 20%, 52 we will have a sample size of 2683.
About half of our cohort has missing information for HPV status. As we did not believe HPV
status influences risk of late LCNP, only exploratory analysis of HPV status was conducted
in our study and was not be the focus of any of our power analysis estimates.
We used the following formula to calculate the 95% confidence interval of our cumulative
incidence estimates of 0.02-0.10.
Formula of 95% Confidence Interval for Incidence Proportion
95%CI = P ± 1.96 √ (P (1-P) / N)
Where P= incidence proportion and N= sample size

41

Confidence Interval and Precision of Estimate of Incidence N= 2683
LCNP Event
Rate

95% Lower
Bound CI

95% Upper
Bound CI

0.02

.015

.025

0.03

.023

.036

00.04

.032

.047

0.05

.042

.058

0.06

.051

.069

0.07

.061

.079

0.08

.070

.090

0.09

.080

.101

0.10

.096

.104
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Literature Review, Research and Methods for Specific Aim 1 (b): Risk Prediction

Literature Review Specific Aim 1
Earlier studies have revealed that age, tumor subsite, tumor stage (T-stage) and pretreatment swallowing scores as per MDADI may have an impact on swallowing scores as per
MDADI overtime. 53-55Similarly another review among OPC patients treated with transoral
robotic surgery, also reported that pre-treatment swallowing function, T-stage, N-stage,
primary subsite involving base of tongue and adjuvant chemoradiation may predict
swallowing outcomes and toxicity.56

Treatment Intensity: HNC patients treated with non-surgical therapy had previously
reported, that treatment intensity as per patients treated with less <50 Gy had significantly
better swallowing scores on the MDADI, than those treated with higher RT dose or
chemoradiation (p< 0.001).57 Therefore patients treated more aggressively with greater
treatment intensity or combined modality, may be more likely to develop late toxicities like
late LCNP.

Swallowing scores prior to treatment: In a previous study, swallowing scores prior to
treatment explained 13% of the variance in long-term swallowing scores among HNC
patients.57 Therefore, patients not eating solid food at baseline (prior to treatment) may have
some pre-treatment swallowing dysfunction, which may be tumor-associated and may
eventually contribute to development of late LCNP overtime.
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Tumor Stage (T-Stage): OPC patients withT1 and T2 tumors, have reported significantly
better swallowing scores as per MDADI (+15.9, p=0.0001 and + 10.9, p=0.0049
respectively) than patients with T4 tumors.53 This may be due more aggressive treatment of
advanced OPC tumors, which may have a detrimental impact on long term toxicities like late
LCNP and late-RAD.

Smoking: Current smokers have also reported significantly worse swallowing scores as per
MDADI (- 9.4 points, p=0.0007) compared to nonsmokers.53 Further smoking can lead to
worse functional outcomes and inferior prognosis overtime, for both HPV positive as well as
negative disease.53 Smokers therefore may experience greater disease morbidity and late
treatment -related toxicities like late LCNP.

Age: An earlier study reported that younger HNC patients reported worse swallowing scores
overtime.57 This may be due to higher expectations of younger patients to resume work and
daily activities after treatment, which when unmet lead to greater dissatisfaction and higher
disease burden. Given the long latency period for late LCNP, these patients may eventually
develop late toxicities like late LCNP.

Survival Time: Further long-term survival of OPC patients, may also contribute to higher
chances of them developing late LCNP. Survival time will refer to difference between time
of diagnosis and time of last follow-up.
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In summary, age, T and N staging, sub-site, pre-treatment swallowing dysfunction,
smoking and survival time may act as potential confounders, contributing to development of
late toxicities like late LCNP. These variables were evaluated and controlled for in our
analysis to obtain adjusted effect estimates for predictors of late LCNP in our study. 52, 54, 55, 57

Effect Modifiers: There was insufficient evidence in literature to suggest any specific effect
modifiers, and given that late LCNP was rare, we did not have enough power to explore
effect modification in this study. We however conducted exploratory analysis of biologically
plausible interaction terms between treatment variables including RT dose, age, survival time
and smoking.

Research and Methods

Study Design: Same as Aim 1 a

Study population: Same as Aim 1 a

Exclusion criteria: Same as Aim 1 a

Data Collection
Primary Outcome Variable: Same as Aim 1 a. The primary outcome variable for this aim
was late LCNP, among all OPC survivors in our study population.
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Definition of Late LCNP: Same as Aim 1 and Aim 2
Diagnosis of Lower Cranial Neuropathy (LCNP): Same as Aim 1 a
Primary Exposure: Radiation therapy (RT) was the exposure of interest for this aim, as
most OPC patients receive either RT alone or in combination with systemic therapy and
exposure to surgery alone or surgery in combination to adjuvant therapy is rare. RT dose
which has been suggested by the literature as one of the main predictors of LCNP was the
primary exposure for this aim.14-16

Predictors
RT dose, mode of RT, RT fractionation schedule, chemotherapy, surgery, eating solid food at
baseline and smoking are some of the variables based on literature review which may
influence risk of late LCNP and may act as predictors along with our main predictor RT
dose.15,17,18,42,46 Thereby these variables were assessed in our proposed study and investigated
as potential predictors of late LCNP among OPC survivors.

Covariates
Demographic, clinical information, treatment related factors, health behaviors and HPV
status were abstracted in Aim 1 a.
Demographic covariates included age, sex, gender, race and education.
Clinical covariates included T stage, sub-site, treatment modality, RT dose, mode of RT, RT
fractionation schedule, chemotherapy, surgery, lack of solid food diet at baseline and
smoking
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Survival Time was defined as the number of years a patient survives after diagnosis.

Power Analysis
The power analysis of this aim addressed the specific hypothesis that risk of LCNP,
would be correlated with tumor subsite and stage, radiation dose, fractionation schedule,
smoking status, and chemotherapy. A previous study revealed that the event rate of late
LCNP among 59 OPC survivors was 5%.15
We assumed reasonable tumor regression rates and that 95% OPC patients are alive at
3 months, so late LCNP outcome could be assessed among these patients. We also assumed a
loss to follow-up and missing data rate of 20%, 52 therefore we would have a sample size of
2683. Assumptions derived from unpublished pilot data (PA11-0809, PI: Hutcheson),
included a standard deviation for radiation dose of 2.59.
A previous study conducted among NPC survivors reported that total radiation dose
to nasopharynx above 70Gy may be a significant predictor for cranial neuropathy (RR =
1.961, p =0.009) and lower cranial neuropathy (RR= 3.088, p < 0.001).20 Given the low event
rate of late LCNP, retrospective study design, loss to follow-up, and possibility of missing
data we assumed we would find a small effect size of 1.4 according to Cohen’s conventions
for small effects. Therefore, assuming hazard ratios for late LCNP a range of 1.1 – 1.4 we
calculated the power for this aim.
As per the reasons stated above we also assumed that the R square or the variation in
our primary predictor RT dose explained by the 13 predictors in the cox model would range
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from 0.2, 0.3 and 0.4. This would allow us to derive power calculations for this study
capturing a range of effect sizes which fit Cohen’s conventions for medium and large effect
sizes for multiple R square which was a plausible assumption for this model.
Proc Power in SAS with assumptions mentioned above was used for the power calculations
and are listed in the table below.
R-square

Hazard Ratio

Power

0.2
0.2
0.3
0.3
0.4
0.4

1.1
1.2
1.1
1.2
1.1
1.2

0.725
0.998
0.667
0.996
0.601
0.988

Therefore, we observed that at a modest assumption of R-square of the important
covariates explaining only 20% of the variation in radiation dose, assuming late LCNP event
rate of 5%, loss to follow-up and missing data rate of 20%, standard deviation of radiation
dose of 2.59, hazard ratio range of 1.1 – 1.4 with a R-square range of 0.2 – 0.4 with n=2683,
we would have 99% power to detect a reasonable hazard ratio of 1.2 for radiation dose and
late LCNP
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Research and Methods for Specific Aim 2 (a) & (b): Symptom Burden & Functional
Burden

Study Design
This study was a cross-sectional survivorship study.

Study population for Aim 2
This study will include a sub-cohort (907) of the population in Aim 1, who responded to a
cross-sectional survivorship survey that was conducted among OPC survivors treated at MD
Anderson Cancer Center during January 2000 -December 2013.

Key exclusion criteria
1. Patients who were deceased, had a secondary primary malignancy (SPM) or recurrent
malignancy of the head and neck preceding the survey administration
2. Patients lost to follow up or refused contact by MD Anderson prior to survey
administration
3. Patients whose primary spoken language is not English.
4. Patients diagnosed with LCNP or with clinical signs of LCNP before starting cancer
treatment i.e. LCNP at baseline.
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Survey Characteristics
Cross-sectional Survey: A cross-sectional patient reported outcome survey was
administered to OPC survivors in Fall, 2015, and included the following validated
instruments and study-specific items: MD Anderson Dysphagia Inventory (MDADI), MD
Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN), decisional
regret, and adapted patient-reported version of Performance Status Scale for Head and Neck
cancer (PSS-HN), EQ5D, and adapted NHANES terminology for head and neck specific
health problems (osteoradionecrosis, lymphedema, aspiration, thyroid problems, stricture of
throat or esophagus, pneumonia and hospitalization), as well items pertaining to feeding tube,
tracheostomy, smoking, and employment status .

MD Anderson Dysphagia Inventory (MDADI) is a validated patient reported outcomes
(PRO) survey, with 20 questions that quantify perceived limitations in swallowing ability of
OPC patients and their impact on day to day activities of these patients. 58 MDADI was
validated among HNC patients and has internal consistency scored by Cronbach’s alpha of
0.96 and was documented to have test-rest reliability correlations ranging from 0.69 to
0.88.58
The survey provides subscale scores which are comprised of emotional (based on 6
questions), physical (based on 8 questions), and functional scores (based on 5 questions). It
also estimates a global summary score (based on 1 question- “My swallowing limits my day
to day activities”) and composite score (based on 19 questions). The composite MDADI
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score is comprised of responses from 19 questions on the survey which are considered to
reflect overall swallowing related quality of life.54, 58-60

Scoring of MDADI: The questions related to swallowing function are Likert scaled with the
options strongly agree, agree, no opinion, disagree and strongly disagree, scored on a scale of
1-5, respectively, with the exception of two questions (E7 and F2) for which reverse scoring
is calculated. After summation of response scores, mean is estimated and multiplied by 20 to
estimate total score.54 Total scores range from 20-100 with higher scores reflecting higher
perceived swallowing-related QOL.54, 58-60We can use MDADI scores as continuous or
categorical variables. For categorical variables MDADI scores will be classified in the
following categories: ≥80 as optimal, 60-79 as adequate and < 60 as poor.53

MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN) is a
validated patient reported survey used to evaluate severity of cancer treatment related
symptoms and their subsequent impact on functional status, as well as day to day activities of
head and neck cancer patients. MDASI-HN comprises 28-items including 13 questions to
assess core symptoms common across all cancers, 9 questions to assess symptoms specific to
HNC like presence of mucus, swallowing problems, choking, voice problems, pain,
constipation, taste issues, presence of sores and oral problems. 61-64 The head and neck
specific items relate to common treatment related toxicity experienced by HNC patients due
to radiotherapy or chemoradiotherapy .62 Further, there are 6 interference questions to assess
the impact of symptoms experienced by patient on daily function with respect to “general
activity”, “walking”, “work”, “mood”, “relations with other people” and “enjoyment of life”.
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The internal consistency reliability for MDASI-HN has been estimated with Cronbach alpha
of 0.72 to 0.92.62

Scoring of MDASI-HN: MDASI-HN symptom severity items have a range from 0 to
indicate “not present” to 10 for “as bad as you can imagine” wherein lower scores on core
and site-specific domains indicate better function. Interference items also have a range from
0 to indicate “do not interfere” to 10 for “interfere completely” such that higher scores
indicate more limitations experienced by patients and indicate lower QOL.61-64 Mean
subscale scores for core, head and neck and interference domains can be estimated as mean
intensity of those specific domains. Mean global score is estimated as mean of scores of all
28 questions on the survey. 61-64
We can also use symptom and interference scores as categorical variable where scores will
be categorized as no symptoms (score=0), mild (1–3), moderate (4–6) and any one item rated
as severe (7–10) symptoms, as per Cleeland et al.64
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Literature Review, Research and Methods for Specific Aim 2 (a): Symptom Burden
We will assess the impact of late LCNP on symptom burden using the MD Anderson
Symptom Inventory Head and Neck Cancer Module (MDASI-HN) survey.
Literature Review

Symptom Burden
Symptom burden is a concept which incorporates severity of symptoms experienced
by patients and the impact of those symptoms on their day-today life.65 Symptom burden
thereby combines symptom severity and symptom interference (surrogate measure for
general functional impairment) reported by a substantial proportion of patients suffering from
a specific disease. Patients may experience symptoms due to disease, recurrence or as a
consequence of treatment related toxicity, which can be acute and occur during or
immediately after treatment.65 Patients can also suffer from late-toxicities such as late LCNP
many years after treatment completion, which can lead to high symptom burden among HNC
and OPC survivors. It has been suggested that a complex interplay between patient level,
cancer and treatment related factors may contribute symptom burden.66

Symptom Burden among HNC and OPC Survivors
HNC patients endure substantial symptom burden, as they often experience
debilitating symptoms which may compromise their physical appearance, swallowing,
speech, oral health and respiratory function.65, 67 HNC treatment may lead to multiple
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complications including mucositis, dry mouth, dysphagia, choking, speech problems, lack of
taste, pain and neurotoxicity among others which can contribute to excessive symptoms,
distress, and overall lower quality of life.68, 69
Patients may also experience fatigue, emotional distress, feel self-conscious, and have
low self-esteem which may contribute to feelings of social isolation. 76, 79 About 22-57%
HNC patients experience depression and symptoms of anxiety, indicating high levels of
psychological distress.70, 71 In fact, studies have even reported that HNC patients may have an
elevated risk for suicide (four times higher) than the general population.72
Thereby, symptoms of distress experienced by HNC patients may have a negative
impact on the physical and emotional domains of health-related QOL.73 Prospective cohort
studies among HNC survivors have reported health related quality of life (HRQOL) scores
(10 years post-diagnosis) to be significantly lower than their pre-treatment HRQOL
scores.83,84 The link between symptom burden and QOL is important, as studies among HNC
patients have reported that QOL domains can predict survival. 76-78 A systematic review
reported improved survival among HNC patients, with less psychosocial distress, high selfefficacy and physical function.79

Predictors of Symptom Severity
According to previous literature, age, sex, race, T-stage, tumor subsite, radiation dose,
fractionation schedule, induction chemotherapy, concurrent systemic therapy, timing of
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radiation treatment (definitive versus post-surgery or adjuvant) and smoking are some of the
variables associated with treatment associated toxicity and symptom burden.68,67
An earlier longitudinal study among HNC patients reported, that pre-treatment MDASI-HN
scores (coefficient = 0.55, p < 0.001), concurrent chemotherapy (coefficient = 18.77,
p=0.016), site of primary tumor (coefficient = 5.03, p=0.016) and definitive versus adjuvant
radiation treatment (coefficient = 15.01, p=0.044) in a multivariate model, were significantly
associated with MDASI-HN scores at week 5 of radiation treatment.
As most OPC survivors have long-term survival, minimizing severity of treatment
related symptoms, are a critical component of OPC treatment today. In our research study we
assessed the impact of late LCNP on severity of treatment related symptoms among OPC
survivors.

Severity of treatment related symptoms: for our study was defined as, severity of core
symptoms common across all cancers and symptoms specific to head and neck cancers and
would be correlated with functional impairment measured by MDASI-HN interference scores
experienced by survivors as a consequence of cancer treatment.

General Functional Impairment (GFI)
General Functional Impairment (GFI) is defined as diminished of ability of a survivor
to take care of himself or herself, manage the household, work, and indulge in activities for
relaxation. Thereby GFI can have an adverse impact on the daily lives of cancer survivors. 80
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OPC patients may endure severe treatment related symptoms (symptom severity) overtime,
which may have a detrimental impact on GFI and symptom interference scores. For some
patients, the impairment is temporary, and with time they return to their normal activity and
functional level. But a substantial number of OPC survivors continue to experience these
limitations, experience disability and may be unable to return to normal activities including
work leading to decline in income.80
There is need to understand the impact of long term GFI in the growing pool of OPC
survivors, as few studies in the past have investigated it and most of the literature related to
GFI is pertaining to its impact on employment.

According to a previous study about 32.9% and 41.9% of HNC patients experienced
unemployment and reduction in income respectively.80 Previous studies among HNC patients
report fatigue, pain, problems in speech, eating and facial appearance as reasons that
survivors do not return to normal activities including work.80 Likewise, advanced clinical
stage disease, alcohol exposure, and less education are some of the factors associated with
disability.89 Among HNC survivors, socioeconomic factors like education and income
particularly are associated with unemployment. 80 Therefore, GFI was a secondary outcome of
interest and impact of LCNP on GFI was assessed, using mean MDASI-HN scores from the
interference component.

Confounders
According to previous literature age, sex, race, T-stage, tumor subsite, radiation dose,
fractionation schedule, induction chemotherapy, concurrent systemic therapy, surgery, eating
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solid food at baseline, timing of radiation treatment (definitive versus post-surgery or
adjuvant) and smoking were some of the variables associated with treatment associated
toxicity and symptom burden.68,67
These variables may affect severity of treatment-related symptoms, MDASI-HN scores and
can act as potential confounders Therefore these variables along with patients eating solid
food at baseline (control for pre-treatment swallowing dysfunction) and survival time were
evaluated as confounders and controlled for in multivariate models, to estimate the adjusted
association between late LCNP and top 5 mean MDASI-HN and mean MDASI-HN
interference scores.

Effect Modifiers: There was insufficient evidence in literature to suggest any specific effect
modifiers, and given that late LCNP is rare we did not have enough power to explore effect
modification in this study; however, exploratory analysis of biologically plausible interaction
terms between treatment variables, age survival time and smoking were assessed.
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Research and Methods

Data Collection

Primary Outcome
Mean MDASI-HN symptom scores, which summarize information from all 22 items
of core and head and neck specific components, were described in association with late
LCNP to reflect overall symptom severity. We also identified a cluster of top 5 most severe
symptoms reported by OPC survivors, to identify most important core and head-neck
symptoms reported by this population. This methodology was supported by other symptom
research studies. Some symptoms may be more commonly reported by this population, be
more severe and may have a greater impact on the life of survivors, whereas others may be
rare. Thereby overall composite MDASI-HN scores may not be a true reflection of treatment
related symptom severity in this population.81, 82
Therefore, mean of Top 5 most severe core and head and neck specific symptoms reported,
by OPC survivors in this study was the primary outcome to reflect severity of most prevalent
treatment-related symptoms in this population.

Primary Exposure: Late LCNP among OPC survivors will be the primary exposure for this
aim. Late LCNP was assessed as described earlier. OPC survivors without late LCNP served
as the comparison group to test differences in MDASI-HN scores by late LCNP status.
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Variables
Covariates for this aim included:
Demographic variables – Age, Sex, Gender, Race, Education
Clinical variables - T and N staging, tumor sub-site, treatment modality, RT dose, mode of
RT, RT fractionation schedule, chemotherapy, surgery, patient eating solid food at baseline,
smoking and overall modality of treatment.
Survival time will be defined as the number of years a patient survives after diagnosis and
will be calculated as the difference between age at diagnosis of OPC and age at time of
survey

Secondary Outcomes for Aim 2b
GFI was a secondary outcome of interest, and impact of LCNP on impairment was
assessed using mean MDASI-HN scores from the interference component. Covariates for this
outcome as suggested by literature included age, education, race, education, T-stage, survival
time, alcohol consumption, marital status, BMI and co morbidity.89 Single item scores of the
top 5 most severe reported core and head and neck specific symptoms were also be assessed,
and associations of LCNP with these important symptoms were determined. We controlled
for the same covariates listed above for primary outcome.
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Power Analysis Aim 2 b
The power analysis of this aim addressed the specific hypothesis that among OPC
survivors with late LCNP, there would be higher symptom scores (per mean of top 5 most
severe core and head and neck specific scores on MDASI-HN survey) than those without late
LCNP. Multiple linear regression modelling this association would control for 13 variables
including age, sex, race, education, survival time, tumor subsite, T-stage, radiation dose,
radiation fractionation schedule, chemotherapy, surgery, smoking, and lack of solid food diet
prior to treatment.68, 67 We assumed a loss to follow-up and missing data rate of 20%52 for
our study, therefore we would have a study sample size of 726. Proc Power in SAS with
assumptions mentioned above testing for a two-sided test with α = 0.05 was used for the
power calculations.
Under a fixed effects model and a conservative assumption of R squared of full model
to be 0.10, we had 98% power to detect a R -squared difference for late LCNP as small as
0.02, which according to Cohen’s conventions for small, medium and large effects could be
classified as a small effect.
Study R square and Cohen’s Conventions for Small, Medium, and Large Effects
Cohen’s
Effects

Cohen’s
F2

Cohen’s
R2

Small

0.02

Medium
Large

R2 of full
model in
study

Power from
study

0.02

R2 for
main
predictor
LCNP
0.02

0.10

0.98

0.15

0.13

0.13

0.30

>0.99

0.35

0.26

0.26

0.30

>0.99
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Assumptions: Fixed effects model, Loss to follow-up and missing data rate of 20%48,
sample size n= 726, two-sided test with α = 0.05, main tested predictor late LCNP controlling
for 13 variables including age, sex, race, education, survival time, tumor subsite, T-stage,
radiation dose, radiation fractionation schedule, chemotherapy, surgery, smoking and lack of
solid food diet prior to treatment.

61

Literature Review, Research and Methods for Specific Aim 2 (b): Functional Burden
Literature Review

Dysphagia and Swallowing-related Quality of Life
Dysphagia is difficulty in swallowing and is most commonly reported functional
toxicity among OPC survivors.56,83 This toxicity may occur due to surgery, radiotherapy or
chemoradiation.56,83 Treatment intensification strategies among HNC in recent times have led
to enhanced locoregional control and survival.68 But these aggressive treatments may also
contribute to debilitating treatment related toxicities including dysphagia, which can have a
devastating impact on the life of HNC patients.84 About 30-50% HNC patients treated with
aggressive non-surgical treatments report dysphagia.85
Some patients may develop acute dysphagia which improves overtime, but others
may report chronic dysphagia with progressive deterioration.85 Dysphagia may occur also
occur many years after cancer treatment, as a late functional toxicity called late-RAD,
discussed earlier.19 A pooled analysis of 3 RTOG trials of concomitant chemoradiotherapy
reported that 35% of OPC survivors reported severe late laryngopharyngeal toxicity.86
Further, a study using SEER population level data reported 3-year prevalence estimates of
about 50% for dysphagia among OPC survivors.87
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Predictors of Dysphagia
A review among HNC patients reported that total RT dose, fractionation schedule,
combined treatment modality, subsite, primary tumor size, age and smoking may contribute
to acute and late dysphagia.84,85 Similarly, another systematic review among OPC patients,
reported pre-treatment swallowing function, T-stage, base of tongue tumors and adjuvant
chemoradiation as predictors of swallowing function.56
Dysphagia-aspiration-related structures (DARS) in the head and neck are vital for
swallowing function and RT dose to these structures may contribute to swallowing toxicity. 85
Literature suggests that delivery of RT dose to pharyngeal constrictors, suprahyoid muscles
and larynx is associated with chronic dysphagia.68 It is also suggested that RT dose > 50 Gy
to the pharyngeal region, may contribute to chronic dysphagia among OPC survivors. 68
Combined modality treatment, concomitant chemotherapy or targeted therapy, surgery after
radiation including DARS regions and smoking have also been reported to contribute to
worse swallowing and functional outcomes.85

Swallowing related Quality of Life
Given the rising numbers of OPC survivors, swallowing outcomes and speech play a
crucial role in quality of life among these survivors.88 Swallowing impairment among HNC
patients can lead to increased risk of impaired airway protection, pneumonia, swallowing
insufficiency, low food intake, extended gastrostomy tube dependence, weight loss and
malnutrition.88 Patients may have to modify their diet, need extended meal times, feel self-
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conscious to eat in social settings and thereby contribute to social isolation and diminished
QOL.88 Literature suggests that Dysphagia has high correlation with swallowing and Quality
of life outcomes over time.53
LCNP may have a significant impact on dysphagia experienced by OPC survivors,
many years after treatment and cause extensive functional impairment and result in poor
swallowing related QOL. The functional impact of LCNP has not been studied in a study
with substantial numbers of OPC survivors and given that it is an area of concern among
LCNP patients, we investigated the impact of late LCNP on dysphagia and swallowing
related QOL among OPC survivors.

Variables in Study
Survival Time: Long-term survival of OPC patients may contribute to higher chances of
them developing late toxicities including chronic dysphagia overtime, which may contribute
to lower swallowing-related QoL scores on MDADI. Earlier reports indicate that age, tumor
subsite, tumor stage, RT dose and MDADI scores prior to cancer treatment may predict
MDADI scores at specific time points and longitudinally overtime. 53,55,57 Another review
among OPC patients treated with transoral robotic surgery also reported that pre-treatment
swallowing function, T-stage, N-stage, primary subsite involving base of tongue and
adjuvant chemoradiation may predict swallowing outcomes and toxicity. 56 Additionally,
another study among OPC patients treated with bilateral intensity-modulated radiotherapy
(IMRT) with systemic therapy, on multivariate analysis revealed that older age; as per 5-year
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increase in age (OR= 1.25; 95% CI = 1.04-1.51), pre-treatment diet restriction (OR= 2.78;
95% CI = 1.31-5.88), total IMRT dose; as per 5 Gy increase (OR= 5.11; 95% CI = 1.7714.81) were significantly associated with increased risk of chronic dysphagia. 66

T-Stage: OPC patients withT1 and T2 tumors, have reported significantly better swallowing
scores as per MDADI (+15.9, p=0.0001 and + 10.9, p=0.0049 respectively) than patients
with T4 tumors.53 This may be due more aggressive treatment of advanced OPC tumors,
which may have a detrimental impact on long term toxicities like Dysphagia.

Treatment Intensity: HNC patients treated with non-surgical therapy, have reported that
treatment intensity i.e. patients treated with less <50 Gy had significantly better swallowing
scores as per MDADI, than those treated with higher RT dose or chemoradiation (p<
0.001).57

Combined modality treatment: Concomitant chemotherapy or targeted therapy and surgery
after radiation including DARS regions have been reported to contribute to worse swallowing
and functional outcomes.85

Reconstructive Surgery: Oral cancer and OPC patients who had reconstructive surgery for
primary tumors, have also reported significantly worse composite MDADI scores (58.8
versus 79.5, p < 0.01) compared to those who did not get treated with reconstructive
surgery.55
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Age: Oral cancer and OPC patients younger than 60 years have also reported significantly
worse physical (65.8 versus 78.4, p = 0.01) and emotional subscale (68.3 versus 82.0, p <
0.01) scores on the MDADI compared those patients older than 60 years. 55

OPC Subsite: OPC patients with base of tongue tumors have also reported significantly
worse functional subscale scores on MDADI in comparison to patients with oral cancer and
OPC patients with tonsillar tumors (66.7, 78.8 and 90.0 respectively, p<0.01). 55

Current smokers: Among OPC patients, current smokers have reported significantly worse
swallowing scores as per MDADI (- 9.4 points, p=0.0007) compared to nonsmokers.53
Further smoking can lead to worse functional outcomes and inferior prognosis overtime, for
both HPV positive as well as negative disease.53

Pretreatment Swallowing: Among HNC patients, earlier studies have reported that
swallowing scores prior to treatment explained 13% of the variance in long-term swallowing
scores. Patient’s not eating solid food at baseline i.e., before treatment, may have some pretreatment swallowing dysfunction, which may eventually contribute to long-term swallowing
impairment and dysphagia. 53, 55-57, 85

Thereby RT dose, Mode of RT, RT fractionation schedule, chemotherapy, surgery,
combined modality treatment, age, subsite, eating solid food at baseline, and smoking were
some of the variables that could affect swallowing outcomes and can act as confounders.53, 55-
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57, 85

They were evaluated as confounders and controlled for in multivariate models, to

estimate the adjusted association between late LCNP and composite MDADI scores.

Effect Modifiers: There was insufficient evidence in literature, to suggest any specific effect
modifiers and given that late LCNP is rare, we did not have enough power to explore effect
modification in this study. However exploratory analysis of biologically plausible interaction
terms between treatment variables, age survival time and smoking were assessed.

Research and Methods
Data Collection
Primary Outcome: The primary outcome for this aim was mean composite MDADI score
reported by OPC survivors and represents swallowing-related QOL. The composite MDADI
scores was calculated as mean of responses from emotional, physical and functional
components of the survey and will reflect overall swallowing related quality of life.54, 58-60

Primary Exposure: Late LCNP among OPC survivors was the primary exposure for this
aim, as the goal was to assess the impact of LCNP on swallowing toxicities reported by OPC
survivors. Late LCNP was assessed as described earlier. OPC survivors without late LCNP
served as the comparison group to test differences in MDADI scores by late LCNP status.
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Covariates
Covariates for this aim included;
Demographic Variables – Age, Sex, Gender, Race, Education
Clinical Variables - T and N staging, tumor sub-site, treatment modality, RT dose, mode of
RT, RT fractionation schedule, chemotherapy, surgery, patient eating solid food at baseline,
smoking
Survival Time was defined as the number of years a patient survives after diagnosis and was
calculated as the difference between age at diagnosis of OPC and age at time of survey.

Power Analysis
The power analysis of this aim, addressed the specific hypothesis that among OPC
survivors with late LCNP, there would be significantly worse swallowing-related QoL (per
MDADI survey) than those without late LCNP. Multiple Linear regression modelling this
association would control for 13 variables including age, sex, race, education, survival time,
tumor subsite, T-stage, radiation dose, radiation fractionation schedule, chemotherapy,
surgery, smoking and lack of solid food diet prior to treatment.53,55-57,85 We assumed a loss to
follow-up and missing data rate of 20%53 for our study therefore we would have a study
sample size of 726.Proc Power in SAS with assumptions mentioned above testing for a twosided test with α = 0.05 was used for the power calculations.
Under a fixed effects model and a conservative assumption of R squared of full model
to be 0.10, we would have 98% power to detect a R-squared difference for late LCNP as
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small as 0.02 which according to Cohen’s conventions for small, medium and large effects
could be classified as a small effect.
Cohen’s Conventions for Small, Medium, and Large Effects
Cohen’s
Effects

Cohen’s
F2

Cohen’s
R2

Small

0.02

Medium
Large

R2 of full
model in
study

Power from
study

0.02

R2 for
main
predictor
LCNP
0.02

0.10

0.98

0.15

0.13

0.13

0.30

>0.99

0.35

0.26

0.26

0.30

>0.99

Assumptions: Fixed effects model, Loss to follow-up and missing data rate of 20%48,
sample size n= 726, two-sided test with α = 0.05, main tested predictor late LCNP controlling
for 13 variables including age, sex, race, education, survival time, tumor subsite, T-stage,
radiation dose, radiation fractionation schedule, chemotherapy, surgery, smoking and lack of
solid food diet prior to treatment.
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Abstract
Background
Lower cranial neuropathy (LCNP) is a rare, but permanent, late effect of radiotherapy
(RT) and other cancer therapies. LCNP is associated with excess cancer-related symptoms,
worse swallowing-related quality of life (QoL) and long-term feeding tube dependence,
aspiration pneumonia, and tracheostomy. The overall objective of this paper is to quantify the
cumulative incidence of late LCNP and identify clinical predictors of late LCNP among
long-term oropharyngeal cancer (OPC) survivors.
Methods
The study population included 2,021 OPC survivors (median survival: 6.8 years) who
received primary treatment at MD Anderson Cancer Center from 2000 to 2013. Late LCNP
events were defined by neuropathy of the glossopharyngeal (IX), vagus (X) and/or
hypoglossal (XII) nerves ≥3-months after cancer therapy. Cumulative incidence of LCNP
was estimated using the Kaplan Meir method with adjustment for competing risks using time
to event as the underlying metric. Log-rank test was used to assess differences between
groups by LCNP status, and multivariable Cox proportional hazard models were fit.
Results
4.4% (n=88) of OPC survivors were diagnosed with late LCNP with median time to
LCNP onset after treatment of 5.4 (range: 0.3-14.1; IQR: 1.6-8.5) years post-treatment.
Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI: 0.02-0.03), 0.06
(95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and 18 years of
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follow-up, respectively. Multivariable Cox regression identified T4 stage vs T1 stage (HR:
3.82; 95%CI: 1.85-7.86, p<0.001) and accelerated RT fractionation vs standard RT
fractionation (HR 2.15, 95%CI 1.34-3.45, p=0.002) independently associated with late LCNP
status, adjusting for age, subsite, T-stage, smoking, and therapeutic modality.
Conclusion
While rare in the population overall, risk of late LCNP progressed over time to
exceed 10% cumulative risk over survivors’ lifetime. Our prediction model identified OPC
survivors who had T4 tumors and those who received accelerated fractionation RT treatment
as having a higher risk of late LCNP. Further efforts are necessary to investigate the risk and
predictors for this disabling late effect of cancer treatment experienced by growing numbers
of relatively younger OPC survivors who are expected to survive decades after treatment.
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INTRODUCTION
Oropharyngeal cancer (OPC) incidence is increasing by 5% each year, attributable to
the epidemic of Human Papilloma virus (HPV)-associated OPC. It is projected that by 2030
about half of head and neck cancers (HNC) will be OPC.1 In recent decades, HPV-associated
OPC has dramatically transformed the OPC patient population such that today’s typical OPC
patients are middle aged, male, white, non-smokers and non-drinkers, have a high
socioeconomic status, and are often diagnosed at a more advanced stage (per AJCC 7th
edition).1-4 As a consequence of modern regimens of organ preserving radiotherapy,
favorable biology, and improved prognosis due to better response to treatment, these patients
have excellent prognosis and are often expected to live for decades despite advanced stage
disease at presentation.2-4 HPV associated HNC patients have better 3-year (HPV: 82.0% vs.
HPV-negative 57.0%) and 5-year (RR=0.40; 95%CI 0.20-1.08) overall survival rates in
comparison to HPV negative HNC patients.2,3 As the lifespan of OPC survivors increase,
they are more likely to experience severe side-effects over time due to delayed tumor and
cancer treatment-related toxicities. For most part, OPC survivors experience excess
morbidity and disability compared to other cancer survivors. These late effects may lead to
debilitating problems in critical physiological functional activities including swallowing,
eating, breathing, and speaking. In fact, according to a survey study in 2004, 52% of HNC
patients of mixed sites experienced disability due to cancer treatment and were unable to
work due to these problems.5

Lower cranial neuropathy (LCNP) is a rare but permanent and potentially devastating
late effect induced by normal tissue injury due to radiotherapy (RT) or surgery and other
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HNC therapies. HNC treatment-associated fibrosis of nerve tracts or adjacent soft tissues
may lead to delayed but progressive neuro-vascular damage and eventually cranial
neuropathy which over time causes profound functional impairments.6 LCNP can occur
unilaterally or bilaterally and can affect glossopharyngeal (IX), vagus (X), accessory (XI),
and hypoglossal (XII) nerves which are crucial for oropharyngeal phase of swallowing
mechanism, speech production, and shoulder function.6-10 In a large survey study, OPC
survivors with late LCNP reported significantly worse cancer treatment-related symptoms
with largest effect size and detrimental impact on swallowing, speech, mucus problems,
choking, and fatigue.11 Further, survivors with late LCNP reported poor swallowing-related
quality of life (QoL). Notably, late feeding tube, tracheostomy, and aspiration pneumonia
events were almost exclusively seen in survivors who developed LCNP compared to their
LCNP-free counterparts. 12
It is also postulated that LCNP potentially leads to the accelerated functional decline
among HNC patients suffering from a severe form of dysphagia which occurs many years
post-RT called late RT-associated dysphagia (late RAD).9 Late RAD is characterized by
extreme functional impairment in oropharyngeal phases of swallowing, which causes
swallowing inefficiency, oropharyngeal residue, and silent aspiration.9 Over time, about 85%
of OPC survivors with late-RAD develop pneumonia and more than 60% of them require
long-term gastronomy tube placement.9 Overall, literature suggests substantial functional
burden including profound impairment in swallowing, speech, voice, and overall low quality
of life (QoL) in OPC survivors who develop LCNP.6-9
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The incidence of late LCNP among 59 OPC survivors was 5% at 5.7years according
to an earlier study, 7 however another cohort study among HNC survivors reported 14%
cranial neuropathy incidence rates over a 10-year follow-up, suggesting progressively
increasing LCNP risk over time in this population.14 Further, LCNP has delayed occurrence.
A previous study among NPC patients reported late LCNP occurrence between 12 to 240
months post-RT treatment thereby highlighting the need for long-term surveillance of late
LCNP among HNC and OPC patients.7-9
Most OPC patients receive either curative RT treatment alone or in combination with
systemic therapy. Definitive surgery or surgery in combination with adjuvant therapy while
historically rare is increasing with adoption of transoral robotic surgery methods. Despite this
rising popularity of primary TORS for OPC, still the vast majority of modern OPC patients
receive RT as definitive or adjuvant therapy. In practice, cranial nerves are historically
considered to be relatively resistant to radiation injury but RT-associated cranial nerve injury
occurs both at acute and late (months and years after RT treatment) recovery intervals. 7 It is
postulated that late LCNP may be caused by peripheral nerve and brainstem injury and RTassociated peripheral nerve injury may occur by axonal degeneration, suppression of
Schwann cell proliferation, and fibrosis of connective tissues entrapping nerve fibers. 7
Total RT dose is most commonly suggested in literature as the chief predisposing
factor for late LCNP, but the contributing threshold dose is not known.7 It has also been
suggested that the dose to regions-of interest (ROI) in the RT field including among others
the superior pharyngeal constrictor (SPC) region, which comprises minor nerve tracts and the
constrictor and longitudinal pharyngeal muscles, which are important for pharyngeal
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shortening during swallowing for bolus propulsion into the esophagus may play a more
pivotal role in late treatment related toxicity than total RT dose. 15 Previous literature suggests
potential risk factors for treatment-associated late LCNP include RT dose, field, mode and
fractionation, surgery, systemic therapy, smoking, and individual sensitivity to treatment. 7,
10,16-18

However, previous studies investigating LCNP have predominantly been case series

among nasopharyngeal cancer (NPC) survivors and few studies have addressed late LCNP
among OPC survivors. The largest to date comprised only 3 late LCNP cases in a cohort of
59 OPC survivors. With a rapidly growing pool of OPC survivors who have received
curative doses of radiotherapy, there is urgent need to investigate this disabling late effect of
therapy. Late LCNP is a debilitating, permanent condition and can have a profound impact
on QoL of OPC survivors, yet we know little about risk and predictors of late LCNP in this
population. For the growing numbers of OPC survivors at risk for experiencing late LCNP,
there is need to identify risk profiles of those most vulnerable to late LCNP and subsequent
late effects to help in the development of more targeted preventive strategies and
interventions. Therefore, the overall objective of this study was to quantify the cumulative
incidence of late LCNP and identify clinical predictors for late LCNP among long-term OPC
survivors. The hypothesis for this study was that that 5-year incidence rate of LCNP would
approximate 5% and risk of LCNP would correlate with age, tumor subsite and stage, RT
dose, fractionation schedule, smoking status, and systemic therapy.
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MATERIALS AND METHODS

Study Design, Eligibility and Consent
All OPC patients (n=3627) who completed treatment with curative intent at MD
Anderson Cancer Center (MDACC) between January, 2000 and December, 2013, were
assessed for eligibility in this retrospective cohort study. All eligible participants were ≥ 18
years of age at diagnosis, had oropharyngeal squamous cell carcinoma (OPSCC), and at time
of new patient registration within the institution had consented to future research
participation. Patients who had recurrent HNC, those treated at other institutions, those
deceased < 3 months post-treatment, and those with secondary primary malignancy (SPM) or
persistent/recurrent malignancy of the head and neck < 3 months post-treatment were
excluded. As this study investigated late LCNP as a treatment-associated late-effect, patients
with LCNP of any cause at the time of cancer diagnosis or with clinical signs of LCNP
(n=168) prior to cancer treatment were also excluded. A total of 2,021 OPC survivors were
included in the final study analysis. Details of study participants inclusion and exclusion are
presented in Figure 1.

Primary Outcome Variable
The primary outcome variable for this study was late LCNP. LCNP status among
patients was assessed by clinical examination of cranial nerves by the head and neck surgeon,
radiation oncologist, and/or speech pathologist and was recorded in medical charts. Late
LCNP for this study was defined as swallowing associated neuropathy of glossopharyngeal
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(IX), vagus (X) and hypoglossal (XII) nerves, which were critical to the oropharyngeal phase
of swallowing mechanism and speech production.19,20 As CN XI palsy was inconsistently
recorded in medical charts, it was excluded from LNCP analysis in this study, with the intent
to focus on swallowing-associated LCNP.
Late effects of cancer treatment are often defined as severe treatment associated toxicities
which occur ≥ 3 months post-cancer treatment ,21 therefore, late LCNP was defined as onset
of swallowing-associated neuropathy of at least one of the glossopharyngeal (IX), vagus (X),
and hypoglossal (XII) nerves with minimum onset ≥ 3 months after the end of cancer
treatment. Medical records were reviewed to identify cases of LCNP and case status was
verified by head and neck specialized physician (R.G.) review. Time to event of LCNP
diagnosis and information about other competing events were also collected. Details are
presented in an earlier publication.11

Clinical and Demographic Variables
Demographic, clinical, treatment-related factors, health behaviors, and HPV status
were also abstracted from medical charts using a structured study form. Demographic
variables included age and sex; clinical variables included T and N staging (7 th edition
AJCC), sub-site, HPV status, OPC treatment modality, RT dose, type/mode, and
fractionation schedule, chemotherapy, surgery, lack of solid food diet at baseline (as a
surrogate of baseline dysphagia), and smoking status at diagnosis. Survival time was
calculated as the difference between date of first visit to head and neck clinic and date of
LCNP diagnosis or competing event diagnosis or date of last follow-up. RT dose, mode and
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fractionation schedule, chemotherapy, surgery, solid food diet at baseline and smoking were
some of the variables based on literature review which may influence risk and may act as
predictors of late LCNP.7, 10,16-18 Thereby, these variables were investigated as potential
predictors of late LCNP among OPC survivors.

Statistical Analysis
Descriptive statistics were computed to explore relationship between variables of
interest. Cumulative incidence of LCNP was calculated using the Kaplan Meier method, with
adjustment for competing risks for all OPC survivors using time to event as an underlying
metric.
Differences in LCNP risk by co-variables of interest were also assessed and Log-rank
test was used to investigate between group differences by LCNP status. Multivariable Cox
proportional hazards models were fit regressing LCNP status as the dependent variable on
clinical and demographic predictors. Model building followed the purposeful variable
selection method of Hosmer and Lemeshow.22 Univariate analysis was conducted to estimate
hazard ratios for the crude effect of each variable of interest. Candidate predictors with p <
0.25 on Wald test along with literature-based a priori defined clinically important covariates
including age, t-stage, subsite, treatment modality, and smoking were entered into
multivariable proportional hazards model. Variables that associated with late LCNP (Wald
test p < 0.05) along with clinically important covariates were entered into the preliminary
main effects model. Pruned models were compared to full models using partial likelihood
ratio test; change in hazard ratio estimate ≥10% magnitude for each covariate was the
threshold for re-entry of variables back into the model. Further, we added variables not
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selected in earlier steps into model one at a time, checked the Wald statistic or partial
likelihood ratio test and retained variables that made important contributions. Biologically
plausible interaction terms and other model building strategies like stepwise regression were
also explored. Multicollinearity was assessed using variance inflation factors. The
proportional hazard assumptions of the final model were also assessed and the fit of the final
model were tested using overall goodness-of-fit χ 2 test. Subgroup analyses were conducted
among single versus multimodality treatment groups and surgically treated versus nonsurgically treated groups, and those with HPV-associated disease among others. Hazard
ratios (unadjusted and adjusted) and corresponding 95%confidence interval (CI) were
estimated. All reported p-values were two-sided and were considered to be statistically
significant at p <0.05 and statistical analysis was conducted using the STATA software,
version 14.0 (StataCorp LP, College Station, TX).
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RESULTS
Sample Characteristics
Two thousand twenty-one (n=2,021) eligible OPC survivors with a median survival
time of 6.8 (range, 0.3-18.4; IQR: 4.3-10.2) years were included in this study. Table 1
displays the distribution of demographic, tumor, and treatment-related characteristics in the
study population. Among study participants, median age at diagnosis was 56 (range, 28-86;
IQR: 50-63) years; 86.1% were male, 93.5% had either tonsil or base of tongue tumors, 72%
had T1-T2 tumors, 90.3% had nodal involvement, and 89.9% could eat a normal solid-food
diet prior to treatment. About 99.0% were treated with RT with a median RT dose of 70 Gy
(range, 40-75; IQR: 66-70 Gy) and 60.7% were treated with intensity-modulated
radiotherapy split-field technique (IMRT-SF).

Late Lower Cranial Neuropathy
4.4% (88/2,021) OPC survivors were diagnosed with late LCNP with median time to
LCNP onset post-treatment of 5.4 years (range, 0.3-14.1; IQR:1.6-8.5). Among LCNP cases,
median RT dose was 70 (range, 66-73.5; IQR: 66-72) Gy. However, 73.9% (65/88) of LCNP
cases received an RT dose of ≥70Gy in comparison to 52.9% (1,022/1,933) of those without
LCNP. 51.1% (45/88) of LCNP cases were treated for T1-T2 tumors, 48.9% (43/88) had T3T4 tumors, and 89.8% (79/88) reported eating a solid-food diet prior to treatment. All LCNP
cases received curative RT, 75% (66/88) were treated with RT in combination with systemic
therapy, 37.5% (33/88) received IMRT-SF, and 36.4% (32/88) received accelerated RT
fractionation therapy. In total, 7.6% (154/2021) of all survivors and 21.6% (19/88) LCNP

82

cases received concomitant boost accelerated RT treatment (p <0.001). Lastly, one (1.1%)
LCNP case underwent transoral robotic surgery to the primary OPC tumor and 29.5%
(26/88) had neck dissection.
Among LCNP cases, CN XII (hypoglossal nerve) neuropathy was most common
(78.4%; 69/88). As isolated CN IX neuropathy was hard to detect; CN X/CN IX palsies were
combined and 44.3% (39/88) patients had CN X/CN IX neuropathy. Polyneuropathy which
included CN X/CN IX palsy and CN XII palsy was diagnosed in 22.7% (20/88) of LCNP
cases. Among LCNP cases, 63.6% (56/88) had ipsilateral nerve damage, 9.1% (8/88) had
contralateral nerve damage, and 26.1% (23/88) had bilateral nerve damage.

Cumulative Incidence of LCNP
Cumulative incidence of LCNP among all OPC survivors was 0.02 (95% CI: 0.020.03), 0.06 (95% CI: 0.05-0.08), and 0.10 (95% CI: 0.08-0.13) at 5 years, 10 years, and 18
years of follow-up, respectively. Overall cumulative incidence has been presented in Figure
2. Table 1 displays the cumulative incidence of late LCNP across demographic, tumor and
treatment-related characteristics in the study population over an 18-year follow-up period.
Cumulative Incidence of late LCNP increased proportionally with higher T-stage category
with highest incidence of 0.26 (95% CI: 0.15-0.42, p=<0.001) among survivors with T4
tumors. Among OPC survivors; cumulative incidence of LCNP among those who did not eat
a solid-food diet prior to treatment was 0.42 (95%CI: 0.12-0.91, p=0.086), those treated with
multimodality treatment was 0.14 (95%CI: 0.09-0.20, p=0.003), those treated with
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accelerated RT fractionation treatment was 0.19 (95%CI: 0.13-0.26, p=<0.001) and those
treated with intensity modulated radiotherapy whole-field technique (IMRT-WF) and
volumetric-modulated arc therapy (VMAT) was 0.14 (95%CI: 0.09-0.22, p=<0.001).

Risk Factors for LCNP
Univariate analysis identified smoking status, T-stage, single vs multimodality
treatment, RT dose, type, and fractionation schedule, and chemotherapy as significantly
associated with late LCNP status (p<0.05). Multivariable Cox regression identified T4 stage
(HR: 3.82; 95%CI: 1.85-7.86, p=0.000) and accelerated RT fractionation (HR 2.15, 95%CI
1.34-3.45, p=0.002) independently associated with late LCNP status, adjusting for age,
subsite, T-stage, smoking and therapeutic modality. Results of univariate and multivariate
analysis are summarized in Table 2. Further, statistically significant interaction was
identified between RT schedule and subsite of primary tumor (p=0.021) but as effect
estimates of the model with the interaction term were similar to full regression model without
the interaction term, estimates of final statistical model without interaction were reported for
ease of clinical interpretation.

Subgroup Analysis: LCNP among those treated with Non-surgical Therapy
Among non-surgically treated patients, chemotherapy was further investigated as a
predictor of late LCNP. The majority of non-surgically treated patients (67.6%; 1,342/1,986)
received RT in combination with systemic therapy and 31.6% (628/1,986) received single
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modality RT. About 52.5% (1,042/1,986) received concurrent chemotherapy, 31.5%
(625/1,986) received induction chemotherapy (IC), and 17.3% (344/1,986) received both
induction and concurrent chemotherapy. Among those who received induction
chemotherapy, 38.7% (242/625) received Induction TPF (docetaxel, cisplatin, and
fluorouracil), 5.8% received Induction CTPF (cetuximab, docetaxel, cisplatin, and
fluorouracil), 20.2% (126/625) received Induction PCC (paclitaxel, carboplatin, cetuximab)
and the remaining survivors received varied induction chemotherapy regimens. Among nonsurgically treated patients, Induction TPF chemotherapy (HR: 2.37; 95%CI: 1.28-4.38;
p=0.006) and Induction C-TPF (HR: 4.0; 95%CI: 1.22-13.13, p=0.022) were identified in
addition to T-stage (model with TPF; HR: 3.72, 95%CI: 1.81-7.65, p=<0.001; model with
CTPF; HR: 3.97, 95%CI: 1.92-8.21, p=<0.001 ) and accelerated RT fractionation (model
with TPF; HR: 2.56, 95%CI: 1.55-4.21, p=<0.001, model with CTPF; HR: 2.28, 95%CI:
1.41-3.68, p=0.001) as significantly associated with late LCNP adjusting for the same
covariates as the final model.

Validating Model Assumptions
None of the predictors in the final model violated the proportionality assumption of
the Cox model except T-stage, but when a Cox model stratified on T-stage was fit, effect
estimates for predictors in final model remained unchanged. Further, on inclusion of
previously identified interaction RT schedule and subsite of primary tumor, none of the
variables violated the proportionality assumption. Therefore, estimates for the unstratified
Cox model were reported for ease of clinical interpretation. Goodness-of-fit of the final
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model was assessed using the goodness-of-fit χ 2 test which was not significant (p=0.406)
and Cox-Snell residuals and in conclusion the final model fit the data well.

DISCUSSION
Late lower cranial neuropathy is a rare but progressive and functionally devastating
late toxicity in OPC survivorship.11,12 Late effects are of great concern among an evergrowing pool of younger OPC survivors with prospects of long-term cure, many of whom are
expected to survive decades after treatment. This single-center retrospective cohort study is
to our knowledge the first of its kind. The cohort represents the largest (n=2,021) to date
among OPC survivors over an 18-year surveillance period and thus provides a high degree of
precision in estimates of risk of late LCNP in terms of cumulative incidence and
identification of clinical risk predictors of LCNP. Results of this study suggest that risk of
late LCNP, though initially small, progressed over time to exceed 10% cumulative risk over
survivors’ lifetime. Multivariate analysis revealed that T-stage and accelerated RT
fractionation treatment are significant risk factors of late LCNP. Further, among nonsurgically treated patients, induction TPF chemotherapy with or without cetuximab (C-TPF)
were additionally identified as significant risk factors of late LCNP.
The progressively increasing cumulative incidence estimates reported in this study are
deeply troubling as the majority of OPC survivors in this study were middle-aged at the time
of diagnosis supported by the 50-63 years interquartile range (IQR) for age at diagnosis
which is similar to the age distribution of most HPV-positive OPC patients today.23 This
progressive increase in LCNP risk over time is similar to a study among 59 OPC survivors
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treated by IMRT, which reported a cumulative risk of 2.1% (95% CI: 0.2-10%), 6.1%
(95%CI: 0.9%-19%), and 11.0% (95%CI: 2.4%-28%) at 6-year, 7-year, and 8-year followup. 7 Another study among NPC patients also reported a progressive increase in late LCNP
cumulative incidence of 5.7%, 17.4%, 27.1%, and 37.3% over a 5, 10, 15 and 20-year follow
up respectively.24-The cumulative incidence estimates in current study are quite precise
supported by their narrow 95% confidence intervals and risk estimates increased as expected
by disease severity (as per T-stage), use of RT, use of systemic therapy, neck dissection, and
increase in treatment intensity with use of multimodality treatment including chemoradiation
and accelerated RT fractionation. Tight confidence intervals and expected performance in
subgroup stratifications support both accuracy and validity of these cumulative incidence
estimates.
The progressive trajectory of LCNP has long-term clinical implications on the
functional status of HNC survivors as was suggested by a prospective study among 3 OPC
survivors with LCNP, which suggested that LCNP cases could experience severe decline in
function over time, as per multiple functional metrics. 7 Long-term deterioration of
swallowing function was noted using both patient-reported MDADI scores and clinicianrated modified barium swallow (MBS) scores as per validated Dynamic Imaging Grade of
Swallowing Toxicity (DIGEST) criteria, as well as diet score rated on the Performance Status
Scale of Head and Neck Cancer (PSS-HN).7 In fact, survivors with LCNP may be compelled
to modify their diet, need extended meal times, feel self-conscious to eat in social settings, be
socially isolated, and experience poor QOL.26 The investigators have previously reported
worse cancer treatment-related symptoms, poor swallowing-related QoL, and worse
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functional status metrics including long-term feeding tube dependence, lack of normalcy of
diet, dietary restrictions in public, weight loss, aspiration pneumonia, and tracheostomy
among long-term OPC survivors with late LCNP.11,12 Further, the devastating impact of
cranial neuropathy on the life of LCNP cases was reflected by their qualitative remarks in the
present study which suggested, profound distress and suffering with loss of swallowing
function to an extent where these patients regretted pursuing any OPC treatment at all. It is
also worrisome, that a recent report indicated that OPC incidence is now rising among the
older population.27 These patients are likely to have comorbidities and experience more sideeffects with multimodality treatment including concurrent chemoradiation and are also likely
to experience bigger deficits in swallowing function overtime and even more
poor/diminished QoL. These findings altogether suggest that as OPC survival probabilities
continue to improve, the number of survivors at risk of substantial functional morbidity
associated with late LCNP grows too. These survivors eventually transition from oncologic
management to care of primary care physicians and there is need for increased surveillance to
assess and treat late effects.
The results from this multivariate analysis suggest, on an average, OPC patients with
T4 stage tumors were 3.8 times more likely to develop late LCNP than those with T1 tumors
after adjusting for age, subsite, smoking, therapeutic modality, and RT fractionation
schedule. Identification of T-stage as a predictor in this study is plausible given that locally
advanced OPC tumors are bulky tumors. As per AJCC 7th edition TNM staging in this study,
T3 tumors are > 4cm with possible extension to lingual epiglottis, whereas T4 tumors are
even bigger with T4a tumors being moderately advanced invading other head neck sites
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possibly including the larynx/tongue muscles/hard palate/ mandible and T4b tumors
including very advanced extensive tumors invading the lateral pterygoid muscles, lateral part
of the nasopharynx and even the skull base and carotid artery (AJCC 7 th edition). In case of
larger tumors, the RT treatment planning target volume is more extensive, requiring a
relatively larger gross tumor volume, clinical target volume (to incorporate subclinical
disease), and additional marginal area (to account for errors). 28 These larger irradiation fields
may include neurovascular structures including cranial nerves and adjacent normal tissues,
the injury of which may precipitate cranial neuropathy. Additionally patients with T4 tumors
may have also have a greater risk of subclinical baseline neve injury by compression of nerve
tracts by large tumors.29-31 According to previous literature primary tumor size among other
clinical variables may also contribute to acute and late dysphagia including late-RAD among
HNC patients 32,33 and tumor stage may predict swallowing function (as per MDADI scores)
at specific time points and longitudinally.34-36 Another prospective study among 529 HNC
patients treated with curative RT which reported T3-T4 vs T1-T2 stage (OR:2.38, 95%CI:
1.36-4.19, p=0.003) was positively significantly associated with grade 2-4 RTOG
swallowing dysfunction at 6 months post-treatment.37 Therefore, tumor stage can not only
contribute to late LCNP but also potentially play a role in development of late functional
toxicities including late RAD.
Advanced stage cancers are also treated more intensely/aggressively with
multimodality treatment regimens including either chemoradiotherapy (CRT) or surgery
followed by CRT or chemotherapy. Chemoradiotherapy is regarded as standard of care for
locally advanced OPSCC but multimodality treatment regimens can result in acute and
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persistent tissue changes and lead to severe acute and late treatment-related toxicities.38,39 A
trial in France demonstrated that multimodality treatment was associated with an increase in
grade 3 or 4 acute toxicity though these findings were not statistically significant.40 Thus,
collectively among patients with T4 tumors larger irradiation fields and greater treatment
intensification may contribute to higher risk of late LCNP.
In this study, OPC patients treated with accelerated RT fractionation were 2.2 times
more likely to develop late LCNP than those who received standard RT fractionation after
adjusting for age, subsite, smoking, T-stage, and therapeutic modality. Accelerated RT
fractionation treatment regimens incorporate several RT fractions in a day with the goal to
shorten total treatment time and also to overcome tumor cell regeneration/repopulation
during RT treatment.41,42 Thereby, accelerated RT fractionation therapy may also include an
increase in average RT dose per week above the standard 10 Gy dose per week of
conventional RT fractionation which may contribute to an increase in late effects of RT
treatment.28 Further, regeneration/repair in some normal tissues maybe slower and as a
consequence of longer half-time for repair; these tissues may be more susceptible to RTinduced injury.28 Lastly, an increase in RT dose per week may contribute to an increase in
early tissue injury like mucositis or other severe and extensive/protracted acute effects which
may result in chronic normal tissue injury and consequential late effects.28
Pure acceleration, split-course treatment acceleration, accelerated hyper-fractionation,
and concomitant boost are some of the strategies used in accelerated RT fractionation
therapy.42 In this study, more than 20% LCNP cases received concomitant boost accelerated
RT treatment. Concomitant boost RT technique incorporates initial irradiation of gross tumor
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volume and clinical target volume, followed by a second boost RT dose delivered to a
smaller clinically identifiable tumor area to ensure the highest RT dose is given to the
smallest region to reduce potential of late RT-associated toxicity/morbidity. 42 In this
institution concomitant boost RT strategy includes a total RT dose of 72 Gy, given in 42
fractions during 6 weeks.42,44 During the last/final two weeks of RT treatment, the patient
receives twice a day treatment with the second dose administered as boost RT dose.42,44
However, in a previous phase II Radiation Therapy Oncology Group Trial (RTOG 99-14),
advanced HNC patients treated with concomitant boost accelerated RT regimen/strategy with
cisplatin had better survival but endured severe acute toxicity and alarmingly higher rates of
late toxicities including late gastrostomy tube dependence. 43 Another randomized trial among
NPC patients also reported, accelerated hyper-fractionation therapy was associated with
significantly higher risk of RT-associated central nervous system injury including damage to
cranial nerves, temporal lobe, and brainstem.44
Some patients (n=8) in this study also received Danish Head and Neck Cancer Group
(DAHANCA) moderate accelerated RT fractionation strategy which incorporated 6 instead
of 5 weekly radiation fractions during RT.45 A previous randomized trial among patients with
glottic cancer reported that patients treated with the DAHANCA regimen suffered more
frequently from severe acute mucositis even though frequency of late effects were
comparable among patients treated with 6 vs 5 RT fractions. 45 It was postulated that
effectiveness of RT treatment may be influenced by inherent radio-sensitivity of cells,
hypoxia of the tumor microenvironment, and regeneration of stem cells during RT
treatment.45 Another randomized trial among NPC patients, also reported that accelerated
hyper-fractionation radiation treatment was associated with higher late LCNP incidence than
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conventional fractionation (13.0% vs 8.7%) over a median follow-up of 59.2 months.44
Finally, the effect estimates in this study for accelerated RT are robust and similar to a
previous study among NPC, which reported RT fractionation schedule (RR: 2.91, 95%CI:
1.07-7.91, p=0.036) as a significant predictor of upper cranial nerve neuropathy and but not
as a significant predictor of lower cranial nerve neuropathy. 24 In summary, accelerated RT
fractionation treatment regimens can contribute to an increase in risk of nerve fibrosis and
cranial nerve injury.
Among non-surgically treated patients, the present study identified Induction TPF and
Induction C-TPF followed by chemoradiotherapy or RT as risk factors associated with late
LCNP. Chemotherapy drugs are cytotoxic and modify radiation sensitivity of cells either by
altering their cell-cycle phase or by interfering with repair of radiation initiated double-strand
DNA breaks.46,47 Thus, while enhancing tumor control, they can also contribute to late
toxicity like LCNP. A prior study among NPC patients reported that chemotherapy was
significantly associated with development of cranial neuropathy (RR=1.42, p=0.021). 24
Another clinical trial among stage III and stage IVB NPC patients revealed that late cranial
neuropathy was significantly increased among patients treated with RT and concurrent
adjuvant chemotherapy (p=0.042) than those treated with RT only. 48 Similarly, in a previous
study 6.3% of HNC patients, who received intra-arterial Cisplatin therapy developed cranial
neuropathy shortly after treatment.49 Thus, while various authors have associated concurrent
chemotherapy with LCNP after NPC radiotherapy, the results of this study are, to our
knowledge, the first to link induction chemotherapy to elevated risk of LCNP in OPC.
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Induction chemotherapy (IC) is a treatment alternative for patients with locally
advanced head and neck squamous cell carcinoma (HNSCC) with goals of shrinking tumors,
reducing risk of distant metastasis, and organ preservation for operable and inoperable
tumors. 51-53 Induction TPF is considered the gold-standard evidence-based IC treatment
regimen and is considered superior to PF (cisplatin combined with 5-FU).52,53 However, the
use of IC in case of unresectable disease followed by RT or chemoradiation (CXRT) is
controversial. 52,53 TPF may also be more toxic than concurrent chemoradiotherapy and
contribute to greater morbidity and death, as some trials have reported IC toxicity-related
death rates of 2%-7%.52 The TPF regimen in the United States includes a combination of 3
drugs, including 3 cycles of docetaxel 75 mg/m2 combined with cisplatin 100 mg/m2 and
1000 mg/m2 5FU infusion for 4 days, for every 3 weeks.53 Each one of these drugs has it’s
individual toxicity profile. Cisplatin can contribute to neuropathy, hearing problems, renal
toxicity, and cardiovascular adverse events, 5FU can result in severe mucositis and
hematological problems, docetaxel can also contribute to neuropathy, erythema and
hypotension.53 In case of CTPF, the cetuximab component can additionally contribute to
severe anaphylactic toxic reactions.53 Therefore, in combination these drugs may contribute
to late effects like LCNP. Lastly, IC therapy including drugs like Cisplatin may lead to
increased radio-sensitivity to subsequent RT which in turn can play a role in development of
late treatment-related toxicity and late LCNP.54
The results from this study are of paramount importance in the realm of OPC
survivorship as they have the potential to inform/advocate for long-term screening and
surveillance recommendations to monitor and treat late effects like LCNP, inform future late
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effects research, and advise the development and implementation of targeted risk-reduction
and preventive interventions. These strategies could be implemented early and be
personalized via risk stratification methods to meet individual needs for symptom
management and psychosocial support to allow for more strategic allocation of resources and
potentially lower health care cost. Risk-based OPC treatment planning, use of targeted
therapies, nerve-sparing RT planning to decrease irradiation of vital structures which play an
important role in swallowing, or sequential chemoradiotherapy may help to alleviate late
effects like LCNP and improve function among survivors. Knowledge about predictors of
late LCNP and its consequent impact on swallowing function and overall symptom severity
may also allow more effective delineation of de-escalation targets.
With more than 2,000 OPC survivors, this is to our knowledge, the largest
retrospective cohort study to date to estimate risk of late LCNP and identify clinical
predictors of late LCNP. However, there are limitations to acknowledge. Study participants
had varying survival time and may be susceptible to survival bias. As a consequence of the
long latency period for late LCNP development, risk would be highest among survivors with
greater survival time. Nonetheless, consistently precise and robust effect estimates on late
LCNP were identified which varied across clinical and demographic covariates as expected.
The low event rate of late LCNP and loss-to-follow-up among survivors may also have
contributed to low statistical power to identify additional potential predictors like RT dose
among others. But the substantial study sample of OPC survivors, allowed for identification
of possibly the most impactful predictors of LCNP. There may be some misclassification of
study variables due to the retrospective study design but as study results varied as would be
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expected by clinical and demographic variables their impact on study results is likely to be
minimal. HPV testing had also not been conducted in about half of the cohort, therefore
accurate estimates of risk based on HPV status in study population could not be assessed.
However, sensitivity analysis of study results by HPV status did not have an impact on effect
estimates for late LCNP, suggesting study results were valid and accurate. As this study was
conducted at a tertiary care cancer center and there were small numbers of surgical patients
there may be some limitations to generalizability of study results to more diverse
populations. Further, late LCNP risk may have been underestimated in this study, as LCNP
diagnosis was primarily via clinical signs of loss of motor function only and did not take into
account loss of sensory function. Further, CN XI palsy was excluded to focus on swallowing
associated late LCNP only. Isolated CN IX palsies were not detected in this study. Therefore,
actual risk of LCNP among OPC survivors may most likely be higher than reported in our
study. Lastly, individual susceptibility and impact of genetic predictors on LCNP could not
be assessed and should be addressed by future studies assessing the risk of late LCNP.
It is of utmost importance going forward to investigate evidence-based risk
identification and early risk reduction strategies for late effects detection and management.
Effective screening interventions, may consider the use of patient-reported outcomes tools
like MD Anderson Dysphagia Inventory (MDADI) and MD Anderson Symptom Inventory –
Head and Neck module (MDASI-HN) among others for surveillance and detection of late
effects. Potential treatment for late LCNP also needs to be investigated in prospective clinical
trials. Future studies need to further assess the role of dose to organs at risk (including the
salivary glands, pharyngeal constrictors, cricopharyngeal muscle, base of tongue, supraglottic
and glottic larynx and other critical structures), induction chemotherapy, and transoral
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robotic surgery in development of late effects like LCNP. 55 Further, it is crucial that HNC
treatment selection must take into account long-term treatment-related morbidity and should
be prioritized based on individual patient preferences to reduce disease burden due to late
effects. Better RT techniques need to be developed to modify dose delivery and less toxic
chemotherapy agents need to be investigated. Treatment de-intensification strategies need to
be explored which maintain cure and prevent late effects.

CONCLUSION
While rare in the population overall, quantitative estimates of lifetime risk of late
LCNP over an almost 18-year follow-up into OPC survivorship demonstrate that one out of
10 OPC survivors middle-aged at time of diagnosis are likely to develop late LCNP. The
progressively increasing risk of late LCNP of 2%, 6%, and 10% at 5, 10, 18-year follow-up
also indicates that risk of LCNP overtime is much higher than previously believed. The
potential impact of late LCNP on the life of OPC survivors is devastating as late LCNP and
accompanying late-RAD is refractory to treatment, life-long, and permanent. In this study
patients with big bulky tumors had large irradiation fields possibly including cranial nerves,
they were likely to be treated most aggressively with multimodality treatment regimens
including, IC, RT, and systemic therapy, thereby they were more likely to develop late
LCNP. In summary, the long-term treatment-related burden of OPC is becoming more
apparent, there is urgent need to find ways to treat cancer, minimize late effects like LCNP
and improve QoL among OPC survivors.
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TABLES
Table 1: Patient Characteristics (N=2,021)
Variables

All patients
(n=2021)

LCNP
(n=88)

No LCNP
(n=1,933)

Pvalue**

Age at diagnosis, median
(range), IQR
Survival time, median
(range), IQR yrs
RT Dose, Gy median
(range), IQR
RT Fractions (range), IQR

56 (28-86),
(50-63)
6.8(0.3-18.4)
(4.3-10.2)
70(40-75),
(66-70)
33(15-44),
(28-43)

57(33-80)
(51-63)
5.4(0.3-14.1)
(1.6-8.5)
70(66-73.5)
(66-72)
33(30-43)
(32-40.5)

55(28-86)
(50-63)
6.8(0.3-18.4)
(4.4-10.3)
70(40-75)
(66-70)
33(15-44)
(30-33)

0.734

281(13.9)
1740(86.1)

15(5.3)
73(4.2)

266(94.7)
1667(95.8)

944(46.7)
945(46.8)
132(6.5)

40(4.2)
45(4.8)
3(2.3)

904(95.8)
900(95.2)
129(97.7)

686(33.9)
770(38.1)
358(17.7)
207(10.2)

18(2.6)
27(3.5)
20(5.6)
23(11.1)

668(97.4)
743(96.5)
338(94.4)
184(88.9)

Sex
Female
Male
Primary Site
Tonsil
Base of Tongue
Others
T classification
1
2
3
4
N classification (AJCC 7th
Ed)
N0
N1+2a
2b+3
2c
HPV status
Negative
Positive
Unknown
Smoking
Never
Former
Current
Missing
Solid Food pre-Tx
Yes
No
Treatment Group
Single Modality
Multimodality
Treatment Group
RT alone
Surgery alone
RT plus systemic

Cumulative Incidence

< 0.001
< 0.001
< 0.001
0.429

0.399
0.096 (0.055-0.165)
0.098 (0.073-0.132)

0.453

0.6418
0.101 (0.0678-0.152)
0.100 (0.070- 0.142)
0.039 (0.012-0.128)

< 0.001

< 0.001
0.046(0.027-0.077)
0.087 (0.049-0.151)
0.178 (0.109-0.283)
0.259 (0.154-0.417)

0.212
196(9.7)
510(25.2)
968(47.9)
347(17.2)

6(3.1)
16(3.1)
46(4.8)
20(5.8)

190(96.9)
494(96.9)
922(95.2)
327(94.2)

110(5.4)
817(40.4)
1094(54.2)

6(5.5)
22(2.7)
60(5.4)

104(94.6)
795(97.3)
1034(94.5)

861(42.6)
842(41.7)
294(14.6)
24(1.2)

39(4.5)
33(3.9)
16(5.4)
0(0)

822(95.5)
809(96.1)
278(94.6)
24(100.0)

1816(89.9)
205(10.1)

79(4.4)
9(4.4)

1737(95.6)
196(95.6)

647(32.0)
1374(68.0)

21(3.3)
67(4.9)

626(96.8)
1307(95.1)

628(31.1)
19(0.9)
1342(66.4)

21(3.3)
0(0.0)
66(4.9)

607(96.7)
19(100.0)
1276(95.1)

Log rank
Test p
value

0.0445
0.082 (0.031-0.207)
0.052 (0.030-0.088)
0.127 (0.084-0.188)
0.127 (0.075- 0.211)

0.007

0.681
0.142 (0.054-0.345)
0.080 (0.033-0.175)
0.098 (0.073-0.131)

0.559

0.087
0.101 (0.065-0.154)
0.088 (0.059-0.131)
0.131 (0.070-0.240)
0.000
0.086

1.000

0.092 (0.070-0.121)
0.421 (0.116- 0.912)

0.102

0.003
0.060 (0.038-0.094)
0.136 (0.090-0.201)

0.397
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0.029
0.061 (0.039-0.095)
0.000
0.136 (0.091-0.201)

Variables

Surgery +adjuvant RT
&Chemo
Radiotherapy
No
Yes
Chemotherapy
No
Yes
Surgery
No
Yes- Robotic
Neck Dissection
No
Yes
RT Schedule
Standard Fractionation
Accelerated
Missing (Pt. Without RT)
RT Type
3d Conformal
IMRT-SF
IMRT- WF+VMAT
Proton
IMRT Ipsi
Missing (Pt. without RT)

All patients
(n=2021)

LCNP
(n=88)

No LCNP
(n=1,933)

32(1.6)

1(3.1)

31(96.9)

21(1.0)
2000(99.0)

0(0.0)
88(4.4)

21(100.0)
1912(95.6)

656(32.4)
1365(67.5)

21(3.2)
67(4.9)

635(96.8)
1298(95.1)

1986(98.3)
35(1.7)

87(4.4)
1(2.9)

1899(95.6)
34(97.1)

1500(74.2)
521(25.8)

62(4.1)
26(5.0)

1438(95.9)
495(95.0)

1681(83.2)
319(15.8)
21(1.0)

56(3.3)
32(10.0)
0(0.0)

1625(96.7)
287(90.0)
21(100.0)

234(11.6)
1227(60.7)
377(18.7)
36(1.8)
126(6.2)
21(1.0)

24(10.3)
33(2.7)
25(6.6)
2 (5.6)
4 (3.2)
0(0.0)

210(89.7)
1194(97.1)
352(93.4)
34(94.4)
122 (96.8)
21(1.0)

Pvalue**

Cumulative Incidence

0.032 (0.005-0.208)
1.000

0.447
0.000
0.099 (0.075-0.128)

0.082

0.002
0.060 (0.038-0.093)
0.136 (0.091-0.201)

1.000

0.865
0.098 (0.075-0.128)
0.029 (0.004-0.191)

0.454

0.779
0.091 (0.067-0.123)
0.110 (0.067-0.175)

< 0.001

< 0.001
0.071 (0.047-0.107)
0.187 (0.132-0.260)
0.000

< 0.001

< 0.001
0.174 (0.118-0.251)
0.073 (0.041-0.129)
0.136 (0.085-0.215)
0.056 (0.014-0.204)
0.052 (0.018-0.145)
0.000

Abbreviations: IQR, interquartile range, T, tumor; RT, radiotherapy; IMRT-SF, Intensity modulated
radiotherapy split-field technique; IMRT-WF, Intensity modulated radiotherapy whole-field
technique; IMRT-Ipsi, Intensity modulated radiotherapy ipsilateral treatment; VMAT, Volumetricmodulated arc therapy
Bold denotes statistical significance at p value < 0.05
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Log rank
Test p
value

TABLE 2: Univariate & Multivariate Cox Proportional Hazards models for Late
LCNP (N=2021)
Variables

Age at diagnosis, median (range)
RT Dose, Gy median (range)
RT Fractions
Sex
Female
Male
Primary Site
Others
Tonsil
Base of Tongue
T classification, AJCC 7th Ed
1
2
3
4
N classification, AJCC 7th Ed.
N0
N1+2a
2b+3
2c
HPV status
Negative
Positive
Unknown
Smoking
Never
Former
Current
Solid Food pre-Tx
Yes
No
Treatment Group
Single Modality
Multimodality
Treatment Group
RT alone
Surgery alone
RT plus systemic
Surgery +adjuvant RT &Chemo
Chemotherapy
No
Yes
Surgery
No
Yes- Robotic
Neck Dissection
No

Univariate
Analysis HR
(95%CI)
1.02 (1.00- 1.04)
1.24 (1.14- 1.36)
1.11 (1.07- 1.16)
Reference
0.79 (0.45-1.37)
Reference
1.42 (0.44-4.58)
1.62 (0.50-5.21)
Reference
1.53 (0.84-2.78)
2.72 (1.44-5.14)
6.10 (3.29-11.33)
Reference
0.85 (0.33-2.17)
1.56 (0.67-3.66)
2.01 (0.81-5.00)
Reference
0.67 (0.27-1.66)
0.72 (0.31-1.67)
Reference
0.85 (0.53-1.35)
1.74 (0.97-3.11)
Reference
1.82 (0.91-3.66)
Reference
2.09 (1.27-3.44)
Reference
0.00
2.06 (1.25-3.39)
2.02 (0.27-15.09)
Reference
2.13 (1.30-3.50)
Reference
1.19 (0.16-8.57)
Reference
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P Value

Multivariate Analysis
HR (95%CI)

P Value

0.117
< 0.001
< 0.001
0.412

1.02 (0.99-1.04)

0.163

Reference
0.400
0.624
0.560
0.420
< 0.001
0.161
0.002
< 0.001
0.040

Reference
1.89 (0.58-6.17)
1.85 (0.57-6.05)

0.292
0.309

Reference
1.12 (0.60-2.10)
1.59 (0.76-3.31)
3.82 (1.85-7.86)

0.727
0.218
< 0.001

Reference
0.733
0.302
0.134
0.706
Reference
0.386
0.439
0.038
0.493
0.064
0.117
0.091
0.002
0.004
0.018

Reference
0.76 (0.47-1.22)
1.57 (0.86-2.86)

0.253
0.143

Reference
1.16 (0.56-2.41)

0.685

Reference
1.35 (0.77-2.37)

0.299

Reference
1.000
0.004
0.494
0.002
Reference
0.003
0.868
0.865
0.780

Variables

Yes
RT Schedule
Standard Fractionation
Accelerated
RT Type
3d Conformal
IMRT-SF
IMRT- WF +VMAT
Proton
IMRT Ipsi

Univariate
Analysis HR
(95%CI)
1.07 (0.67-1.69)
Reference
2.53 (1.63-3.92)
Reference
0.32 (0.19-0.55)
0.96 (0.54-1.70)
1.33 (0.31-5.77)
0.33 (0.11-0.94)

P Value

Multivariate Analysis
HR (95%CI)

P Value

0.779
0.000
0.000
< 0.001

Reference
2.15 (1.34-3.45)

0.002

< 0.001
0.888
0.701
0.039

Abbreviations: IQR, interquartile range, T, tumor; RT, radiotherapy; IMRT-SF, Intensity modulated
radiotherapy split-field technique; IMRT-WF, Intensity modulated radiotherapy whole-field
technique; IMRT-Ipsi, Intensity modulated radiotherapy ipsilateral treatment; VMAT, Volumetricmodulated arc therapy
Statistical significance p value < 0.25 after Univariate Analysis
Statistical significance p value < 0.05 after Multivariate Analysis
Bold denotes statistical significance at p value < 0.05
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Figure 1. Consort flow chart showing study participant screening and eligibility criteria

Assessed for eligibility
(n=3627)

Eligibility

Previously treated HNC (n=446)
Not SCC OPC (n= 545)
Treatment OSH (n=217)
Deceased/LRR/RRR/DM/SPM/Not NED< 3m
(n=114)
Not treated Jan 2000- Dec 2013 (n=29)
Metastatic at Diagnosis/ Palliative Tx. (n=77)
Lost to follow-up (n=10)

Retrospective Chart Review

Number of Patients (n=2189)


Excluded from analysis; Baseline LCNP (n=168)

Analysis

Analysed (n=2021)

Late LCNP absent (n= 1933)

Late LCNP present (n= 88)
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Figure 1. Consort flow chart showing study participant screening and eligibility criteria.
Abbreviations:
OPC, oropharyngeal carcinoma, SCC, squamous cell carcinoma, OSH, outside hospital; SPM, second
primary malignancy; LRR, locoregional recurrence; RRR, regional recurrence; DM, distant
metastasis; NED, no evidence of disease; LCNP, lower cranial neuropathy.

Figure 2: Overall Cumulative Incidence of Late LCNP in OPC survivors over an 18-year
surveillance period (n=2,021)
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Figure 3: Adjusted Risk of Late LCNP stratified by T-Stage

Figure 3. Adjusted Risk of Late LCNP stratified by RT T-Stage. Regression model adjusted for age,
subsite, T-stage, smoking and therapeutic modality. Abbreviations: T, tumor; LCNP, lower cranial
neuropathy.
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Figure 4: Adjusted Risk of Late LCNP stratified by RT Fractionation

Figure 4. Adjusted Risk of Late LCNP stratified by RT Fractionation. Regression model adjusted for
age, subsite, T-stage, smoking and therapeutic modality. Abbreviations: RT, radiotherapy; LCNP,
lower cranial neuropathy.
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Key Points
Question What is the impact of late lower cranial neuropathy (LCNP) on severity of cancer
treatment-related symptoms and general functional impairment (GFI) among long-term
oropharyngeal cancer (OPC) survivors?
Findings In this large cross-sectional survey (n=889), OPC survivors with late LCNP
reported significantly worse cancer treatment-related symptoms.
Meaning Further efforts are necessary to lessen symptom burden associated with this
disabling late effect of cancer treatment experienced by OPC survivors.
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Abstract
IMPORTANCE: Lower cranial neuropathy (LCNP) is a rare but potentially disabling late
effect of radiotherapy (RT) and other head and neck cancer therapies. Survivors who develop
late LCNP may experience profound functional impairment with deficits in swallowing,
speech, and voice.
OBJECTIVE: To investigate the impact of late LCNP on severity of cancer treatmentrelated symptoms and their subsequent impact on general functional impairment (GFI)
among oropharyngeal cancer (OPC) survivors. Impact of late LCNP on single item scores of
the most severe symptoms was also assessed. We hypothesized that late LCNP status among
OPC survivors would be associated with significantly worse symptom scores and GFI.
DESIGN: Cross-sectional survey analysis among 889 OPC survivors nested within a
retrospective cohort of OPC survivors treated during January 2000 -December 2013.
SETTING: MD Anderson Cancer Center
PARTICIPANTS: Eligible survey participants were disease-free and completed OPC
treatment ≥1-year prior to survey.
EXPOSURE: Late LCNP defined by onset ≥3-months after cancer therapy.
MAIN OUTCOME: The primary outcome variable was the mean of the top 5 most severely
scored symptoms from MD Anderson Symptom Inventory Head and Neck Cancer Module
(MDASI-HN) out of all 22 core and HNC-specific symptoms. Secondary outcomes included
mean MDASI-HN interference scores and single item scores of the most severe symptoms.
Multivariate models regressed MDASI-HN scores on late LCNP status adjusting for clinical
covariates.
RESULTS: Overall, 4% (n=36) of 889 OPC survivors (median survival time: 7 years)
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developed late LCNP.
Late LCNP was significantly associated with worse mean top 5 MDASI-HN symptom scores
(coefficient, 1.54; 95%CI, 0.8, 2.2) adjusting for age, survival time, sex, therapeutic modality,
T-stage, subsite, type of radiotherapy, smoking, and normal diet prior to treatment. Late
LCNP was also associated with single item scores for difficulty swallowing/chewing
(coefficient, 2.25; 95%CI, 1.3, 3.1), mucus (coefficient, 1.97; 95%CI, 1.0, 2.9), fatigue
(coefficient, 1.35; 95%CI, 0.4, 2.2), choking (coefficient, 1.53; 95%CI, 0.6, 2.4), and voice/
speech symptoms (coefficient, 2.3; 95%CI, 1.6, 3.0) in multivariable models. However late
LCNP was not significantly associated with mean interference scores after correction for
multiple comparisons.
CONCLUSION AND RELEVANCE: In this large survey study, OPC survivors with late
LCNP reported significantly worse cancer treatment-related symptoms demonstrating the
impact of late LCNP on both symptom severity and burden.
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Introduction
The incidence of oropharyngeal cancer (OPC) is increasing by 5% annually in the
1

United States. It is projected that by 2030 half of head and neck cancers (HNC) will be
1

OPC. This phenomenon is attributable to the epidemic of human papillomavirus (HPV)associated OPC, which is usually diagnosed in middle age.

1-4

HPV-disease is biologically

favorable with excellent prognosis for long-term survival despite advanced-stage cancer.

2-4

Despite excellent prognosis, survivors may experience severe side-effects of cancer treatment
impacting critical functions like speech, breathing, and swallowing.
Late lower cranial neuropathies (LCNP) are a rare, but potentially severe late effect
induced by damage due to radiotherapy (RT) and other cancer therapies. Lower cranial
nerves include glossopharyngeal (IX), vagus (X), accessory (XI) and hypoglossal (XII)
nerves, which are critical to the oropharyngeal phases of swallowing, shoulder function, and
speech, respectively.

5-9

Fibrosis of nerve tracts or adjacent soft tissues can lead to delayed,

typically progressive, neuro-vascular damage and eventually neuropathy which over time
5

causes profound functional impairments. According to a recent single institution report, the
incidence of delayed LCNP among 59 OPC survivors was 5% at 5.7 years.

6

Although a rare late effect, case reports suggest profound functional impairments and
overall low quality of life (QOL) among LCNP cases.5-8Symptom burden is defined as
severity of symptoms experienced by patients and the impact of those symptoms on day-to10

day life. Patients may experience symptoms due to disease, recurrence, or as a consequence
10

of treatment-related toxicity. Late toxicities, such as late LCNP, conventionally persist or
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occur ≥ 3 months after treatment completion but may develop even years later.11
General functional impairment (GFI) is defined as a diminished ability to take care of
12

oneself, manage the household, work, and indulge in activities for relaxation. Thus, GFI
12

can adversely impact the daily lives of survivors. Treatment-related symptoms may have
detrimental impact on GFI marked by symptom interference scores. For some patients, the
impairment is temporary, and with time they return to normal activity and function. However,
a substantial number of OPC survivors continue to experience limitations, disability, and may
be unable to return to normal activities including work leading to a long-term economic
impact.12-13
Previous studies examining late radiation-associated LCNP have been case reports or
small case series or cohorts of predominantly nasopharyngeal cancer (NPC) survivors. In
OPC, severe symptoms have been described among LCNP cases, but the late LCNP and
symptom relationship has yet to be quantified, nor has impact on GFI.7, 8 For the growing
numbers of OPC survivors at risk for experiencing LCNP, it is critical to quantify the impact
of late LCNP on severity of cancer treatment-related symptoms and GFI to inform
development and implementation of targeted strategies for late effect surveillance and
management.
The purpose of this analysis was to investigate the severity of cancer treatmentrelated symptoms (per primary endpoint of top 5 MDASI-HN symptom mean) and their
subsequent impact on GFI (per secondary endpoint of mean MDASI-HN interference score)
by late LCNP status among OPC survivors. Impact of late LCNP on overall mean symptom
burden single item scores of most severe symptoms, and categorical ratings of top 5
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symptoms was also assessed to explore impact on diverse symptom metrics. We
hypothesized that late LCNP status would be associated with significantly worse symptom
scores and GFI.

Methods

Patient Eligibility
An IRB-approved cross-sectional patient-reported outcome (PRO) survey was
conducted among survivors of a retrospective cohort of OPC survivors treated at MD Anderson
Cancer Center (MDACC) between January, 2000 and December, 2013. Eligible participants
were ≥ 18 years of age at diagnosis, completed OPC treatment ≥ 1 year prior to survey, and
consented to future research participation at new patient registration within the institution.
Deceased patients, those who had a secondary primary malignancy (SPM) or recurrent
malignancy of the head and neck prior to survey, and those whose primary language was not
English were excluded. Patients with LCNP of any cause at the time of cancer diagnosis or
with clinical signs of LCNP before starting cancer treatment were also excluded. Details of
survey administration and response have been published previously.

14

OPC Treatment
Institutional practices regarding OPC treatment during the time period of this study
have been previously described.15 Standard of care treatment during the current study time
period for stage I/II OPC was definitive radiation and for patients with locally advanced OPC
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(III/IV) was definitive chemoradiation.15-17 During 2000-2006, both IMRT and 3D conformal
radiation technique were routinely used, but after 2006 IMRT became the primary modality
of treatment.15 The recommended radiation dose for small volume primary tumors was 66 Gy
and for more advanced tumors was 70-72 Gy.15 For treatment of primary tumors and nodes in
the upper neck region predominantly IMRT approach was used, whereas for nodes in the
lower neck anterior beam technique with laryngeal and or full midline block was used.
Further, for treatment of primary tumors and the neck region when split-field IMRT was not
possible whole-field IMRT technique was used. Individual extent of primary disease and preexisting comorbidities were taken into account to decide whether patients would receive
systemic therapy or not. Definitive surgery via transoral resection to primary site was rare but
after 2009, a small number of patients were treated with Transoral robotic surgery (TORS)
with adjuvant therapy based on pathologic features. 15-17

Demographic and Clinical Variables
Age at diagnosis, sex, race, education, smoking history, and HPV/p16 status were
abstracted from electronic medical records. Clinical and treatment data abstracted included
subsite of primary OPC tumor, tumor and nodal stage (AJCC version VII), treatment
modality, RT dose, modality and fractionation, surgery, chemotherapeutic regimen, and
ability to eat solid food at baseline (surrogate for baseline dysphagia). Survival time was
calculated as the difference between age at diagnosis and age at time of survey.
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Survey Items
The MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASIHN) is a 28-item validated PRO instrument that evaluates symptom severity and interference
in HNC patients. MDASI-HN includes 13 questions to assess core symptoms common across
all cancers and 9 questions to assess HNC-specific symptoms. MDASI-HN symptom severity
item scores range from 0 “not present” to 10 “as bad as you can imagine.” MDASI-HN also
includes 6 interference questions to assess the impact of symptoms on daily function with
respect to general activity, walking, work, mood, relations with other people, and enjoyment
of life. These item scores range from 0 “do not interfere” to 10 “interfere completely,” such
that higher scores indicate more limitations and lower QOL.

14-21

Symptom and interference

scores are commonly classified as: 0 “no symptom”; 1-3 “mild”; 4-6 “moderate” and 7-10
22

“severe” symptoms. Mean subscale scores have been shown to be internally consistent
(Cronbach alpha: 0.72-0.92).

14-21

Primary Exposure
Late LCNP was assessed during surveillance and rehabilitation visits by clinical
examination of cranial nerves by head and neck surgeons, radiation oncologists, and speech
pathologists, and recorded in medical charts. Late LCNP was defined as onset of swallowingassociated neuropathy of at least one of the glossopharyngeal (IX), vagus (X), and
hypoglossal (XII) nerves with minimum onset ≥ 3 months after the end of cancer treatment.
Three months is considered the start of late toxicity interval as per the NCI – Common
Toxicity Criteria Manual, “Late radiation effects are defined as effects that occur 90 days and
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onwards after initiation of RT treatment.”11 For this reason, we elected to code any onset of
LNCP after 3 months and up until the survey response as a late LCNP. Polyneuropathy was
present in some patients with LCNP but there was no standard method to document degree of
neuropathy in medical charts. Medical records were reviewed to identify LCNP cases.
Physical examination reports were reviewed in detail. Objective methods such as endoscopy
and radiographic swallow studies were not universally available for such a large study
sample but were reviewed in detail when available. CT and MRI were used to verify LCNP,
but they were not a requirement for case status assessment. Case status was verified through
independent review of a head and neck surgeon with review of surveillance CT and MRI to
rule out malignancy or other sources of neuropathy. Electromyography was not routinely
used.

Primary Outcome: The primary outcome variable for this study was the mean of the top 5
most severely scored symptoms out of all 22 core and HNC-specific symptoms. This
methodology, reported in the MDASI user guide and previous symptom research studies,
serves as an estimate of the severity of the most impactful and prevalent symptoms reported
by this population.23-26

Secondary Outcome: Results of the MDASI-HN can be summarized in various ways.
Therefore, four secondary outcomes of the MDASI-HN were evaluated to fully explore the
impact of late LCNP on symptom burden. Secondary outcomes included: 1) overall mean of 22
symptom items, 2) mean interference, 3) single item scores of the top 5 most severe symptoms,
and 4) categorical ratings of top 5 symptoms.
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Overall mean symptom scores summarize all 22 items of core and HNC- specific
symptoms to reflect overall symptom severity. Mean interference serves as a marker of GFI
with sub-domains of activity-related interference (using item scores related to general activity,
work, and walking) and psychosocial-related interference (using item scores related to mood,
relations with other people and enjoyment of life). Single item scores of the top 5 most severe
symptoms, while extant in our primary endpoint (mean of top 5) were evaluated to reflect
impact of LCNP on individual symptoms to provide insight on particular functional domains
where LCNP had the greatest negative impact that might be helpful to focus supportive care
efforts for this population. Finally, categorical ratings were examined to allow ease of clinical
interpretation to identify proportions of patients experiencing high grade symptoms
(supplementary analysis).22

Statistical Analysis
Descriptive and univariate analyses were first performed. For the primary outcome,
mean top 5 MDASI-HN symptoms, multiple linear regression was next used to investigate
associations between LCNP status and MDASI-HN scores, controlling for age, sex, race, Tstage, subsite, RT dose, fractionation, and modality, chemotherapy, surgery, eating solid food
at baseline, survival time, and smoking, which according to previous literature, are co-factors
27, 28

that associate with toxicity and symptom burden.

Model building followed the purposeful variable selection method of Hosmer and
29

Lemeshow. Candidate predictors with p < 0.25 on univariate Wald test were entered into
multivariable models and removed stepwise (p > 0.2). Age, T-stage, subsite, treatment

120

modality, and smoking were a priori retained as clinically important covariates and included
in all models. Coefficients (unadjusted and adjusted) and corresponding 95% confidence
interval (CI) were estimated. Impact of late LCNP on secondary outcomes were evaluated
using multiple regression methods adjusting for the same variables as the primary outcome
analysis. All data were analyzed without imputation for missing information. Given our
consideration of multiple MDASI-HN parameters as symptom burden outcomes, analysis of
all twelve primary and secondary outcomes including top5 mean, overall 22-item mean,
mean interference including activity-related and psychosocial domains, individual scores for
top 5 symptoms, voice and categorical ratings was corrected for multiple comparisons. After
Bonferroni correction (α=0.05/12), statistical significance was conferred at p < 0.004.
Statistical analysis was conducted using the STATA software, version 14.0 (StataCorp LP,
College Station, TX).

Results

Sample Characteristics
889 eligible survivors were included in the final analytic sample with a median
survival duration at time of survey of 7.0 years (range: 1-16). OPC survivors were mostly
white (92%, 821/889), male (84%, 753/889), and had higher than high school education
(72%, 637/889). Almost all were treated with RT (99%, 881/889), and few were treated with
definitive surgery (3%, 24/889).
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Late Lower Cranial Neuropathy
Overall, 4% (n=36) of OPC survivors were diagnosed with late LCNP and these
cases had longer survival (median, 10.5 years). The median time to onset among LCNP cases
in our study was 5.25, (range: 0.25 to 12.3) years after RT. Among late LCNP cases, 58%
(22/36) had T1-T2 tumors, 42% (15/36) received accelerated RT, 25% (9/36) were treated
with 3-D conformal RT and 64% (23/36) received IMRT-SF and almost all could
functionally eat a normal diet prior to treatment.
Median RT Dose among respondents with LCNP was slightly higher (70 Gy, range:
60-72 Gy) in comparison to those without late LCNP (69.3 Gy, range: 40-73 Gy). 68%
(605/889) of respondents received chemotherapy and rate of LCNP was slightly higher
among respondents who received chemotherapy (risk difference; 0.26, 95% CI: -2.6, 3.0) in
comparison to those who did not.

Treatment-related Symptom Burden (Mean of Top 5 symptoms)
The mean of each of the top 5 most severe symptoms reported by OPC survivors are
summarized in Table 1 and included in descending order: dry mouth (mean 3.9± 2.9),
swallowing/chewing (mean 2.6±2.8), mucus (mean 2.3±2.4), fatigue (mean 2.0± 2.5), and
choking (mean 2.0± 2.6). Overall treatment-related symptom burden among all survivors was
low (mean 2.6, median 2.0, range 0-10). Late LCNP cases reported significantly worse mean
treatment-related symptom scores compared to those without LCNP (LCNP: 4.5 vs. no
LCNP: 2.5, mean difference; -2.0; 95%CI, -2.7, -1.3).
.
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Unadjusted univariate analyses showed survival time, T-classification, therapeutic
modality, chemotherapy, RT dose, fractionation, and modality, and smoking had significant
associations with mean scores. Multiple linear regression identified that late LCNP was
significantly associated with worse mean top 5 MDASI-HN symptom scores (Coefficient,
1.54; 95%CI, 0.8, 2.2, adjusted R2, 0.08) adjusting for age, survival time, sex, therapeutic
modality, T-stage, subsite, RT modality, smoking, and normal diet prior to treatment.

Overall Mean (22-item) MDASI-HN
LCNP cases reported significantly worse mean overall 22-item mean scores
compared to those without LCNP (LCNP: 2.4 vs. no LCNP: 1.4, mean difference; -1.0;
95%CI, -1.5, -0.5). Late LCNP remained significantly associated with worse overall 22-item
mean scores (Coefficient, 0.75; 95%CI, 0.2, 1.2,) after multivariable adjustment.

GFI/ Mean Interference
Late LCNP was not significantly associated with worse mean interference scores
after multivariable adjustment and correction for multiple testing. Impact of late LCNP on
individual domains of interference scores categorized as activity-related and psychosocialrelated was also not statistically significant after correction for multiple comparison.

Individual Top 5 Symptoms and Voice/Speech Symptom
Individual symptoms that were most severe among late LCNP cases, in rank order of
means, included difficulty swallowing/chewing (LCNP: 5.5 vs. no LCNP: 2.5, mean
difference;-2.9; 95%CI, -3.9,-2.0), dry mouth (LCNP: 4.9 vs. no LCNP: 3.8, mean difference;
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-1.0; 95%CI, -2.0,-0.4), mucus (LCNP: 4.7 vs. no LCNP: 2.3, mean difference; -2.5; 95%CI,
-3.4,-1.5), voice/speech (LCNP: 4.4 vs. no LCNP: 1.3, mean difference; -3.1; 95%CI, -3.9,2.3) and choking (LCNP: 4.1 vs. no LCNP: 1.9, mean difference; -2.1; 95%CI, -3.0,-1.3).

Late LCNP was significantly associated with worse mean swallowing/chewing scores
(coefficient, 2.25; 95%CI, 1.3, 3.1adjusted R2, 0.10), mucus problems (coefficient, 1.97;
95%CI, 1.0, 2.9, adjusted R2, 0.07), fatigue (coefficient, 1.35; 95%CI, 0.4, 2.2, adjusted R2,
0.03), and choking/coughing (coefficient, 1.53; 95%CI, 0.6, 2.4, adjusted R2, 0.07) adjusting
for the same variables as the primary outcome analysis. However, late LCNP was not
significantly associated with worse dry mouth after multivariable adjustment. As late LCNP
can include vocal cord paralysis and/or lingual paralysis (with associated impact on voice and
speech production), the impact of late LCNP on voice/speech was assessed in exploratory
post hoc analysis despite its exclusion from the top 5 items in the overall sample. Late LCNP
was independently associated with worse mean MDASI-HN voice scores (Coefficient, 2.3;
95%CI, 1.6, 3.0, adjusted R2 – 0.17) after multivariable adjustment.
Among LCNP cases, a higher proportion reported severe (LCNP: 20% vs no LCNP:
5%) and moderate (LCNP: 40% vs no LCNP: 15%) symptoms. Additionally, among LCNP
cases, severe scores (≥7) were reported by 43% (15/35) for swallowing/chewing symptoms
and 37% (13/35) for voice/speech problems. Among 35 late LCNP cases, 6 patients rated
difficulty swallowing, 4 rated voice/speech problems, 4 rated choking, and 3 rated mucus as
10 of 10 severity, the worst possible score on MDASI-HN (Supplementary Figure 1).
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Discussion
This large cross-sectional survivorship survey yields a comprehensive, quantitative
assessment of the significant impact of late LCNP on cancer treatment-related symptoms and
their subsequent impact on GFI among OPC survivors. Survey results in almost 900 OPC
survivors treated during 2000-2013 indicated that, although overall treatment-related
symptom burden among all survivors was low, the small subgroup of late LCNP cases (4%)
reported significantly worse treatment-related symptom severity. While the impact of late
LCNP is clinically recognized, prior studies have yet to quantitatively estimate the burden of
this late effect.

Our results suggest, on average, mean of top 5 MDASI-HN items is 1.54 points worse
among survivors with LCNP compared to those without LCNP, even after adjusting for age,
survival time, sex, therapeutic modality, T-stage, subsite, RT modality, smoking, and normal
diet prior to treatment. This reflects a moderate effect size of LCNP on most prevalent
2

symptoms in this survivor population. The adjusted R of the model suggested that late
LCNP explained 8% of the variation in top 5 MDASI-HN mean after accounting for the
2

effects of other covariates. This modest/moderate adjusted R for a single exposure may
reflect the variability of nerve paresis effects on symptoms among survivors due to their
cross-sectional sampling along the continuum of nerve paresis (partial through complete
30

denervation) as progressive deterioration over time is characteristic of late LCNP. That is,
LCNP cases responded to the survey from 2 to 16 years after treatment, a timeframe during
which the clinical course of LCNP was likely to vary. This observation is consistent with
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previous case reports suggesting that functional status of cases approximated the trajectories
7

of their neuropathies. That is, as late LCNP remained clinically stable, physiologic
impairment remained steady and, as late LCNP progressed, coincident severe decline in
function and body weight occurred.

7

OPC treatment may lead to multiple local symptoms in the treatment field including
dry mouth, dysphagia, mucositis, choking, speech problems, and lack of taste, among others,
which can contribute to excessive distress and lower QOL.

27, 31

The top 5 symptom means

reported by our study population predominantly featured similar local head and neck specific
side effects (4/5, except fatigue). Given their central role in daily functioning, it is not
surprising that late LCNP cases also reported higher levels of GFI that highly correlated with
symptom severity but this relationship was not statistically significant after multiple
comparison correction. Interestingly, among individual components of the interference
domain, late LCNP seemed to be more strongly associated with activity-related interference
but not psychosocial-related scores, but this relationship was not statistically significant.
These findings may perhaps suggest a more lasting impact of LCNP on activity as opposed to
emotional distress. It is speculated that psychosocial distress associated with late effects may
attenuate over time as patients learn to cope with the emotional distress associated with
physical impairment. Similarly, a previous study investigating QOL among oral cancer
patients per the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N)
demonstrated significantly improved emotional scores in the same time that functional scores
32

deteriorated between 1 month and 6 months after treatment. The authors attributed this to a
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“response shift” which they described as emotional adaptation to decline in physical
functioning and improved coping with the “new normal” level of functioning. 32 These trends
are also consistent with results of a study among HNC patients using the MD Anderson
Dysphagia Inventory (MDADI), which reported better scores for the emotional versus
functional component.

33

Overall, late LCNP most strongly associated with worse swallowing/chewing and
speech/voice symptoms, with LCNP explaining 10% and 17% of the variation in these
scores, respectively. These findings agree with those reported by a longitudinal study among
57 OPC survivors wherein 3 LCNP cases experienced severe decline in swallowing function
over time, as per patient-reported MDADI scores, clinician-rated radiographic dysphagia
6

grades (DIGEST), and standard diet scales (PSS-HN). Late LCNP also strongly associated
with worse mucus and choking scores in the present survey, which may reflect symptoms
associated with swallowing effects of LCNP. Inefficient swallows described previously in
LCNP cases impact the ability to effectively clear food and liquids through the oropharynx,
7

including mucus. Mucus accumulation can lead to unpleasant symptoms of gagging and
choking. This may also reflect aspiration of food and liquids during swallowing as previously
reported in 100% of cases with neuropathy mediated late radiation-associated dysphagia
34

(late-RAD) comprised largely of long-term OPC survivors >5-years post-treatment.
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Lower cranial nerves are critical to the oropharyngeal phase of swallowing as well as
voice and speech production.

5-9

CN IX palsy may lead to swallowing problems by way of

loss of function of the stylopharyngeus muscle and loss of pharyngeal sensation, whereas CN
X injury can cause paralysis of the pharyngeal constrictors and/or vocal cords (depending on
the branch), and thereby contribute to dysphagia as well as voice impairment. Neuropathy of
CN XII results in tongue paresis, atrophy, and fibrillations with implications also to
swallowing and speech precision.

5-9

Therefore, the specific patterns of symptom burden

detected in this survey align with the clinical impact of specific LCNPs among OPC patients.
Fatigue is widely prevalent in HNC survivors but was also reported with greater
severity among LCNP cases, which may be because of late LCNP-associated mucus
35

problems that could exacerbate sleep disturbance. LCNP-associated swallowing
dysfunction can also contribute to long-term micronutrient deficiency and complications like
anorexia, malnutrition, anemia, and cachexia. Cachexia especially has been linked in past
36

studies to functional limitations and fatigue. Furthermore, lack of association between late
LCNP and dry mouth is expected, given that dry mouth is not a consequence of lower cranial
nerve injury and is instead caused by RT-induced hypofunction of salivary glands.

37

With approximately 900 OPC survivors, this study is the first to quantitatively
estimate the impact of late LCNP on treatment-related severity of symptoms. There are,
however, limitations to acknowledge. Cross-sectional survey administration led to
respondents with varying survival time and survival bias. Given the long latency period for
late LCNP development, risk is highest among responders with greater survival time. For this
reason, survival time was accounted for in all regression models. The small number of events
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is a limitation inherent to studies of LCNP, as it is known to be a rare late effect.
Nonetheless, consistently robust effect estimates on study outcomes were identified that
reflect expected outcomes from clinical observations. This study was conducted in a tertiary
care cancer center making it subject to referral bias that can limit generalizability of results to
other hospitals and communities, but sample characteristics are common of modern OPC in
the US, therefore, impact of this issue is expected to be negligible. The largest threat to
validity is the possibility of misclassification. Late LCNP ascertainment may be incomplete
due to loss to follow-up, missing chart details, or differential follow-up among patients
displaying mild cranial neuropathy symptoms insufficient to merit return to clinic for late
LCNP. Therefore, exposure misclassification in this study would most likely lead to underreporting of LCNP and consequently to underestimation of LCNP impact on symptom
burden. Thus, if misclassification was substantial, actual coefficients for LCNP and symptom
burden may be higher than reported in this study. With cross-sectional survey, degree or time
course of LCNP was not standard in all cases. There was, for instance, no standard method to
document degree of neuropathy in medical records. Likewise, the impact of LCNP on diet
and other functional parameters was not assessed and will be investigated in future
publications. We also did not obtain detailed validated measures of anxiety and depression
and therefore the impact of late LCNP on these domains need to be investigated in future
studies using other more robust measures.
Symptom burden can be reflected by many parameters of the MDASI-HN. Each of
the MDASI-HN outcomes we report in this analysis is described in the MDASI user guide as
options to report findings from the instrument. It is important to acknowledge, however, that
the top 5 mean MDASI-HN metric has not been evaluated for validity in a dedicated
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publication. It is, however, supported by both the MDASI user manual and by expected
performance relative to clinical and demographic classifiers in this report and other
publications. 23-26Evaluation of individual items as a secondary endpoint also suggested that
late LCNP had a greatest negative impact on difficulty swallowing, speech, mucus problems,
choking, and fatigue symptoms among OPC survivors. For this reason, the functional
translation of late LCNP may lead to placement of feeding tubes, tracheostomy tubes,
aspiration, and pneumonia, as has been described in smaller series with more objective
metrics.6-8Smaller series, however, fail to include non-LCNP controls such that effect sizes
from these more objective metrics are not available in current literature. It is our hope that
these survey-based quantifications offer initial progress toward quantifying the impact of this
rare but devastating late effect of treatment.
This research can inform development of supportive care interventions among OPC
survivors to target these symptom domains through personalized speech and swallowing
therapy and nutritional consultations and such implications need to be assessed in future
studies. Given the high degree of symptom burden, the authors support the integration of
interdisciplinary supportive care early to potentially attenuate or slow the functional impact
of LCNP. Diverse symptoms likely merit involvement of speech pathologists, oral
oncologists, physiatrists, physical therapists, nutrition, and oncology nursing among others to
optimize outcomes. Targeted and individualized treatments must take into consideration
patient perspectives and routine symptom screening using validated PROs such as MDASIHN in patients with LCNP may also be of value to prioritize areas for intervention.
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Conclusions
In this large survey study, late LCNP cases reported significantly worse cancer
treatment-related symptoms, and worse symptoms associated with motor functions of the
upper aerodigestive tract (swallowing, voice), demonstrating the relevance of late LCNP to
both symptom severity and QOL. Among LCNP cases, a higher proportion reported severe
(LCNP: 20% vs no LCNP: 5%) and moderate (LCNP: 40% vs no LCNP: 15%) symptoms.
There is a clear need for long-term surveillance of late LCNP among HNC and OPC patients,
particularly in light of epidemiologic trends that suggest growing numbers of OPC survivors
at risk of late effects in immediate years ahead.6-8 Further, efforts are necessary to lessen
symptom burden associated with this disabling late effect among OPC survivors.
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Table 1: Patient Characteristics 889 (N=889), Top 5 mean MDASI-HN:
Variables

Age at diagnosis,
median (range)
Survival time, median
(range)
Radiation Dose, Gy.
median (range)
Sex
Female
Male
Education
≥Highschool
>Highschool
Missing
Race
Others
White
Missing
Primary Site
Tonsil
Base of Tongue
T classification
1
2
3
4
N classification
N0
N1+2a
2b+3
2c
HPV status
Negative
Positive
Unknown
Smoking
Never
Former
Current
Solid Food pre-Tx
Yes
No
Treatment Group
Single Modality
Multimodality
Treatment Group
RT alone
Surgery alone
RT plus systemic

No. of Patients

LCNP Rate (%)

Top 5 mean MDASIHN Score (+/-Standard
Deviation)
All patients (n=906)
56 (32-84)
7(1-16)
70 (40-73)

136 (15.3)
753 (84.7)

5(3.7)
31(4.1)

2.81 ± 2.3
2.57 ± 2.1

168(18.9)
637(71.7)
84(9.4)

8(4.8)
27(4.2)
1(1.2)

2.95 ± 2.4
2.49 ± 2.1
2.86 ± 2.3

59(6.6)
821(92.4)
9(1.0)

3(5.0)
32(3.9)
1(11.1)

2.79 ±2.7
2.60 ± 2.1
2.44 ± 1.7

438(49.3)
451(50.7)

17(3.8)
19(4.2)

2.58 ± 2.2
2.64 ± 2.2

334(37.6)
345(38.8)
131(14.7)
79(8.9)

8(2.4)
13(3.8)
8(6.1)
7(8.9)

2.37 ±2.1
2.52 ±2.1
2.89 ±2.3
3.56 ±2.5

81(9.1)
236(26.5)
429(48.3)
143(16.1)

3(3.7)
7(2.9)
19(4.4)
7(4.9)

2.58 ±2.3
2.48 ±2.2
2.50 ±2.0
3.16 ±2.4

56(6.3)
429(48.3)
404(45.4)

2(3.6)
9(2.1)
25(6.2)

2.37 ±1.9
2.46 ±2.1
2.80 ±2.3

409(46.0)
422(47.5)
58(6.5)

16(3.9)
17(4.0)
3(5.2)

2.49 ±2.1
2.64 ±2.1
3.22 ±2.5

879(98.9)
10(1.1)

35(4.0)
1(10.0)

2.56 ±1.8
2.61 ±2.2

278(31.3)
611(68.7)

11(4.0)
25(4.1)

2.34 ±2.1
2.73 ± 2.2

270(30.4)
8(0.9)
596(67.0)

11(4.1)
0
23(3.9)

2.38 ±2.1
0.80 ±0.7
2.73 ±2.2
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Surgery plus adjuvant
Radiotherapy
No
Yes
Chemotherapy
No
Yes
Surgery
No
Yes
Neck Dissection
No
Yes
RT Schedule
Standard Fractionation
Accelerated
Missing
RT Type
3d Conformal
IMRT-SF
IMRT- WF
Proton
IMRT Ipsilateral

15(1.7)

2(13.3)

2.64 ±2.3

8(0.9)
881(99.1)

0
36(4.1)

0.80 ±0.8
2.62 ±2.2

284(32.0)
605(68.0)

11(3.9)
25(4.1)

2.34 ±2.1
2.73 ±2.2

865(97.3)
24(2.7)

34(3.9)
2(8.3)

2.63 ±2.2
1.91 ±2.0

665(74.8)
224(25.2)

27(4.1)
9(4.0)

2.64 ±2.2
2.52 ±2.2

778(88.3)
95(10.8)
8(0.9)

21(2.7)
15(15.8)
0

2.54 ±2.1
3.40 ±2.4
1.76 ±1.9

50(5.7)
675(76.6)
33(3.8)
23(2.6)
100(11.3)

9(18.0)
23(3.4)
1(3.0)
1(4.4)
2(2.0)

4.34 ±2.6
2.63 ±2.1
2.72 ±2.3
2.14 ±1.6
1.8 ±1.6

Abbreviations: T, tumor; RT, radiotherapy; MDASI-HN, MD Anderson Symptom Inventory Head
and Neck Cancer Module (MDASI-HN
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Table 2. Top 5 MDASIHN Univariate and Multivariate Regression (n=889)
Variables
Late LCNP
No
Yes
Age at diagnosis
Survival Time
Radiation Dose
Sex
Female
Male
Education
≤Highschool
>Highschool
Missing
Race
Others
White
Missing
Primary Site
Tonsil
Base of Tongue
T classification
1
2
3
4
Smoking
Never
Former
Current
Solid Food pre-Tx
Yes
No
Treatment Group
Single Modality Tx.
Multimodality Tx.
Radiotherapy
No
Yes
Chemotherapy
No
Yes
Surgery
No
Yes,
Neck Dissection
No
Yes
RT Schedule
Standard Fractionation
Accelerated

Univariate Analysis Coefficient
(95%CI)

Multivariate Analysis Coefficient
(95%CI)

Reference
2.00 (1.28, 2.72) ***
0.001 (-.02, .02)
0.06 (.02, .09) *
0.10 (.04, .15) *

Reference
1.54 (.82, 2.27) ***
0.007 (-.01, .02)
0.02 (-.03, .06)

Reference
-0.24 (-.64, .16)

Reference
-0.32 (-.71, .08)

Reference
-0.46 (-.83 -.09) *
-0.09 (-.66, .48)

Reference

Reference
-0.20 (-.78, .39)
-0.35 (-1.87, 1.18)

Reference

Reference
0.07 (-.22, .36)

Reference
-0.08 (-.38,.23)

Reference
0.15(-.17, .48)
0.52 (.08, .96) *
1.19 (.65, 1.73) ***

Reference
0.007 (-.33,.35)
0.06 (-.42, .54)
0.73 (.16,1.30) **

Reference
0.14 (-.15, .44)
0.73 (.12, 1.33) *

Reference
0.12 (-.18,.41)
0.62 (.03, 1.22) **

Reference
0.06 (-1.29, 1.42)

Reference
0.60 (-.64,1.85)

Reference
0.40 (.09, .71) *

Reference
0.17 (-.20, .53)

Reference
1.83 (.32,3.33) *
Reference
0.40 (.09, .70) *

Reference

Reference
-0.72 (-1.61, .18)

Reference

Reference
-0.11 (-.46,.22)

Reference

Reference
0.85 (.39, 1.32) ***

Reference
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Missing
RT Type
3d Conformal
IMRT-SF
IMRT- WF
Proton
IMRT-Ipsilateral

-0.77 (-2.27, .74)
Reference
-1.71 (-2.33, -1.10) ***
-1.62 (-2.55, -.68) *
-2.20 (-3.25, 1.15) ***
-2.54 (-3.27, -1.81) ***

-1.34 (-2.02, -.66) ***
-1.33 (-2.29, -.38) **
-1.76 (-2.89, -.63) **
-2.06 (-2.89, -1.23) ***

Abbreviations: T, tumor; RT, radiotherapy; MDASI-HN, MD Anderson Symptom Inventory Head
and Neck Cancer Module (MDASI-HN)
* Statistical significance p value < 0.05 after Univariate Analysis
** Statistical significance p value < 0.05 after Multivariate Analysis
*** Statistical significance p value < 0.001
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FIGURE 1: Consort flow chart

Figure 1. Consort flow chart showing study participant recruitment and eligibility criteria.
Abbreviations: SPM, second primary malignancy; LRR, locoregional recurrence; DM, distant
metastasis; LCNP, lower cranial neuropathy; MDASI-HN, MD Anderson Symptom Inventory Head
and Neck Cancer Module (MDASI-HN).
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Figure 2: Crude/Unadjusted Difference in means of individual MDASI-HN symptom
severity by Late LCNP status.

Appetite 1.26 (0.5, 1.9) *

Choking/Coughing 2.15 (1.3, 3.0) *
Constipation 0.45 (-0.2, 1.1)

MDASI-HN Core and Head and Neck 22 Symptoms

Disturbed Sleep 0.89 (0.1, 1.7) *
Drowsy 1.14 (0.4, 1.9)
*
Dry mouth 1.02 (0.04, 2.0) *
Fatigue 1.47 (0.6, 2.3) *
Memory 0.09 (-0.7, 0.9)
Mucus 2.48 (1.6, 3.4) *
Nausea 0.25(-0.1, 0.6)
Numbness 1.35 (0.5, 2.2) *
Pain 0.58 (-0.1, 1.3)
Sad 0.39 (-0.3, 1.1)
Shortness of Breath 0.68 (0.02, 1.3) *
Skin 0.24 (-0.2, 0.7)
Sores 0.04 (-0.5, 0.5)

Swallowing/Chewing 2.94 (2.0, 3.9) *
Taste 0.8 (-0.1, 1.7)
Teeth 0.26 (-0.6, 1.1)
Upset 0.7 (0.02, 1.4) *
Voice/Speech 3.1 (2.3, 3.9) *

Vomiting 0.1 (-0.1, 0.4)

-2

-1

0

1

2

3

4

5

Difference in means by Late LCNP status and 95% Confidence Interval

Figure 2. Crude/Unadjusted Difference in means of individual MDASI-HN symptom severity by Late
LCNP status. Darkened circles represent estimate of difference in means and bars represent 95%
Confidence Intervals. * Denotes statistical significance conferred if 95% confidence for the estimate
did not include the null value. Abbreviations: MDASI-HN, MD Anderson Symptom Inventory Head
and Neck Cancer Module (MDASI-HN); LCNP, lower cranial neuropathy.
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Figure 3: Multivariate Adjusted Coefficients for Late LCNP and MDASI-HN Scores.
1.54 (0.8-2.2) **
1.53 (0.6-2.4) **
1.35 (0.4-2.2) **
1.97 (1.0-2.9) **
2.25 (1.3-3.1) **
0.63 (-0.3-1.6)
2.30 (1.6-3.0) **
0.75 (0.2-1.2) **
0.72 (0.09-1.3) *

LCNP better

LCNP worse symptoms

Figure 3. Multivariate Adjusted Coefficients for Late LCNP and MDASI-HN Scores.
All regression models adjusted for age, survival time, sex, therapeutic modality, T-stage, subsite, RT
modality, smoking, and normal diet prior to treatment. * Denote statistically significant in
multivariate model before multiple comparison correction. ** Denote statistically significant in
multivariate model after multiple comparison correction (p < 0.004). Abbreviations: MDASI-HN,
MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN); LCNP, lower
cranial neuropathy.
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Abstract
Background: The purpose of this study was to quantify the association of late lower cranial
neuropathy (late LCNP) with swallowing-related quality of life (QOL) and functional status
among long-term oropharyngeal cancer (OPC) survivors.
Methods: Eight hundred eighty-nine OPC survivors (median survival time: 7 years) who
received primary treatment at a single institution between January, 2000 – December, 2013
completed a cross-sectional survey (56% response rate) that included the MD Anderson
Dysphagia Inventory (MDADI) and self-report of functional status. Late LCNP events ≥3months after cancer therapy were abstracted from medical records. Multivariate models
regressed MDADI scores on late LCNP status adjusting for clinical covariates.
Results: Overall, 4.0% (n=36) of respondents developed late LCNP with median time to
onset of 5.25 years post-treatment. LCNP cases reported significantly worse mean composite
MDADI (LCNP: 68.0 vs. no LCNP: 80.2, p<0.001). Late LCNP independently associated
with worse mean composite MDADI (β= -6.7, p=0.015, 95%CI: -12.0, -1.3) as well as all
MDADI domains after multivariate adjustment. LCNP cases were more likely to have a
feeding tube at time of survey (OR= 20.5; 95%CI, 8.6 to 48.9), history of aspiration
pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), and tracheostomy (OR= 26.9; 95%CI, 6.0 to
121.7).
Conclusions: In this large survey study, OPC survivors with late LCNP reported
significantly poorer swallowing-related QOL and had significantly higher likelihood of poor
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functional status. Further efforts are necessary to optimize swallowing outcomes to improve
QOL in this subgroup of survivors.
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INTRODUCTION
Swallowing is a complex and multifaceted neuromuscular process that involves 5
cranial nerves (CN) and almost 30 muscles in the upper aero-digestive tract. Patients with
oropharyngeal cancer (OPC) receive local treatments, radiotherapy (RT), and/or surgery, to
this functionally critical region that can cause chronic dysphagia with adverse impact on
swallowing-related quality of life (QOL). 1-6 Dysphagia is one of the most impactful and
prevalent functional toxicities reported in approximately 30-50% of survivors. 7-10 Prior
analysis of this OPC survivorship found that, among 22 symptoms queried, the severity of
dysphagia symptoms most strongly associated with decisional regret about cancer
treatment.11 The rising incidence of highly curable HPV-associated OPC leads to greater
numbers of OPC survivors at risk of dysphagia with great impetus to understand factors that
associate with poor swallowing outcomes and adversely impact QOL in this growing
population. Dysphagia also leads to excessive morbidity, negatively impacting functional
status and health of OPC survivors. Impaired airway protection can lead to aspiration
pneumonia, and inefficient bolus clearance may result in low food intake, extended
gastrostomy tube dependence, weight loss, and malnutrition. 12 Patients with dysphagia often
modify their diet, need extended meal times, feel self-conscious to eat in social settings, and
thereby experience social isolation and diminished QOL.12
Radiation-associated dysphagia is typically linked with soft tissue injuries including
inflammation, edema, fibrosis, and stricture.13 Acute tissue injury results from cell depletion
and inflammation that contribute to edema, erythema, and mucositis of the oropharyngeal
region.13,14 Late RT injury is defined classically as 3 months or more after cancer treatment,
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and may represent persistence of early injury (i.e., “consequential late effects”) or new
damage linked to excessive collagen accumulation, microvascular damage, and
overproduction of pro-fibrotic growth factors β (TGF-β1) resulting in fibrosis and
atrophy.14,15 The superior pharyngeal constrictor (SPC) region comprises minor nerve tracts
and the constrictor and longitudinal pharyngeal muscles, which are important for pharyngeal
shortening and constriction during swallowing for safe and efficient bolus propulsion into the
esophagus.16 Irradiation to this region, specifically the mean SPC region dose, has been
reported in numerous studies to be associated with chronic and late radiation associated
dysphagia (late-RAD).16-19 Thereby dysphagia may occur as consequence of reduced base of
tongue retraction and elevation of larynx, inadequate retroflexion of epiglottis, pharyngeal
transit delay, and inadequate swallowing muscle action.14
Surgical treatment for OPC including tongue resection involving geniohyoid or
mylohyoid muscles, mandibulotomy-related genioglossus injury and loss of occlusion, lateral
soft palate resection may also cause muscle and nerve injury and contribute to dysphagia.13
Site and extent of tumor resection thereby contribute to severity of dysphagia. 13 Reports also
suggest that head and neck (HNC) patients treated with surgery followed by post-operative
RT may experience cumulative effects and more accelerated effects of RT.6, 13, 20 This may
contribute to additional decline in swallowing function due to diminished oropharyngeal
swallow efficiency. 6, 13, 20
Lower cranial neuropathies (LCNP) are a rare, but permanent late effect of HNC
treatment that injures the glossopharyngeal (IX), vagus, (X), accessory (XI), and/or
hypoglossal (XII) nerves.1, 21-24 These nerves (except XI) play a pivotal role in the
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oropharyngeal swallowing mechanism and thereby their damage can contribute to profound
functional impairment in terms of dysphagia often with co-existing problems in speech and
voice and shoulder impairment. 1, 16, 21-25 A previous study among 59 OPC survivors treated
with intensity modulated radiotherapy (IMRT) reported a 5% incidence rate of late LCNP at
median follow-up of 5.7 years (range: 4.6-7.6 years).1 Among LCNP cases, onset of
neuropathy preceded quantifiable, clinically significant decline in both patient-reported (per
MD Anderson Dysphagia Inventory; MDADI) and clinician-rated (per Modified Barium
Swallow Study; MBS) swallowing function.1 Likewise, the investigators recently published a
large survey of 889 long-term OPC survivors in which LCNP was significantly associated
with excess symptom burden and had the greatest impact on swallowing/ chewing and
voice/speech symptoms among the 22 symptom items rated using the MD Anderson
Symptom Inventory Head and Neck Cancer Module (MDASI-HN), a validated multisymptom survey instrument.26
Previous literature also specifically implicates LCNP as a major contributor to late
radiation associated dysphagia (late-RAD).21, 22 Patients with late RAD often have clinically
detectable LCNP with unilateral paralysis, muscle wasting leading to atrophy of lingual and
pharyngeal musculature with clinical series supporting a prominent role of nerve injury in the
functional decline experienced by these patients. 25 A series of 29 HNC survivors with lateRAD reported that 48% of cases had clinically-detectable cranial neuropathies, and cranial
nerve XII and X palsies were most common.25 Several small published series and case
reports consistently describe severe problems in swallowing, eating, and extreme functional
impairment in pharyngeal phase of swallowing among survivors with late LCNP, with
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associated swallowing inefficiency, pharyngeal residue, and silent aspiration. 1, 16, 21-25
Consequently, about 85% of OPC survivors with late-RAD develop pneumonia and more
than 60% require long-term gastrostomy tube placement highlighting the possible extreme
functional relevance of late LCNP if it indeed is a driver of late dysphagia. 16, 22
The previous literature and prior analysis of symptom burden suggests a strong
association between late LCNP and the severity of dysphagia, however the nature of this
association has not been comprehensively evaluated or quantified in a large population of
survivors. Few studies have addressed late LCNP among OPC survivors, as most of the
published literature on LCNP has been comprised of case reports or studies primarily
conducted among nasopharyngeal cancer (NPC) survivors.27, 28 Studies suggest that risk of
cranial nerve damage increases over time 1, 22, 28 and as survival probabilities improve for
OPC, there is an ever-growing pool of OPC survivors who have received surgery and/or
curative doses of radiotherapy sufficient to induce LCNP. Therefore, there is urgent need to
understand to our fullest ability the functional impact of this disabling late effect of therapy.
Thus, the purpose of this analysis was to quantify the association of late LCNP with
swallowing-related QOL using the MDADI and functional status metrics. We hypothesized
that late LCNP among OPC survivors would be associated with significantly worse
swallowing-related QOL (per MDADI survey scores) and LCNP status would relate to
differences in functional status metrics.
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MATERIALS AND METHODS

Study Design, Eligibility and Consent
This cross-sectional survey was conducted in 2015 among a cohort of OPC survivors
who received primary cancer treatment at MD Anderson Cancer Center (MDACC) between
January, 2000 and December, 2013. An institutional review board-approved patient-reported
outcome (PRO) survey was administered to eligible OPC survivors in the cohort who were ≥
18 years of age at diagnosis, completed their treatment at least 1 year prior to survey
administration, and consented to the study. Exclusion criteria were: patients who were
deceased, those with second primary malignancy (SPM) or recurrent head and neck cancer
tumors preceding survey, and those whose primary spoken language was not English. For
this analysis, patients diagnosed with LCNP or with clinical signs of LCNP prior to initiation
of OPC treatment were excluded. The survey items included in this analysis were the
MDADI, a patient-reported adaptation of the Performance Status Scale for Head and Neck
cancer (PSS-HN) with questions on normalcy of diet and public eating, as well as self-report
of aspiration pneumonia, current feeding tube status, and current weight. A previous
publication provides details of survey administration and response.7

MD Anderson Dysphagia Inventory (MDADI)
The MD Anderson Dysphagia Inventory (MDADI) is a 20-item validated patient
reported outcomes (PRO) instrument that quantifies perceived limitations in swallowing
ability and their impact on day to day activities. 29 MDADI provides subscale scores which
are comprised of emotional (6 questions), physical (8 questions), and functional components
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(5 questions). It also estimates a global summary score (based on 1 question- “My
swallowing limits my day to day activities”) and a composite score (based on 19 questions
excluding the global item).29-32

Scoring of MDADI: The questions related to swallowing function are Likert scaled
with the options of ‘strongly agree’, ‘agree’, ‘no opinion’, ‘disagree’, or ‘strongly disagree’,
scored on a scale of 1-5, respectively, with the exception of two questions (E7 and F2) for
which reverse scoring is calculated. After summation of response scores, mean is estimated
and multiplied by 20 to estimate total score.33 Total scores range from 20-100 with higher
scores reflecting higher perceived swallowing-related QOL. 12, 29, 32, 33 MDADI scores can
be analyzed as continuous or categorical variables with scores classified in the following
categories: ≥80 as optimal, 60-79 as adequate and <60 as poor.10 MDADI was validated
among HNC patients and has internal consistency scored by Cronbach’s alpha of 0.96 and
was documented to have test-rest reliability correlations ranging from 0.69 to 0.88.29

Performance Status Scale for Head and Neck (PSS-HN) Adaptation
An adapted version of the PSS-HN, a validated, clinician-rated interview-based
measure of performance status among HNC patients was included in the survey instrument. 1
The scale was adapted for patient-reported administration and comprised of questions
pertaining to the survivor’s diet level and public eating experience. 1 Normalcy of diet options
included the following: full diet no restriction, full diet with liquid assist, solid food but avoid
some hard to eat foods, soft chewable foods, non-chewable or pureed foods, drink warm and
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cold liquids only, or nothing orally only use a feeding tube. Public eating was coded as the
following: no restriction of place, food, or companion, no restriction of place, restrict diet in
public, eat only in the presence of selected person in selected places, only eat at home with
selected persons, or always eat alone.

Primary and Secondary Outcomes
The primary outcome for this study was mean composite MDADI score which serves
as an estimate of overall swallowing-related quality of life.29-33 The secondary outcomes for
analysis included the emotional, physical and functional subscale and the global MDADI
scores as well as self-reported functional status metrics including current feeding tube status,
normalcy of diet, public eating, history of aspiration pneumonia, current weight,
understandability of speech, and current tracheostomy. Chart abstracted functional data
included baseline weight to calculate percent change in weight between weight at time of
survey and pre-treatment weight, and history of dilations due to presence of stricture. Current
feeding tube status, aspiration pneumonia history, and current tracheostomy were coded as
binary variables. Change in weight was calculated as baseline weight minus current weight
and percent change in weight was calculated as change in weight divided by baseline weight.
Survey questions on functional status metrics have been listed in Appendix 2.

Primary Exposure
Late LCNP was the primary exposure for this analysis. Late LCNP case status was
ascertained by detailed review of medical records of survivors as previously described. 26 For
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this study late LCNP was defined as clinical evidence of neuropathy of at least one of the
glossopharyngeal (IX), vagus (X), and hypoglossal (XII) nerves ≥ 3 months after the end of
cancer treatment.26 The time period was defined considering the NCI-Common Toxicity
Manual’s definition of late radiation effects as occurring 90 days and onwards after RT
therapy initiation.34

Clinical and Demographic Variables
Demographic variables including age at diagnosis, sex, race, and education, and
clinical variables including primary tumor subsite, tumor and nodal staging (AJCC version
VII), treatment modality, chemotherapy, surgery, neck dissection, RT dose, fractionation,
and modality were abstracted from the electronic medical records. Pre-treatment diet (ability
to eat solid foods) was also collected as a surrogate variable for presence of baseline
dysphagia. Survival time for this population was estimated as the difference between age of
diagnosis and age at the time of the survey. History of pharyngoesophageal dilation was used
as a surrogate variable for stricture which can contribute to dysphagia and act as a
confounder in our analysis.

Statistical Analysis
Demographic, clinical, and treatment variables and distribution of MDADI scores by
these variables were summarized using descriptive statistics and univariate analysis. With a
rare event leading to small case numbers for our primary exposure (LCNP), imputation of
MDADI scores was conducted to minimize loss of statistical power due to skipped or
missing MDADI items. Imputation used the mean of responses to MDADI items among
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those patients who responded to that specific item (mean score among non-missing on that
item).35 Post-hoc sensitivity analysis was conducted to assess the impact of imputed, missing
MDADI responses on study results.

Multiple linear regression was used to investigate the association between late LCNP
and MDADI scores controlling for confounders following model building strategies using the
purposeful variable selection method.36 Age, subsite, T-stage, treatment modality and
smoking based on previous literature were defined a priori as clinically important variables
and retained for adjustment in all models. Variance inflation factor was used to assess
collinearity among variables. Biologically plausible interaction terms were also assessed
using the likelihood ratio tests and were considered statistically significant when p-values
were < 0.05. Adequacy and fit of model were assessed using R squares, adjusted R squares,
and Chi-square goodness of fit tests. Coefficients (univariate and multivariate adjusted) for
impact of late LCNP on MDADI scores and their 95% confidence intervals (CI) were
estimated. As secondary analyses, the relationships between late LCNP and functional status
metrics were assessed according to their distributions using the Fisher’s exact test, Wilcoxon
rank-sum test, and Kruskal Wallis test. All reported p-values are two-sided and considered
statistically significant at p-value of ≤ 0.05. Statistical analysis was conducted using the
STATA software, version 14.0 (StataCorp LP, College Station, TX).
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RESULTS
Sample Characteristics
A total of 889 eligible OPC survivors with a median survival time 7.0 (range, 1-16)
years were included in the analysis. Table 1 displays the distribution of demographic, tumor,
and treatment-related characteristics in the study population. The patient characteristics of
this study population have been described fully in an earlier publication. 19 Briefly, 84.7%
were male, 92.4% were white, 71.7% were educated beyond high school, 76.4% had been
treated for T1-T2 tumors, 98.9% could eat a normal solid-food diet prior to treatment, 99.1%
were treated with RT of which 76.6% were treated with intensity-modulated radiotherapy
split-field technique (IMRT-SF), and median radiation dose was 70 Gy (range, 40-73 Gy).
Definitive surgery was rare (2.7%).

Late Lower Cranial Neuropathy
Overall, 36 (4.0%) OPC survivors were diagnosed with late LCNP with median time
to LCNP onset after treatment of 5.3 (range, 0.3-12.3) years. Among them, 21 (58.3%) of
LCNP cases had been treated for T1-T2 tumors, 35 (97.2%) reported eating a normal solidfood diet prior to treatment, all 36 of them received RT, 23 (63.9%) were treated with RT in
combination with systemic treatment, 2 (5.6%) had surgery to the primary OPC tumor, 9
(25.0%) had neck dissection, and 23 (63.9%) were treated with IMRT-SF. Median time from
LCNP onset to survey completion was 2.7 (range, 0.1-14.0) years. Among patients without
LCNP, composite MDADI scores had a mean of 80.1±16.3 and median of 83.2, (range, 26.3100) whereas LCNP cases had a mean of 68.0±17.4 and median of 67.4 (range, 36.8-97.9).
Among LCNP cases, CN XII palsy was most common and present in 86.1% (31/36) of
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LCNP cases. Isolated IX nerve palsy was difficult to ascertain, rather those with pharyngeal
paresis were included as CN IX/X nerve palsy and 50% (18/36) of LCNP cases had CN IX
or/and CN X neuropathy. Polyneuropathy was also present among 36.1% (13/36) of LCNP
cases.

MDADI composite scores
The MDADI composite scores reported by OPC survivors are summarized in Table 1.
Lowest (worse) scores were reported by patients with T4 tumors (68.7 ± 18.9) and those
treated with 3-dimensional conformal RT technique (67.8 ± 20.4), whereas the highest
(better) scores were reported by patients who did not receive RT (89.9 ± 9.4) and those
treated with proton therapy (87.5 ± 11.3). Unadjusted univariate analyses demonstrated that
survival time, education, T-classification, smoking, therapeutic modality, chemotherapy, RT
dose, fractionation, and modality, and stricture had significant associations (p<0.25) with
composite MDADI scores. Composite MDADI scores were also significantly different based
on patient-reported diet levels at the time of survey (p< 0.001).

Late LCNP cases reported significantly worse composite MDADI scores compared to
those without LCNP (LCNP: 68.0 ± 17.4, 95%CI, 62.1 to 73.9 vs. no LCNP: 80.2 ± 16.3,
95%CI, 79.1 to 81.3, p< 0.001). Multiple linear regression identified that late LCNP was
significantly associated with lower (worse) composite MDADI scores (coefficient, -6.7;
95%CI, -12.0 to -1.3; p value = 0.015; adjusted R2, 0.13) after adjusting for age, survival
time, sex, education, subsite, T-stage, smoking, therapeutic modality, RT modality, solid
food diet prior to treatment, and stricture. These results have been summarized in Table 2.
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When MDADI composite scores were categorized, 38.9% (14/36) LCNP cases had poor
swallowing scores (MDADI<60) in comparison to 12.9% (110/853) patients without LCNP
(OR= 4.3; 95%CI, 2.2 to 8.6).

MDADI Subscale Scores
Late LCNP cases reported significantly lower (worse) scores on all MDADI
subscales and on global MDADI scores. The associations remained significant in multiple
linear regression models after adjusting for significant covariates. These results are
summarized in Table 3. Additionally, global MDADI scores were also highly correlated with
composite MDADI scores (Spearman's rho = 0.8, p<0.001).
Figure 1 summarizes multivariate adjusted coefficients for late LCNP and MDADI Scores
We also compared composite MDADI scores among patients without LCNP, LCNP IX/X
only, LCNP XII only and polyneuropathy illustrated in Figure # 2. Lowest (worst) mean
scores and least variability of scores were reported by LCNP cases with polyneuropathy
which may be suggestive of worsening swallowing function with more cranial nerve injury
indicating a dose-response relationship. Of great concern was that LCNP cases with
polyneuropathy, reported a drop of 18.2 in mean scores in comparison to patients without late
LCNP with about half of them reporting poor composite scores indicating a clinically
meaningful reduction in MDADI scores but this was not statistically significant.
Sensitivity analysis was also conducted including RT dose and HPV status in final
models for all MDADI scores and as the effect estimates for late LCNP remained unchanged
therefore these variables were excluded. Results are presented in Appendix Table 2 and
Table 3.
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Functional status metrics
LCNP status also significantly associated with (p ≤0.001) worse functional outcomes
and health metrics reported by the patient or chart abstracted at the time of survey as detailed
in Table 4. LCNP cases were more likely to have a current feeding tube (OR= 20.5; 95%CI,
8.6 to 48.9), history of aspiration pneumonia (OR= 23.5; 95%CI, 9.6 to 57.6), tracheostomy
(OR= 26.9; 95%CI, 6.0 to 121.7), and were more likely to have undergone dilation for
stricture (OR= 12.3; 95%CI, 4.2 to 36.3) than patients without LCNP. LCNP cases were also
more likely to report restricted oral diets at the time of survey (LCNP: OR= 3.5; 95%CI, 1.5
to 8.3). Mean percentage of reported weight loss from baseline weight to weight at time of
survey was also significantly higher among LCNP cases than patients without LCNP (LCNP:
mean 11.7% vs. no LCNP: 6.0%, p=0.002).

DISCUSSION
Late LCNP is rare with reports of incidence ranging from 3.7% to 25.6%. However,
another cohort study reported 14% incidence of LCNP in 10-year survivors of HNC,
suggesting that risk increases over time.37Our previous report confirmed high symptom
burden among OPC survivors who developed LCNP, with largest effect sizes (coefficient,
2.3 of 10) on swallowing-related symptoms.26 This phenomenon is also clinically recognized,
but previous work has failed to quantify the impact of LCNP on individual swallowing
domains and functional metrics. This large single-center cross-sectional survivorship survey
study among OPC survivors provides a comprehensive evaluation and found significant
associations with moderate effect size between late LCNP and overall swallowing-related
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quality of life, domain-specific swallowing function, as well as functional status metrics
related to swallowing.

Overall, swallowing-related quality of life among all 889 OPC respondents suggested
most survivors perceived acceptable levels of functioning (as per composite MDADI means
of 79.7 ± 16 and 55.2% of survivors reported composite scores ≥80), but the small group of
survivors (n=36) with late LCNP reported a clinically meaningful reduction of > 10 points
difference relative to survivors without LCNP in univariate analyses. 38 This meaningful
reduction was observed for all summary and domain-specific MDADI scores. After
multivariate adjustment for clinical covariates, on an average, composite MDADI scores
were 6.7 points lower (worse) among late LCNP cases versus those without late LCNP. The
adjusted R2 demonstrated that late LCNP explained 13% of the variation in composite
MDADI scores after accounting for the effect of other covariates, which according to
Cohen’s criteria is a moderate effect.39 This moderate effect size is consistent with effect
estimate for the impact of LCNP on patient-reported MDASI-HN swallowing/chewing
symptoms (coefficient, 2.3 of 10) reported in an earlier study and may in part reflect the
subjective nature of PROs that likely vary with individuals’ overall contentment and
satisfaction with life and functional abilities. 12, 13, 40

Late LCNP was also significantly associated with all domain-specific MDADI
subscale scores. Late LCNP cases experienced the greatest deterioration of physical subscale
scores which represent patient perception of swallowing ability; LCNP explained 10% of the
variation in this domain controlling for important confounders. Previous studies have also
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reported lowest MDADI scores on the physical subscale among HNC patients. 10, 38 Further,
among late LCNP cases, the least impact of nerve injury was on the emotional subscale
scores. Emotional subscale scores reflect psychological response to diminished swallowing
ability and functional subscale scores reflect the impact of swallowing impairment on daily
functioning and activities.32 Previous studies among HNC patients have reported the highest
subscale scores in the functional domain and substantial recovery of emotional MDADI
scores over time.10, 40 This may be indicative of adjustment and adaptation to a decline in
swallowing function overtime.40

It is generally believed that PRO instruments may underestimate the prevalence of
dysphagia.41, 42 For this reason, we also explored the relationship between LCNP with other
functional status measures of swallowing ability. As expected, late LCNP status was also
significantly associated with worse functional status metrics including current feeding tube
status, normalcy of diet, public eating, self-reported history of aspiration pneumonia, weightloss since diagnosis, understandability of speech, tracheostomy, and esophageal dilations due
to presence of stricture. Thereby late LCNP was consistently associated with substantial
functional morbidity among OPC survivors. These results are not surprising given the degree
of swallowing dysfunction previously reported among long-term OPC survivors in earlier
case reports that suggested that treatment-related LCNP may play a major role in late RAD,
and precipitate delayed but extreme oropharyngeal impairment as recorded by MBS studies. 1,
21, 22

These observations also align to numerous reports of significant swallowing dysfunction

caused by lower cranial nerve deficits among populations due to traumatic injury, vascular
causes, and infection, documented primarily in case reports. 43-47
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Approximately one-third (28.6%) of late LCNP patients in our study, reported having
a feeding tube at the time of survey. High rates of gastrostomy dependence among LCNP
cases again support a high prevalence of dysphagia in this population. In an earlier study
among OPC patients with advanced stage treated with concurrent RT and chemotherapy,
feeding tube use had the maximum impact on QOL (-30 points compared to controls)
evaluated by SF36 and HNQOL.48 Late LCNP cases also had significantly higher rates of
aspiration pneumonia (32.3% LCNP versus 2.0% no LCNP ), which support association with
high dysphagia-related morbidity. Similarly, a study using SEER data among HNC patients
treated with chemoradiation reported 23.8% five-year rates of aspiration pneumonia.49
Additionally, as late LCNP occurs many years after treatment with a tendency for silent
aspiration, symptoms of LCNP may be missed due to lack of adequate surveillance among
OPC survivors. This may further enhance risk of aspiration pneumonia and contribute to
debilitating functional morbidity with increased feeding tube dependence, hospitalization,
weight loss, and life-threatening complications.

Overall, late LCNP with accompanying dysphagia is a clinical condition of great
concern as it does not typically respond well to treatment. With progressive long-term
functional decline with aspiration and recurring aspiration-pneumonia, long-standing feeding
tube dependence and elective laryngectomy may be required. 1, 16, 21, 22, 50 Therefore, riskreduction and management of late effects like LCNP, late-RAD and associated functional
toxicities need to be prioritized in contemporary OPC treatment and management. That is,
providers should be alerted that survivors found to have a new IX, X, or XII nerve palsy in
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routine surveillance likely merit return to the speech pathologist for instrumental swallowing
evaluation, counseling, and therapy as well as interdisciplinary consideration of risk
reduction strategies for aspiration that preserve oral intake but diminish pneumonia risk.
This research may also help to provide benchmarks for novel interventions and surveillance
efforts. Routine PRO administration coupled with instrumental examination using fiberoptic
endoscopic evaluation of swallowing (FEES) and MBS may also help identify patients in
need of more intense, targeted therapy.50 Multi-disciplinary supportive treatment including
routine swallowing and speech assessment, risk-based treatment planning, swallowing and
nutritional therapy, counselling to improve coping skills, and guidance in effective meal
preparation may help to attenuate the impact of late LCNP-associated swallowing
impairment, diminish life-threatening complications, and enhance swallowing-related QOL.50

This study is the first to quantify the association between late LCNP and swallowingrelated quality of life in a study population of almost 900 OPC survivors finding the
hypothesized significant associations. However, there are limitations to acknowledge.
Complete case analysis was not feasible as 126/889 (14.2%) respondents returned surveys
with skipped or missing MDADI items. Thus, complete case analysis would have contributed
to attrition of approximately one-third of LCNP cases that would have substantially
diminished power in our study that focused on a rare event like LCNP. Therefore, we
imputed missing MDADI scores for 27% (10/36) of late LCNP patients. The validity of our
imputed results is supported by sensitivity analyses finding similar effect size estimates using
imputed vs non-imputed data (Appendix: Table 1). Imputed composite MDADI scores and
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non-imputed composite MDADI scores by LCNP status have also been presented as
Supplementary figure # 1 and their distribution is similar which was expected given
imputation was conducted using scores from non-missing items only. Post-imputation,
unadjusted means and accompanying standard deviations of composite, global, emotional,
physical, and functional scores were similar to estimates of means and standard deviations of
an earlier study among HNC patients.38 Further, consistency of results with previous
literature was demonstrated as survivors in our study treated with multimodality treatment
versus single modality, those who did not receive chemotherapy versus those who did, those
treated with accelerated RT versus standard fractionation, those who received conventional
3D conformal RT versus IMRT/ proton therapy and current smokers versus never smokers
reported significantly worse composite scores and those with early stage versus more
advanced stages reported significant positive trend for better swallowing scores 5, 8-10, 33, 50
These results indicate that our primary outcome variable, composite MDADI variable
consistently performed well and showed expected variation across clinical and tumor-related
factors. Large and statistically significant differences in functional metrics by LCNP status
also support our findings of high functional morbidity among LCNP cases. Our study results
also support a previous survey analysis in this study population, which used complete case
analysis of MDASI-HN, with low attrition of cases due to missing data and demonstrated a
strong impact of LCNP on swallowing, choking, mucus, fatigue, and voice symptoms. 26

Our study may also be subject to limitations inherent to cross-sectional PRO survey
collection including survival bias, which we tried control by including survival time in all our
multivariate models. MDADI and PSS-HN scores prior to late LCNP diagnosis were not
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available to fully control for subtle differences in baseline function. Rather, oral diet at
baseline was included as a covariate in analysis; among LCNP cases all but one could eat a
solid food diet pre-treatment suggesting functional baseline swallow in the vast majority of
LCNP cases. Further, chart abstraction of the LCNP case status precluded the ability to
identify sensory deficits associated with LCNP as clinical documentation focused on motor
deficits. We suspect that inclusion of sensory deficits of late LCNP might have led to higher
number of late LCNP cases detected. Several factors may limit generalizability of these
results. Given that few patients in our study received definitive surgery, our study results may
have less application to OPC patients treated with primary surgery. Our study population was
treated at a single tertiary cancer care institution and thus demographic characteristics may
limit generalizability to other more varied populations. However, the study population
demographics are similar to those expected among OPC patients across the US. Finally, it
was beyond the scope of this work to identify predictors of late LCNP as would be necessary
avoid this severe late functional toxicity. However, a recent cohort study among 10-year
survivors identified an association between primary tumor site, RT dose, chemotherapy, and
post-RT neck dissection as clinical predictors of cranial neuropathy on univariate analysis.37
Predictors of LCNP will be addressed in future work by the authors, as well.
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CONCLUSIONS
In this large cross-sectional analysis, OPC survivors with late LCNP had significantly
lower (worse) swallow-related QOL as per MDADI scores with significantly higher
likelihood of adverse functional status metrics like dietary restrictions, nutritional
impairment, weight-loss, decline in public food consumption with possible consequences of
social isolation, aspiration pneumonia, long-term feeding tube dependence, and
tracheostomy. These data support and quantify the detrimental relationship of late LCNP
with swallowing-related measures.
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Table 1: Patient Characteristics (N=889), late LCNP rate, and mean composite MDADI
scores

Variables

All Patients
(n=889)

Patients with
LCNP (n=36)

56 (32-84)

57 (42-72)

rho = -0.034

0.306

7 (1-16)

10.5 (2-16)

rho = -0.076

0.023

70 (40-73)

70 (60-72)

rho = -0.201

< 0.001

All Patients
n (%)

n (%) Patients
with LCNP

All patients
(n=889)

P-value b

136 (15.3)
753 (84.7)

5(3.7)
31(4.1)

78.3 ±17.5
79.9 ±16.3

Continuous Variables
Age at diagnosis, median
(range)
Survival time, median
(range)
Radiation Dose, Gy.
median (range)
Categorical Variables
Sex
Female
Male
Education
≤Highschool
>Highschool
Missing
Race
Others
White
Missing
Primary Site
Tonsil
Base of Tongue
T classification
1
2
3
4
N classification
N0
N1+2a
2b+3
2c
HPV status
Negative
Positive
Unknown
Smoking
Never
Former
Current

Composite MDADI Score ±
Standard Deviation)
All patients
P-value a, b
(n=889)
P-value a

0.443

< 0.001
168(18.9)
637(71.7)
84(9.4)

8(4.8)
27(4.2)
1(1.2)

75.6 ±16.7
80.9 ±15.9
78.6 ±18.9

59(6.6)
821(92.4)
9(1.0)

3(5.0)
32(3.9)
1(11.1)

78.5 ±20.0
79.8 ±16.2
78.4 ±19.3

438(49.3)
451(50.7)

17(3.8)
19(4.2)

80.3 ±16.4
79.1 ±16.6

334(37.6)
345(38.8)
131(14.7)
79(8.9)

8(2.4)
13(3.8)
8(6.1)
7(8.9)

82.6 ±15.2
80.8 ±15.7
75.8 ±17.0
68.7 ±18.9

81(9.1)
236(26.5)
429(48.3)
143(16.1)

3(3.7)
7(2.9)
19(4.4)
7(4.9)

79.9 ±16.1
81.8 ±14.7
80.1 ±16.4
74.7 ±18.9

56(6.3)
429(48.3)
404(45.4)

2(3.6)
9(2.1)
25(6.2)

80.9 ±16.8
81.0 ±15.9
78.1 ±17.0

0.983

0.200

< 0.001

0.007

0.033

< 0.001
409(46.0)
422(47.5)
58(6.5)

16(3.9)
17(4.0)
3(5.2)
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81.4 ±16.2
79.0 ±16.3
72.5 ±17.9

Composite MDADI Score ±
Standard Deviation)
Variables
All Patients
Patients with
All patients
P-value a, b
(n=889)
LCNP (n=36)
(n=889)
Solid Food pre-Tx
0.846
Yes
879(98.9)
35(4.0)
79.9 ±14.0
No
10(1.1)
1(10.0)
79.7 ±16.5
Treatment Group
< 0.001
Single Modality
278(31.3)
11(4.0)
83.2 ±14.3
Multimodality
611(68.7)
25(4.1)
78.1 ±17.2
Treatment Group
0.001
RT alone
270(30.4)
11(4.1)
83.0 ±14.4
Surgery alone
8(0.9)
0
89.9 ±9.4
RT plus systemic
596(67.0)
23(3.9)
78.1 ±17.3
Surgery plus adjuvant
15(1.7)
2(13.3)
78.4 ±14.2
Radiotherapy
0.068
No
8(0.9)
0
89.9 ±9.4
Yes
881(99.1)
36(4.1)
79.6±16.5
Chemotherapy
< 0.001
No
284(32.0)
11(3.9)
83.0 ±14.3
Yes
605(68.0)
25(4.1)
78.1 ±17.2
Surgery
0.403
No
865(97.3)
34(3.9)
79.6 ±16.6
Yes
24(2.7)
2(8.3)
83.0 ±13.8
Neck Dissection
0.431
No
665(74.8)
27(4.1)
79.9 ±16.5
Yes
224(25.2)
9(4.0)
79.0 ±16.5
RT Schedule
0.002
Standard Fractionation
778(88.3)
21(2.7)
80.3 ±16.1
Accelerated
95(10.8)
15(15.8)
73.5 ±18.3
Other
8(0.9)
0
78.3 ±24.3
RT Type
< 0.001
3d Conformal
50(5.7)
9(18.0)
67.8 ±20.4
IMRT-SF
675(76.6)
23(3.4)
79.6 ±16.1
IMRT- WF
33(3.8)
1(3.0)
74.7 ±17.8
Proton
23(2.6)
1(4.4)
87.5 ±11.3
IMRT Ipsilateral
100(11.3)
2(2.0)
84.9 ±14.3
Dilation/ Stricture
< 0.001
No
873 (98.2)
31(3.6)
80.0 ± 16.3
Yes
16 (1.8)
5(31.3)
61.0 ± 14.6
Abbreviations: T, tumor; RT, radiotherapy; MDADI, MD Anderson Dysphagia Inventory (MDADI);
rho, Spearman rho; pre-Tx, pre-treatment; 3d Conformal, Three Dimensional (3D) Conformal
Radiation Therapy; IMRT-SF, Intensity-modulated radiation therapy with split field technique;
IMRT-WF, Intensity-modulated radiation therapy with whole field technique. a P-value for
Continuous Variables and Composite scores calculated using Spearman Test. b P-value for
Categorical Variables and Composite scores calculated using Kruskal Wallis Test.

169

Table 2: Univariate and Multivariate Regression: Composite MDADIa (N=889)
Variables

Late LCNP
No
Yes
Age at diagnosis
Survival Time
Radiation Dose
Sex
Female
Male
Education
≤Highschool
>Highschool
Missing
Race
Others
White
Missing
Primary Site
Tonsil, soft palate, &
pharyngeal wall
Base of tongue & GPS
T classification
1
2
3
4
Smoking
Never
Former
Current
Solid Food pre-Tx
Yes
No
Treatment Group
Single modality Tx.
Multimodality Tx.
Radiotherapy
No
Yes
Chemotherapy
No
Yes
Surgery

Univariate Analysis
Coefficient (95%CI)

P value

Reference
-12.2 (-17.6, -6.7)
-0.1 (-0.2, 0.1)
-0.4 (-0.7, -0.1)
-1.1 (-1.5, -0.7)

< 0.001
0.328
0.009
< 0.001

Reference
1.6 (-1.4, 4.6)

Multivariate
Analysis
Coefficient
(95%CI)

P value

Reference
-6.6 (-12.0, -1.3)
-0.1 (-0.2, 0.1)
-0.2 (-0.6, 0.1)

0.015
0.275
0.151

0.305

Reference
2.3 (-0.6, 5.2)

0.119

Reference
5.3 (2.5, 8.1)
3.0 (-1.3, 7.3)

< 0.001
0.167

Reference
4.2 (1.5, 6.9)
2.8 (-1.4, 7.0)

0.002
0.196

Reference
1.3 (-3.1, 5.7)
-0.1 (-11.7, 11.5)

0.556
0.987

Reference

Reference

-1.2(-3.4, 1.0)

0.282

-1.1 (-3.4, 1.2)

0.334

Reference
-1.8 (-4.2, 0.6)
-6.9 (-10.1, -3.6)
-14.0 (-17.9, -10.0)

0.139
< 0.001
< 0.001

Reference
-1.1 (-3.6, 1.5)
-3.3 (-6.8, 0.3)
-9.9 (-14.1, -5.8)

0.407
0.069
< 0.001

Reference
-2.4 (-4.6, -0.1)
-8.9 (-13.4, -4.3)

0.039
< 0.001

Reference
-1.6 (-3.8, 0.5)
-7.0 (-11.4, -2.7)

0.141
0.001

Reference
-0.2 (-10.5, 10.1)

0.965

Reference
-2.1 (-12.0, 7.8)

0.675

Reference
-5.1 (-7.4, -2.8)

< 0.001

Reference
-2.7 (-5.4, -0.1

0.046

Reference
-10.4 (-21.9, 1.1)

0.077

Reference
-4.9 (-7.2, -2.6)

< 0.001
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Variables

Univariate Analysis
Coefficient (95%CI)

P value

Multivariate
Analysis
Coefficient
(95%CI)

P value

No
Reference
Yes,
3.5 (-3.2, 10.1)
0.310
Neck Dissection
No
Reference
Yes
-0.9 (-3.4, 1.6)
0.497
RT Schedule
Standard Fractionation
Reference
Accelerated
-6.9 (-10.4, -3.4)
< 0.001
Missing
-2.0 (-13.5, 9.4)
0.731
RT Type
3d Conformal
Reference
Reference
IMRT-SF
11.8 (7.2, 16.4)
< 0.001
8.1 (3.1, 13.1)
0.002
IMRT- WF
6.9 (-0.2, 14.0)
0.057
5.9 (-1.3, 13.0)
0.107
Proton
19.7 (11.7, 27.7)
< 0.001
14.4 (6.0, 22.9)
0.001
IMRT-Ipsilateral
17.1 (11.6, 22.5)
< 0.001
9.9 (3.8, 16.0)
0.002
Stricture/Dilation
No
Reference
Yes
-19.0 (-27.1, -10.9)
< 0.001
-13.1 (-21.1, -5.2)
0.001
Abbreviations: T, tumor; RT, radiotherapy; MDADI, MD Anderson Dysphagia Inventory (MDADI);
rho, Spearman rho; pre-Tx, pre-treatment; 3d Conformal, Three Dimensional (3D) Conformal
Radiation Therapy; IMRT-SF, Intensity-modulated radiation therapy with split field technique;
IMRT-WF, Intensity-modulated radiation therapy with whole field technique. Statistical significance
p value < 0.25 after Univariate Analysis. Statistical significance p value < 0.05 after Multivariate
Analysis. aMissing values imputed.
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Table 3: MDADI Scores by late LCNP Status (N=889)

MDADI
SCORESa

Composite

Mean ± SD
(95%CI)
Patients with
Patients
LCNP
without
(n=36)
LCNP
(n=853)
68.0 ± 17.4
80.2 ±16.3
(62.1 to 73.9) (79.1 to 81.3)

Analysis Coefficient (95%CI)
P value

Univariate
(95%CI)

Multivariate
(95%CI)

P value

< 0.001

-12.2 (-17.6 to -6.7) - 6.7 (-12.0 to -1.3)

0.015

Global

65.1 ± 28.9
(55.3 to 74.8)

81.3 ± 23.2
(79.8 to 82.9)

< 0.001

-16.3 (-24.1 to -8.4) -9.1 (-17.0 to -1.3)

0.023

Emotional

70.1±19.2
(63.6 to 76.5)

81.0±16.4
(79.9 to 82.1)

< 0.001

-10.9 (-16.5 to -5.4) -5.9 (-11.4 to -0.3)

0.038

Physical

62.5±18.0
(56.4 to 68.6)

75.9±19.0
(74.6 to 77.2)

< 0.001

-13.5 (-19.8 to -7.1) -7.7 (-14.0 to -1.3)

0.018

Functional 74.4±20.7
(67.4 to 81.4)

86.0±16.1
(84.9 to 87.1)

< 0.001

-11.6 (-17.1 to -6.1) -6.0 (-11.4 to -0.6)

0.028

Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial
neuropathy. Multiple linear regression models adjusted covariates including, age, survival time, sex,
education, subsite, T-stage, smoking, therapeutic modality, RT modality, solid food diet prior to
treatment, and stricture. The regression model for global scores adjusted for an additional variable,
neck dissection. aMissing values imputed.
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Table 4: Functional Status Metrics by late LCNP status (n=889)
Variables

Current Feeding Tube
No
Yes
Normalcy Diet
Full Diet no restrictions
Full Diet with liquid assist
Solid food but avoid some hard to eat foods
Soft chewable foods
Non-chewable or pureed foods
Warm and cold liquids
Not eat or drink anything by mouth
Public Eating
No restriction of place/ food/companion
No restriction of place, but restrict diet in
public
In presence of selected person in selected
places
Only eat at home with selected persons
Always eat alone
Aspiration Pneumonia
No
Yes
Weight loss
No
Yes
Change in Weight; mean, median (range)a
% Change in Weight; mean ± SD, median,
(range)b
Understandability of Speech
Always understandable
Understandable most of the time
Usually understandable
Difficult to understand
Never understandable
Tracheostomy
No
Yes
Dilation/ Stricture
No
Yes

Patients with
LCNP
n (%)

Patients without
LCNP n (%)

25 (71.4)
10 (28.6)

819 (98.1)
16 (1.9)

P-value

Crude OR
(95%CI)

< 0.001
Reference
20.5 (8.6 to 48.9)
< 0.001
6 (18.2)
8 (24.2)
10 (30.3)

357 (43.7)
315 (38.5)
96 (11.7)

2 (6.1)
1 (3.0)
2 (6.1)
4 (12.1)

33 (4.0)
3 (0.4)
10 (1.2)
4 (0.5)

8 (25.8)
14 (45.2)

582 (70.3)
191 (23.1)

7 (22.6)

36 (4.3)

1 (3.2)
1 (3.2)

14 (1.7)
5 (0.6)

21 (67.7)
10 (32.3)

741 (98.0)
15 (2.0)

Reference
3.5 (1.5 to 8.3)

< 0.001
Reference
6.8 (3.1 to 15.1)

< 0.001
Reference
23.5 (9.6 to 57.6)
0.050
4 (11.4)
31 (88.6)
22.9,
16.8(14.2,87.8)
11.7±10.4,
9.9(-7.9,33.4)

202 (24.4)
626 (75.6)
13.3,
9.4(103.1,164.6)
6.0 ±10.7,
5.1(-96.4, 43.4)

Reference
2.5 (0.9 to 6.9)
0.005
0.002
< 0.001

6 (17.6)
16 (47.1)
3 (8.8)
8 (23.5)
1 (2.9)

528 (63.3)
269 (32.3)
19 (2.3)
17 (2.0)
1 (0.1)

31 (91.2)
3 (8.8)

834 (99.6)
3 (0.4)

31 (86.11)
5 (13.89)

842 (98.71)
11 (1.29)

Reference
8.1 (3.4 to 19.2)

0.001
Reference
26.9(6.0 to 121.7)
< 0.001
Reference
12.3 (4.2 to 36.3)

P values estimated by Fishers Exact Test. a, b P values estimated by Wilcoxon Rank-Sum Test. Odds
Ratio for normalcy of diet calculated with full diet no restrictions as reference category and all other
categories collapsed. Odds Ratio for public eating calculated with no restriction of place/
food/companion as reference category and all other categories collapsed. Odds Ratio for
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understandability of speech calculated with always understandable as reference category and all other
categories collapsed.

Figure 1: Multivariate Adjusted Coefficients for Late LCNP and MDADI scores

-7.7 (-14.0 to -1.3) *

-9.1 (-17.0 to -1.3) *

-6.0 (-11.4 to -0.6) *

-5.9 (-11.4 to -0.3) *

-6.7 (-12.0 to -1.3) *

Late LCNP worse MDADI

Late LCNP better

Figure 1. Multivariate Adjusted Coefficients for Late LCNP and MDADI Scores. Multiple linear
regression models adjusted for age, survival time, sex, education, subsite, T-stage, smoking,
therapeutic modality, RT modality, solid food diet prior to treatment, and stricture. The regression
model for global scores adjusted for an additional variable, neck dissection.
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial
neuropathy.
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FIGURE 2: Imputed composite MDADI scores by Type of LCNP

No LCNP
n=853

LCNP IX/X only
n=19

LCNP XII only
n=31

Polyneuropathy
n=13

Figure 2. Imputed composite MDADI scores among patients without LCNP, LCNP IX/X only, LCNP
XII only and polyneuropathy. Polyneuropathy included LCNP cases with both CN XII and CN IX/X
palsy. Patients without LCNP had higher (better) scores than LCNP cases, but lowest (worst) mean
scores and least variability of scores were reported by LCNP cases with polyneuropathy.
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); LCNP, lower cranial
neuropathy; IX/X, Glossopharyngeal or Vagus Nerve; XII Hypoglossal Nerve.
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CONCLUSION
The results of this study clearly establish late LCNP as a serious treatment-related
toxicity among long-term OPC survivors and was associated with significantly worse cancer
treatment-related symptoms and significantly worse swallow-related QOL.
While rare in the population overall, quantitative estimates of lifetime risk of late LCNP over
an almost 18-year follow-up into OPC survivorship demonstrate that one out of 10 OPC
survivors middle-aged at time of diagnosis are likely develop late LCNP. The progressively
increasing risk of late LCNP of 2%, 6%, and 10% at 5, 10, 18-year follow-up also indicates
that risk of LCNP overtime is much higher than previously believed. The potential impact of
late LCNP on the life of OPC survivors is devastating as late LCNP and accompanying lateRAD is refractory to treatment, life-long, and permanent. Our prediction model enabled
identification of OPC survivors who had T4 tumors and those who received accelerated
fractionation RT treatment as having higher risk of late LCNP. In this study patients with big
bulky tumors, had large irradiation fields possibly including cranial nerves, were likely to be
treated most aggressively with multimodality treatment regimens including, IC, accelerated
RT, and systemic therapy, thereby they were more likely to develop late LCNP.
In the large cross-sectional survey analysis, late LCNP cases reported significantly
worse cancer treatment-related symptoms, and worse symptoms associated with motor
functions of the upper aerodigestive tract (swallowing, voice), demonstrating the relevance of
late LCNP to both symptom severity and QOL. Among LCNP cases, a higher proportion
reported severe (LCNP: 20% vs no LCNP: 5%) and moderate (LCNP: 40% vs no LCNP:
15%) symptoms.
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OPC survivors with late LCNP also reported had worse swallow-related QOL as per
MDADI scores with significantly higher likelihood of adverse functional status metrics like
dietary restrictions, nutritional impairment, weight-loss, decline in public food consumption
with possible consequences of social isolation, aspiration pneumonia, long-term feeding tube
dependence, and tracheostomy.
Future studies need to further assess the role of dose to ROI (regions of interest
involving critical structures), IC, and transoral robotic surgery in development of late effects
like LCNP. Better RT techniques need to be developed to modify dose delivery and less toxic
chemotherapy agents need to be investigated. Treatment de-intensification strategies need to
be explored which maintain cure and prevent late effects. There is also a clear need for longterm surveillance of late LCNP among HNC and OPC patients, particularly in light of
epidemiologic trends that suggest growing numbers of OPC survivors at risk of late effects in
immediate years ahead.6-8 Further, efforts are necessary to address severity of treatmentrelated symptoms and optimize swallowing outcomes to improve QoL among growing
numbers of relatively younger OPC survivors, who are expected to survive decades after
treatment. Finally, the long-term treatment-related burden of OPC is becoming more
apparent, there is need to find ways to treat cancer and minimize toxicity.
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APPENDIX
FIGURES
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Supplementary Figure 1: MDASI-HN Scores for Swallowing/Chewing, Voice/Speech and
Choking/Coughing for late LCNP cases (n=35)
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Supplementary Figure 1. MDASI-HN Scores for Swallowing/Chewing, Voice/Speech and
Choking/Coughing for late LCNP cases (n=35). Symptom are classified as: 0 “no symptom”; 1-3
“mild”; 4-6 “moderate” and 7-10 “severe” Abbreviations: MDASI-HN, MD Anderson Symptom
Inventory Head and Neck Cancer Module (MDASI-HN); LCNP, lower cranial neuropathy.
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SUPPLEMENTARY FIGURE 1: Imputed composite MDADI scores and non-imputed
composite MDADI scores by LCNP status

LCNP

No LCNP
Imputed composite MDADI score

Composite MDADI score

Supplementary Figure 1: Imputed composite MDADI scores and non-imputed composite MDADI
scores by LCNP status. Distribution of imputed composite and non-imputed composite MDADI
scores by LCNP status was very similar which was expected given that imputation was conducted
using scores from non-missing items only. Further, there was expected decline in both imputed
composite and non-imputed composite MDADI scores among LCNP cases in comparison to those
without LCNP. This along with our sensitivity analysis in Appendix 1, Table 1 show that imputed and
non-imputed MDADI scores were similar and our study results are valid.
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Table 1: Sensitivity Analysis Comparing Imputed Versus Non-Imputed MDADI Scores
IMPUTED MDADI SCORES

NON-IMPUTED MDADI SCORES

MDADI SCORE

Multivariate
Analysis Coefficient
(95%CI)

P Value

Multivariate
Analysis Coefficient (95%CI)

P Value

Composite

- 6.7 (-12.0 to -1.3)

0.015

-4.8 (-11.3 to 1.6)

0.142

Global

-9.1 (-17.0 to -1.3)

0.023

-10.6 (-18.9 to -2.4)

0.012

Emotional

-5.9 (-11.4 to -0.3)

0.038

-5.6 (-11.7 to 0.6)

0.077

Physical

-7.7 (-14.0 to -1.3)

0.018

-7.8 (-15.0 to -0.6)

0.033

Functional

-6.0 (-11.4 to -0.6)

0.028

-5.3 (-11.1 to 0.5)

0.073

Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI)
Comment: Other than Composite scores all effect estimates are not very different.

Table 2: Sensitivity Analysis Comparing Final Model with and without RT Dose
Final Model with RT Dose

Final Model without RT Dose

MDADI SCORE

Multivariate Coefficient
for late LCNP (95% CI)

P Value

Multivariate Coefficient
for late LCNP (95% CI)

P Value

Composite
Global
Emotional
Physical

-6.6 (-12.0 to -1.2)
-9.1 (-17.0 to -1.3)
-5.8 (-11.3 to -0.3)
-7.6 (-13.9 to -1.2)

0.016
0.022
0.039

- 6.7 (-12.0 to -1.3)
-9.1 (-17.0 to -1.3)
-5.9 (-11.4 to -0.3)
-7.7 (114.0 to -1.3)

0.015
0.023
0.038
0.018

0.019
Functional
-6.0 (-11.4 to -0.6)
0.028
-6.0 (-11.4 to -0.6)
0.029
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); RT Dose (Radiation Dose)
Comment: Effect estimates for all MDADI scores for LCNP are similar.
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Table 3: Sensitivity Analysis Comparing Final Model with and without HPV
Final Model with HPV status

Final Model without HPV status

MDADI SCORE

Multivariate Coefficient
P Value
Multivariate Coefficient for P Value
for late LCNP (95% CI)
late LCNP (95% CI)
Composite
- 6.7 (-12.0 to -1.3)
0.015
-6.7 (-12.1 to -1.3)
0.015
Global
-9.1
(-17.0
to
-1.3)
0.023
-9.2 (-17.0 to -1.4)
0.022
Emotional
-5.9 (-11.4 to -0.3)
0.038
-5.9 (-11.4 to -0.4)
0.037
Physical
-7.7 (114.0 to -1.3)
0.018
-7.7 (-14.0 to -1.4)
0.017
Functional
-6.0
(-11.4
to
-0.6)
0.028
-6.0 (-11.4 to -0.7)
0.028
Abbreviations: MDADI, MD Anderson Dysphagia Inventory (MDADI); HPV (Human Papilloma
Virus)
Comment: Effect estimates for all MDADI scores for LCNP are similar.
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APPENDIX 2: Functional Status Metrics Survey Questions
Current Feeding Tube Status
1) Do you currently have a feeding tube?
Yes
No
Normalcy of Diet
2) What kinds of foods you are able to eat? (Mark one)
Please mark the item that represents the highest level of foods or liquids you eat. If you have
a feeding tube, but also eat by mouth, please mark the highest level of foods you eat in
addition to your tube feedings.
7. I eat whatever I would like (full diet no restriction).
6. I eat whatever I would like, but require more liquids than usual with meals (full diet
with liquid assist).
5. I eat solid food but avoid some hard to eat foods (like meats, raw vegetables/ fruits).
4. I eat soft chewable foods (like pasta, cooked vegetables, fish, dry foods).
3. I eat non-chewable or pureed foods.
2. I drink warm and cold liquids.
1. I do not eat or drink anything by mouth; I only use a feeding tube.

Public Eating
3) Select the statement that best reflects if and how you eat in public:
I eat out at any opportunity with no restriction of place, food, or companion.
I eat out with no restriction of place, but I restrict my diet when in public.
I eat only in the presence of selected person in selected places.
I only eat at home with selected persons.
I always eat alone.
Understandability of Speech
4) How well are you understood when speaking to other people?
My speech is always understandable.
My speech is understandable most of the time, I am occasionally asked to repeat
myself.
My speech is usually understandable, but face-to-face contact is necessary.
My speech is difficult to understand.
My speech is never understandable.
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Aspiration Pneumonia
5) Since your cancer treatment, has a doctor or other health professional told you that you
have:
Yes

No

Don’t Know

Pneumonia?

Tracheostomy
6) Do you currently have a tracheostomy tube (or breathing tube)?
Yes
No
7) Since your cancer treatment, has a doctor or other health professional told you that you
have:
Yes

No

Don’t Know

Stricture of the throat or esophagus?
(Stricture is a narrowing or tightness of the
food tube that may cause sticking or
obstruction of food.)

But we did not use this variable we abstracted EGD/Dilation Variable from the Charts.

Current Height and Weight
8) What are your current height and weight?
a) Height: _____ ft. _____in.
b) Weight: _________lbs.
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